



2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

Authors/Task Force Members: Marco Roffi* (Chairperson) (Switzerland), Carlo Patrono* (Co-Chairperson) (Italy), Jean-Philippe Collet† (France), Christian Mueller† (Switzerland), Marco Valgimigli† (The Netherlands), Felicita Andreotti (Italy), Jeroen J. Bax (The Netherlands), Michael A. Borger (Germany), Carlos Brotons (Spain), Derek P. Chew (Australia), Baris Gencer (Switzerland), Gerd Hasenfuss (Germany), Keld Kjeldsen (Denmark), Patrizio Lancellotti (Belgium), Ulf Landmesser (Germany), Julinda Mehilli (Germany), Debabrata Mukherjee (USA), Robert F. Storey (UK), and Stephan Windecker (Switzerland)

Document Reviewers: Helmut Baumgartner (CPG Review Coordinator) (Germany), Oliver Gaemperli (CPG Review Coordinator) (Switzerland), Stephan Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon (Spain), Colin Baigent (UK), Héctor Bueno (Spain), Raffaele Bugiardini (Italy), Scipione Carerj (Italy), Filip Casselman (Belgium), Thomas Cuisset (France), Çetin Erol (Turkey), Donna Fitzsimons (UK), Martin Halle (Germany),

* Corresponding authors: Marco Roffi, Division of Cardiology, University Hospital, Rue Gabrielle Perret-Gentil 4, 1211 Geneva 14, Switzerland, Tel: +41 22 37 23 743, Fax: +41 22 37 27 229, E-mail: Marco.Roffi@hcuge.ch

Carlo Patrono, Istituto di Farmacologia, Università Cattolica del Sacro Cuore, Largo F. Vito 1, IT-00168 Rome, Italy, Tel: +39 06 30154253, Fax: +39 06 3050159, E-mail: carlo.patrono@rm.unicatt.it

† Section Coordinators affiliations listed in the Appendix.

ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers listed in the Appendix.

ESC entities having participated in the development of this document:

Associations: Acute Cardiovascular Care Association (ACCA), European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).

Councils: Council on Cardiovascular Nursing and Allied Professions (CCNAP), Council for Cardiology Practice (CCP), Council on Cardiovascular Primary Care (CCPC).

Working Groups: Working Group on Cardiovascular Pharmacotherapy, Working Group on Cardiovascular Surgery, Working Group on Coronary Pathophysiology and Microcirculation, Working Group on Thrombosis.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

© The European Society of Cardiology 2015. All rights reserved. For permissions please email: journals.permissions@oup.com.

Christian Hamm (Germany), David Hildick-Smith (UK), Kurt Huber (Austria), Efstathios Iliodromitis (Greece), Stefan James (Sweden), Basil S. Lewis (Israel), Gregory Y. H. Lip (UK), Massimo F. Piepoli (Italy), Dimitrios Richter (Greece), Thomas Rosemann (Switzerland), Udo Sechtem (Germany), Ph. Gabriel Steg (France), Christian Vrints (Belgium), and Jose Luis Zamorano (Spain)

The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website <http://www.escardio.org/guidelines>

Keywords

Acute cardiac care • Acute coronary syndromes • Angioplasty • Anticoagulation • Apixaban • Aspirin • Atherothrombosis • Beta-blockers • Bivalirudin • Bypass surgery • Cangrelor • Chest pain unit • Clopidogrel • Dabigatran • Diabetes • Early invasive strategy • Enoxaparin • European Society of Cardiology • Fondaparinux • Glycoprotein IIb/IIIa inhibitors • Guidelines • Heparin • High-sensitivity troponin • Myocardial ischaemia • Nitrates • Non-ST-elevation myocardial infarction • Platelet inhibition • Prasugrel • Recommendations • Revascularization • Rhythm monitoring • Rivaroxaban • Statin • Stent • Ticagrelor • Unstable angina • Vorapaxar

Table of Contents

Abbreviations and acronyms	4	5.1.1 General supportive measures	15
1. Preamble	5	5.1.2 Nitrates	15
2. Introduction	7	5.1.3 Beta-blockers	15
2.1 Definitions, pathophysiology and epidemiology	7	5.1.4 Other drug classes (see Web addenda)	16
2.1.1 Universal definition of myocardial infarction	7	5.1.5 Recommendations for anti-ischaemic drugs in the acute phase of non-ST-elevation acute coronary syndromes	16
2.1.1.1 Type 1 MI	7	5.2 Platelet inhibition	16
2.1.1.2 Type 2 MI	7	5.2.1 Aspirin	16
2.1.2 Unstable angina in the era of high-sensitivity cardiac troponin assays	7	5.2.2 P2Y ₁₂ inhibitors	16
2.1.3 Pathophysiology and epidemiology (see Web addenda)	7	5.2.2.1 Clopidogrel	16
3. Diagnosis	7	5.2.2.2 Prasugrel	16
3.1 Clinical presentation	7	5.2.2.3 Ticagrelor	17
3.2 Physical examination	8	5.2.2.4 Cangrelor	18
3.3 Diagnostic tools	8	5.2.3 Timing of P2Y ₁₂ inhibitor administration	19
3.3.1 Electrocardiogram	8	5.2.4 Monitoring of P2Y ₁₂ inhibitors (see Web addenda)	19
3.3.2 Biomarkers	9	5.2.5 Premature discontinuation of oral antiplatelet therapy	19
3.3.3 'Rule-in' and 'rule-out' algorithms	10	5.2.6 Duration of dual antiplatelet therapy	19
3.3.4 Non-invasive imaging	11	5.2.7 Glycoprotein IIb/IIIa inhibitors	20
3.3.4.1 Functional evaluation	11	5.2.7.1 Upstream versus procedural initiation (see Web addenda)	20
3.3.4.2 Anatomical evaluation	11	5.2.7.2 Combination with P2Y ₁₂ inhibitors (see Web addenda)	20
3.4 Differential diagnosis	12	5.2.7.3 Adjunctive anticoagulant therapy (see Web addenda)	20
4. Risk assessment and outcomes	12	5.2.8 Vorapaxar (see Web addenda)	20
4.1 Clinical presentation, electrocardiogram and biomarkers	12	5.2.9 Recommendations for platelet inhibition in non-ST-elevation acute coronary syndromes	20
4.1.1 Clinical presentation	12	5.3 Anticoagulation	21
4.1.2 Electrocardiogram	12	5.3.1 Anticoagulation during the acute phase	21
4.1.3 Biomarkers	13	5.3.1.1 Unfractionated heparin	21
4.2 Ischaemic risk assessment	13	5.3.1.2 Low molecular weight heparin	22
4.2.1 Acute risk assessment	13	5.3.1.3 Fondaparinux	22
4.2.2 Cardiac rhythm monitoring	13	5.3.1.4 Bivalirudin	22
4.2.3 Long-term risk	14	5.3.2 Anticoagulation following the acute phase	23
4.3 Bleeding risk assessment	14		
4.4 Recommendations for diagnosis, risk stratification, imaging and rhythm monitoring in patients with suspected non-ST- elevation acute coronary syndromes	14		
5. Treatment	15		
5.1 Pharmacological treatment of ischaemia	15		

5.3.3 Recommendations for anticoagulation in non-ST-elevation acute coronary syndromes	23	acute coronary syndrome patients requiring coronary artery bypass surgery	32
5.4 Managing oral antiplatelet agents in patients requiring long-term oral anticoagulants	24	5.6.6.3 Technical aspects and outcomes (see Web addenda)	33
5.4.1 Patients undergoing percutaneous coronary intervention	24	5.6.7 Percutaneous coronary intervention vs. coronary artery bypass surgery	33
5.4.2 Patients medically managed or requiring coronary artery bypass surgery	26	5.6.8 Management of patients with cardiogenic shock . . .	33
5.4.3 Recommendations for combining antiplatelet agents and anticoagulants in non-ST-elevation acute coronary syndrome patients requiring chronic oral anticoagulation	26	5.6.9 Recommendations for invasive coronary angiography and revascularization in non-ST-elevation acute coronary syndromes	34
5.5 Management of acute bleeding events (see Web addenda)	27	5.7 Gender specificities (see Web addenda)	34
5.5.1 General supportive measures (see Web addenda)	27	5.8 Special populations and conditions (see Web addenda)	34
5.5.2 Bleeding events on antiplatelet agents (see Web addenda)	27	5.8.1 The elderly and frail patients (see Web addenda)	34
5.5.3 Bleeding events on vitamin K antagonists (see Web addenda)	27	5.8.1.1 Recommendations for the management of elderly patients with non-ST-elevation acute coronary syndromes	34
5.5.4 Bleeding events on non-vitamin K antagonist oral anticoagulants (see Web addenda)	27	5.8.2 Diabetes mellitus (see Web addenda)	35
5.5.5 Non-access-related bleeding events (see Web addenda)	27	5.8.2.1 Recommendations for the management of diabetic patients with non-ST-elevation acute coronary syndromes	35
5.5.6 Bleeding events related to percutaneous coronary intervention (see Web addenda)	27	5.8.3 Chronic kidney disease (see Web addenda)	35
5.5.7 Bleeding events related to coronary artery bypass surgery (see Web addenda)	27	5.8.3.1 Dose adjustment of antithrombotic agents (see Web addenda)	35
5.5.8 Transfusion therapy (see Web addenda)	27	5.8.3.2 Recommendations for the management of patients with chronic kidney disease and non-ST-elevation acute coronary systems	35
5.5.9 Recommendations for bleeding management and blood transfusion in non-ST-elevation acute coronary syndromes	27	5.8.4 Left ventricular dysfunction and heart failure (see Web addenda)	36
5.6 Invasive coronary angiography and revascularization	28	5.8.4.1 Recommendations for the management of patients with acute heart failure in the setting of non-ST-elevation acute coronary syndromes	36
5.6.1 Invasive coronary angiography	28	5.8.4.2 Recommendations for the management of patients with heart failure following non-ST-elevation acute coronary syndromes	36
5.6.1.1 Pattern of coronary artery disease	28	5.8.5 Atrial fibrillation (see Web addenda)	37
5.6.1.2 Identification of the culprit lesion	28	5.8.5.1 Recommendations for the management of atrial fibrillation in patients with non-ST-elevation acute coronary syndromes	37
5.6.1.3 Fractional flow reserve	29	5.8.6 Anaemia (see Web addenda)	37
5.6.2 Routine invasive vs. selective invasive approach	29	5.8.7 Thrombocytopenia (see Web addenda)	37
5.6.3 Timing of invasive strategy	29	5.8.7.1 Thrombocytopenia related to GPIIb/IIIa inhibitors (Web addenda)	37
5.6.3.1 Immediate invasive strategy (<2 h)	29	5.8.7.2 Heparin-induced thrombocytopenia (Web addenda)	37
5.6.3.2 Early invasive strategy (<24 h)	29	5.8.7.3 Recommendations for the management of thrombocytopenia in non-ST-elevation acute coronary syndromes	37
5.6.3.3 Invasive strategy (<72 h)	30	5.8.8 Patients requiring chronic analgesic or anti-inflammatory treatment (see Web addenda)	37
5.6.3.4 Selective invasive strategy	30	5.8.9 Non-cardiac surgery (see Web addenda)	37
5.6.4 Conservative treatment	30	5.9 Long-term management	38
5.6.4.1 In patients with coronary artery disease	30	5.9.1 Medical therapy for secondary prevention	38
5.6.4.1.1 Non-obstructive CAD	30	5.9.1.1 Lipid-lowering treatment	38
5.6.4.1.2 CAD not amenable to revascularization	31	5.9.1.2 Antithrombotic therapy	38
5.6.4.2 In patients with normal coronary angiogram (see Web addenda)	31	5.9.1.3 ACE inhibition	38
5.6.5 Percutaneous coronary intervention	31	5.9.1.4 Beta-blockers	38
5.6.5.1 Technical aspects and challenges	31		
5.6.5.2 Vascular access	31		
5.6.5.3 Revascularization strategies and outcomes	32		
5.6.6 Coronary artery bypass surgery	32		
5.6.6.1 Timing of surgery and antithrombotic drug discontinuation (see Web addenda)	32		
5.6.6.2 Recommendations for perioperative management of antiplatelet therapy in non-ST-elevation			

5.9.1.5 Mineralocorticoid receptor antagonist therapy	38
5.9.1.6 Antihypertensive therapy	38
5.9.1.7 Glucose-lowering therapy in diabetic patients	38
5.9.2 Lifestyle changes and cardiac rehabilitation	38
5.9.3 Recommendations for long-term management after non-ST-elevation acute coronary syndromes	38
6. Performance measures	39
7. Summary of management strategy	39
8. Gaps in evidence	41
9. To do and not do messages from the guidelines	41
10. Web addenda and companion documents	42
11. Acknowledgements	42
12. Appendix	42
13. References	43

Abbreviations and acronyms

ACC	American College of Cardiology
ACCOAST	Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction
ACE	angiotensin-converting enzyme
ACS	acute coronary syndromes
ACT	activated clotting time
ACTION	Acute Coronary Treatment and Intervention Outcomes Network
ACUITY	Acute Catheterization and Urgent Intervention Triage strategy
ADAPT-DES	Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents
ADP	adenosine diphosphate
AHA	American Heart Association
APPRAISE	Apixaban for Prevention of Acute Ischaemic Events
aPTT	activated partial thromboplastin time
ARB	angiotensin receptor blocker
ATLAS ACS 2-TIMI 51	Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51
ATP	adenosine triphosphate
BARC	Bleeding Academic Research Consortium
BMS	bare-metal stent
CABG	coronary artery bypass graft
CAD	coronary artery disease
CHA ₂ DS ₂ -VASc	Cardiac failure, Hypertension, Age ≥ 75 (2 points), Diabetes, Stroke (2 points)–Vascular disease, Age 65–74, Sex category
CHAMPION	Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition
CI	confidence interval
CK	creatinine kinase

CKD	chronic kidney disease
CK-MB	creatinine kinase myocardial band
COX	cyclooxygenase
CMR	cardiac magnetic resonance
CPG	Committee for Practice Guidelines
CREDO	Clopidogrel for the Reduction of Events During Observation
CRUSADE	Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines
CT	computed tomography
CURE	Clopidogrel in Unstable Angina to Prevent Recurrent Events
CURRENT-OASIS 7	Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events–Seventh Organization to Assess Strategies in Ischaemic Syndromes
CV	cardiovascular
CYP	cytochrome P450
DAPT	dual(oral) antiplatelet therapy
DES	drug-eluting stent
EARLY-ACS	Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome
ECG	electrocardiogram
eGFR	estimated glomerular filtration rate
EMA	European Medicines Agency
ESC	European Society of Cardiology
FDA	Food and Drug Administration
FFR	fractional flow reserve
FREEDOM	Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease
GPIIb/IIIa	glycoprotein IIb/IIIa
GRACE 2.0	Global Registry of Acute Coronary Events 2.0
GUSTO	Global Utilization of Streptokinase and TPA for Occluded Arteries
GWTG	Get With The Guidelines
HAS-BLED	hypertension, abnormal renal and liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (> 65 years), drugs and alcohol (1 point each)
HIT	heparin-induced thrombocytopenia
HORIZONS	Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction
HR	hazard ratio
IABP-Shock II	Intra-Aortic Balloon Pump in Cardiogenic Shock II
IMPROVE-IT	IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
INR	international normalized ratio
ISAR-CLOSURE	Instrumental Sealing of ARterial puncture site–CLOSURE device versus manual compression
ISAR-REACT	Intracoronary stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatment

ISAR-TRIPLE	Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation	TIA	transient ischaemic attack
i.v.	intravenous	TIMACS	Timing of Intervention in Patients with Acute Coronary Syndromes
LDL	low-density lipoprotein	TIMI	Thrombolysis In Myocardial Infarction
LMWH	low molecular weight heparin	TRA 2P-TIMI 50	Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events—Thrombolysis in Myocardial Infarction 50
LV	left ventricular	TRACER	Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome
LVEF	left ventricular ejection fraction	TRILOGY ACS	Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes
MACE	major adverse cardiovascular event	TRITON-TIMI 38	TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel—Thrombolysis In Myocardial Infarction 38
MATRIX	Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX	TVR	target vessel revascularization
MDCT	multidetector computed tomography	UFH	unfractionated heparin
MERLIN	Metabolic Efficiency With Ranolazine for Less Ischaemia in Non-ST-Elevation Acute Coronary Syndromes	VKA	vitamin K antagonist
MI	myocardial infarction	WOEST	What is the Optimal antiplatelet and anticoagulant therapy in patients with OAC and coronary Stenting
MINAP	Myocardial Infarction National Audit Project	ZEUS	Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates
NOAC	non-vitamin K antagonist oral anticoagulant		
NSAID	non-steroidal anti-inflammatory drug		
NSTE-ACS	non-ST-elevation acute coronary syndromes		
NSTEMI	non-ST-elevation myocardial infarction		
NYHA	New York Heart Association		
OAC	oral anticoagulation/anticoagulant		
OASIS	Organization to Assess Strategies for Ischaemic Syndromes		
OR	odds ratio		
PARADIGM-HF	Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure		
PCI	percutaneous coronary intervention		
PEGASUS-TIMI 54	Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54		
PLATO	PLATelet inhibition and patient Outcomes		
POISE	PeriOperative ISchemic Evaluation		
RCT	randomized controlled trial		
RIVAL	Radial Vs femoral access for coronary intervention		
RR	relative risk		
RRR	relative risk reduction		
SAFE-PCI	Study of Access Site for Enhancement of PCI for Women		
s.c.	subcutaneous		
STEMI	ST-segment elevation myocardial infarction		
SWEDHEART	Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies		
SYNERGY	Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors trial		
SYNTAX	SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery		
TACTICS	Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy		

1. Preamble

Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (<http://www.escardio.org/Guidelines-&Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines>). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the

Table 1 Classes of recommendations

Classes of recommendations	Definition	Suggested wording to use
Class I	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.	Is recommended/is indicated
Class II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.	
<i>Class IIa</i>	<i>Weight of evidence/opinion is in favour of usefulness/efficacy.</i>	Should be considered
<i>Class IIb</i>	<i>Usefulness/efficacy is less well established by evidence/opinion.</i>	May be considered
Class III	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.	Is not recommended

risk–benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined in *Tables 1* and *2*.

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (<http://www.escardio.org/guidelines>). Any changes in declarations of interest that arise during the writing period must be notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry.

The ESC CPG supervises and coordinates the preparation of new Guidelines produced by task forces, expert groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task Force. The finalized document is approved by the CPG for publication in the European Heart Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The task of developing ESC Guidelines covers not only integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. To implement the guidelines, condensed pocket guidelines versions, summary slides, booklets with essential messages, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.) are produced. These versions are abridged and thus, if needed, one should always refer to the full text version which is freely available on the ESC website.

Table 2 Levels of evidence

Level of evidence A	Data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B	Data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.

The National Societies of the ESC are encouraged to endorse, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them and implementing them into clinical practice.

Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

2. Introduction

2.1 Definitions, pathophysiology and epidemiology

The leading symptom that initiates the diagnostic and therapeutic cascade in patients with suspected acute coronary syndromes (ACS) is chest pain. Based on the electrocardiogram (ECG), two groups of patients should be differentiated:

- (1) Patients with acute chest pain and persistent (>20 min) ST-segment elevation.

This condition is termed ST-elevation ACS and generally reflects an acute total coronary occlusion. Most patients will ultimately develop an ST-elevation myocardial infarction (STEMI). The mainstay of treatment in these patients is immediate reperfusion by primary angioplasty or fibrinolytic therapy.¹

- (2) Patients with acute chest pain but no persistent ST-segment elevation.

ECG changes may include transient ST-segment elevation, persistent or transient ST-segment depression, T-wave inversion, flat T waves or pseudo-normalization of T waves or the ECG may be normal.

The clinical spectrum of non-ST-elevation ACS (NSTEMI-ACS) may range from patients free of symptoms at presentation to individuals with ongoing ischaemia, electrical or haemodynamic instability or cardiac arrest. The pathological correlate at the myocardial level is cardiomyocyte necrosis [NSTEMI-myocardial infarction (NSTEMI)] or, less frequently, myocardial ischaemia without cell loss (unstable angina). A small proportion of patients may present with ongoing myocardial ischaemia, characterized by one or more of the following: recurrent or ongoing chest pain, marked ST depression on 12-lead ECG, heart failure and haemodynamic or electrical instability. Due to the amount of myocardium in jeopardy and the risk of malignant ventricular arrhythmias, immediate coronary angiography and, if appropriate, revascularization are indicated.

2.1.1 Universal definition of myocardial infarction

Acute myocardial infarction (MI) defines cardiomyocyte necrosis in a clinical setting consistent with acute myocardial ischaemia.² A combination of criteria is required to meet the diagnosis of acute MI, namely the detection of an increase and/or decrease of a cardiac biomarker, preferably high-sensitivity cardiac troponin, with at least one value above the 99th percentile of the upper reference limit and at least one of the following:

- (1) Symptoms of ischaemia.
- (2) New or presumed new significant ST-T wave changes or left bundle branch block on 12-lead ECG.
- (3) Development of pathological Q waves on ECG.
- (4) Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
- (5) Intracoronary thrombus detected on angiography or autopsy.

2.1.1.1 Type 1 MI

Type 1 MI is characterized by atherosclerotic plaque rupture, ulceration, fissure, erosion or dissection with resulting intraluminal thrombus in one or more coronary arteries leading to decreased

myocardial blood flow and/or distal embolization and subsequent myocardial necrosis. The patient may have underlying severe coronary artery disease (CAD) but, on occasion (i.e. 5–20% of cases), there may be non-obstructive coronary atherosclerosis or no angiographic evidence of CAD, particularly in women.^{2–5}

2.1.1.2 Type 2 MI

Type 2 MI is myocardial necrosis in which a condition other than coronary plaque instability contributes to an imbalance between myocardial oxygen supply and demand.² Mechanisms include coronary artery spasm, coronary endothelial dysfunction, tachyarrhythmias, bradyarrhythmias, anaemia, respiratory failure, hypotension and severe hypertension. In addition, in critically ill patients and in patients undergoing major non-cardiac surgery, myocardial necrosis may be related to injurious effects of pharmacological agents and toxins.⁶

The universal definition of MI also includes type 3 MI (MI resulting in death when biomarkers are not available) and type 4 and 5 MI (related to percutaneous coronary intervention [PCI] and coronary artery bypass grafting [CABG], respectively).

2.1.2 Unstable angina in the era of high-sensitivity cardiac troponin assays

Unstable angina is defined as myocardial ischaemia at rest or minimal exertion in the absence of cardiomyocyte necrosis. Among unselected patients presenting with suspected NSTEMI-ACS to the emergency department, the introduction of high-sensitivity cardiac troponin measurements in place of standard troponin assays resulted in an increase in the detection of MI (~4% absolute and 20% relative increase) and a reciprocal decrease in the diagnosis of unstable angina.^{7–10} Compared with NSTEMI patients, individuals with unstable angina do not experience myocardial necrosis, have a substantially lower risk of death and appear to derive less benefit from intensified antiplatelet therapy as well as early invasive strategy.^{2–4,6–13}

2.1.3 Pathophysiology and epidemiology (see Web addenda)

3. Diagnosis

3.1 Clinical presentation

Anginal pain in NSTEMI-ACS patients may have the following presentations:

- Prolonged (>20 min) anginal pain at rest;
- New onset (de novo) angina (class II or III of the Canadian Cardiovascular Society classification);²¹
- Recent destabilization of previously stable angina with at least Canadian Cardiovascular Society Class III angina characteristics (crescendo angina); or
- Post-MI angina.

Prolonged and de novo/crescendo angina are observed in ~80% and ~20% of patients, respectively. Typical chest pain is characterized by a retrosternal sensation of pressure or heaviness ('angina') radiating to the left arm (less frequently to both arms or to the right arm), neck or jaw, which may be intermittent (usually lasting several minutes) or persistent. Additional symptoms such as sweating, nausea, abdominal pain, dyspnoea and syncope may be present. Atypical

presentations include epigastric pain, indigestion-like symptoms and isolated dyspnoea. Atypical complaints are more often observed in the elderly, in women and in patients with diabetes, chronic renal disease or dementia.^{22–24} The exacerbation of symptoms by physical exertion and their relief at rest increase the probability of myocardial ischaemia. The relief of symptoms after nitrates administration is not specific for anginal pain as it is reported also in other causes of acute chest pain.²⁴ In patients presenting with suspected MI to the emergency department, overall, the diagnostic performance of chest pain characteristics for MI is limited.²⁴ Older age, male gender, family history of CAD, diabetes, hyperlipidaemia, hypertension, renal insufficiency, previous manifestation of CAD as well as peripheral or carotid artery disease increase the likelihood of NSTEMI-ACS. Conditions that may exacerbate or precipitate NSTEMI-ACS include anaemia, infection, inflammation, fever, and metabolic or endocrine (in particular thyroid) disorders.

3.2 Physical examination

Physical examination is frequently unremarkable in patients with suspected NSTEMI-ACS. Signs of heart failure or haemodynamic or electrical instability mandate a quick diagnosis and treatment. Cardiac auscultation may reveal a systolic murmur due to ischaemic mitral regurgitation, which is associated with poor prognosis, or aortic

stenosis (mimicking ACS).²⁵ Rarely, a systolic murmur may indicate a mechanical complication (i.e. papillary muscle rupture or ventricular septal defect) of a subacute and possibly undetected MI. Physical examination may identify signs of non-coronary causes of chest pain (e.g. pulmonary embolism, acute aortic syndromes, myopericarditis, aortic stenosis) or extracardiac pathologies (e.g. pneumothorax, pneumonia or musculoskeletal diseases). In this setting, the presence of a chest pain that can be reproduced by exerting pressure on the chest wall has a relatively high negative predictive value for NSTEMI-ACS.^{24,26} According to the presentation, abdominal disorders (e.g. oesophageal spasm, oesophagitis, gastric ulcer, cholecystitis, pancreatitis) may also be considered in the differential diagnosis. Differences in blood pressure between the upper and lower limbs or between the arms, irregular pulse, jugular vein distension, heart murmurs, friction rub and pain reproduced by chest or abdominal palpation are findings suggestive of alternative diagnoses. Pallor, sweating or tremor may point towards precipitating conditions such as anaemia and thyrotoxicosis.²⁷

3.3 Diagnostic tools

3.3.1 Electrocardiogram

The resting 12-lead ECG is the first-line diagnostic tool in the assessment of patients with suspected ACS (Figure 1). It is recommended to




Figure 1 Initial assessment of patients with suspected acute coronary syndromes. The initial assessment is based on the integration of low-likelihood and/or high-likelihood features derived from clinical presentation (i.e., symptoms, vital signs), 12-lead ECG, and cardiac troponin. The proportion of the final diagnoses derived from the integration of these parameters is visualized by the size of the respective boxes. “Other cardiac” includes, among other, myocarditis, Tako-Tsubo cardiomyopathy, or tachyarrhythmias. “Non-cardiac” refers to thoracic diseases such as pneumonia or pneumothorax. Cardiac troponin should be interpreted as a quantitative marker: the higher the level, the higher the likelihood for the presence of myocardial infarction. In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin, echocardiography should be performed/interpreted by trained physicians immediately following a 12-lead ECG. If the initial evaluation suggests aortic dissection or pulmonary embolism, D-dimers and multi-detector computed tomography angiography are recommended according to dedicated algorithms.^{42,43}

Table 3 Clinical implications of high-sensitivity cardiac troponin assays

Compared with standard cardiac troponin assays, high-sensitivity assays:
• Have higher negative predictive value for acute MI.
• Reduce the "troponin-blind" interval leading to earlier detection of acute MI.
• Result in a ~4% absolute and ~20% relative increase in the detection of type I MI and a corresponding decrease in the diagnosis of unstable angina.
• Are associated with a 2-fold increase in the detection of type 2 MI.
Levels of high-sensitivity cardiac troponin should be interpreted as quantitative markers of cardiomyocyte damage (i.e. the higher the level, the greater the likelihood of MI):
• Elevations beyond 5-fold the upper reference limit have high (>90%) positive predictive value for acute type I MI.
• Elevations up to 3-fold the upper reference limit have only limited (50–60%) positive predictive value for acute MI and may be associated with a broad spectrum of conditions.
• It is common to detect circulating levels of cardiac troponin in healthy individuals.
Rising and/or falling cardiac troponin levels differentiate acute from chronic cardiomyocyte damage (the more pronounced the change, the higher the likelihood of acute MI).

MI = myocardial infarction.

obtain it within 10 min of the patient's arrival in the emergency room or, ideally, at first contact with emergency medical services in the pre-hospital setting and to have it immediately interpreted by a qualified physician.²⁸ While the ECG in the setting of NSTEMI-ACS may be normal in more than one-third of patients, characteristic abnormalities include ST depression, transient ST elevation and T-wave changes.^{1,18} If the standard leads are inconclusive and the patient has signs or symptoms suggestive of ongoing myocardial ischaemia, additional leads should be recorded; left circumflex artery occlusion or right ventricular MI may be detected only in V₇–V₉ and V_{3R} and V_{4R}, respectively.² In patients with suggestive signs and symptoms, the finding of persistent ST elevation indicates STEMI, which mandates immediate reperfusion.¹ Comparison with previous tracings is valuable, particularly in patients with pre-existing ECG abnormalities. It is recommended to obtain additional 12-lead ECGs in the case of persistent or recurrent symptoms or diagnostic uncertainty. In patients with bundle branch block or paced rhythm, ECG is of no help for the diagnosis of NSTEMI-ACS.

3.3.2 Biomarkers

Biomarkers complement clinical assessment and 12-lead ECG in the diagnosis, risk stratification and treatment of patients with suspected NSTEMI-ACS. Measurement of a biomarker of cardiomyocyte injury, preferably high-sensitivity cardiac troponin, is mandatory in all patients with suspected NSTEMI-ACS.^{2,6,8} Cardiac troponins are more sensitive and specific markers of cardiomyocyte injury than creatine kinase (CK), its MB isoenzyme (CK-MB) and myoglobin.⁶ If the clinical presentation is compatible with myocardial ischaemia, then a dynamic elevation of cardiac troponin above the 99th percentile of healthy individuals indicates MI.² In patients with MI, levels of cardiac troponin rise rapidly (i.e. usually within 1 h if using high-sensitivity assays) after symptom onset and remain elevated for a variable period of time (usually several days).^{2,6} Advances in technology have led to a refinement in cardiac troponin assays and have improved the ability to detect and quantify cardiomyocyte injury.^{2,6,8,10,29–37} In Europe,

Table 4 Conditions other than acute myocardial infarction type 1 associated with cardiac troponin elevation

Tachyarrhythmias
Heart failure
Hypertensive emergencies
Critical illness (e.g. shock/ sepsis/ burns)
Myocarditis ^a
Tako-Tsubo cardiomyopathy
Structural heart disease (e.g. aortic stenosis)
Aortic dissection
Pulmonary embolism, pulmonary hypertension
Renal dysfunction and associated cardiac disease
Coronary spasm
Acute neurological event (e.g. stroke or subarachnoid haemorrhage)
Cardiac contusion or cardiac procedures (CABG, PCI, ablation, pacing, cardioversion, or endomyocardial biopsy)
Hypo- and hyperthyroidism
Infiltrative diseases (e.g. amyloidosis, haemochromatosis, sarcoidosis, scleroderma)
Myocardial drug toxicity or poisoning (e.g. doxorubicin, 5-fluorouracil, herceptin, snake venoms)
Extreme endurance efforts
Rhabdomyolysis

Bold = most frequent conditions; CABG = coronary artery bypass surgery; PCI = percutaneous coronary intervention.

^aincludes myocardial extension of endocarditis or pericarditis.

the vast majority of cardiac troponin assays run on automated platforms and are sensitive (i.e. allow for detection of cardiac troponin in ~20–50% of healthy individuals) or high-sensitivity (detection in ~50–90% of healthy individuals) assays. High-sensitivity assays are recommended over less sensitive ones.^{2,6,8} The majority of currently used point-of-care assays cannot be considered sensitive or high-sensitivity assays.^{8,35} Therefore the obvious advantage of point-of-care tests, namely the shorter turnaround time, is counterbalanced by lower sensitivity, lower diagnostic accuracy and lower negative predictive value. Overall, automated assays have been more thoroughly evaluated as compared with point-of-care tests.^{2,6,8} As these techniques continue to improve and performance characteristics are both assay and hospital dependent, no recommendation regarding the site of measurement (central laboratory vs. bedside) can be given.^{2,6,8,38} Data from large multicentre studies have consistently shown that sensitive and high-sensitivity cardiac troponin assays increase diagnostic accuracy for MI at the time of presentation as compared with conventional assays, especially in patients presenting early after chest pain onset, and allow for a more rapid 'rule-in' and 'rule-out' of MI (see section 3.3.3 and Table 3).^{2,6,8,29–34}

In most patients with renal dysfunction, elevations in cardiac troponin should not be primarily attributed to impaired clearance and considered harmless, as cardiac conditions such as chronic coronary or hypertensive heart disease seem to be the most important contributor to troponin elevation in this setting.⁴¹ Other life-threatening conditions presenting with chest pain, such as aortic dissection and pulmonary embolism, may also result in elevated troponin levels and should be considered as differential diagnoses (Table 4).




Figure 2 0 h/3 h rule-out algorithm of non-ST-elevation acute coronary syndromes using high-sensitivity cardiac troponin assays.

Among the multitude of additional biomarkers evaluated for the diagnosis of NSTEMI-ACS, only CK-MB and copeptin seem to have clinical relevance.^{2,6,8,10,44–50} CK-MB shows a more rapid decline after MI as compared with cardiac troponin and may provide added value for the timing of myocardial injury and the detection of early reinfarction.^{2,6,8,10} Assessment of copeptin, the C-terminal part of the vasopressin prohormone, may quantify the endogenous stress level in multiple medical conditions including MI. As the level of endogenous stress appears to be invariably high at the onset of MI, the added value of copeptin to conventional (less sensitive) cardiac troponin assays is substantial.^{44–50} Therefore the routine use of copeptin as an additional biomarker for the early rule-out of MI is recommended whenever sensitive or high-sensitivity cardiac troponin assays are not available. Copeptin may have some added value even over high-sensitivity cardiac troponin in the early rule-out of MI.^{44–48}

3.3.3 ‘Rule-in’ and ‘rule-out’ algorithms

Due to the higher sensitivity and diagnostic accuracy for the detection of acute MI at presentation, the time interval to the second cardiac troponin assessment can be shortened with the use of high-sensitivity assays. This may reduce substantially the delay to diagnosis, translating into shorter stays in the emergency department and lower costs.^{2,6,8,10,29–36} It is recommended to use the 0 h/3 h algorithm (Figure 2). As an alternative, 0 h/1 h assessments are recommended when high-sensitivity cardiac troponin assays with a validated algorithm are available (Figure 3). The 0 h/1 h algorithms rely on two concepts: first, high-sensitivity cardiac troponin is a continuous variable and the probability of MI increases with increasing high-sensitivity cardiac troponin values;³⁹ second, early absolute changes of the levels within 1 h can be used as surrogates for




Figure 3 0 h/1 h rule-in and rule-out algorithms using high-sensitivity cardiac troponins (hs-cTn) assays in patients presenting with suspected non-ST-elevation myocardial infarction (NSTEMI) to the emergency department. 0 h and 1 h refer to the time from first blood test. NSTEMI can be ruled-out already at presentation, if the hs-cTn concentration is very low. NSTEMI can also be ruled-out by the combination of low baseline levels and the lack of a relevant increase within 1 h. Patients have a high likelihood for NSTEMI if the hs-cTn concentration at presentation is at least moderately elevated or hs-cTn concentrations show a clear rise within the first hour. Cut-off levels are assay-specific. Cut-off levels for other hs-cTn assays are in development.

absolute changes over 3 h or 6 h and provide incremental diagnostic value to the cardiac troponin assessment at presentation.³⁹ The cut-off levels within the 0 h/1 h algorithm are assay specific.^{36,39,51–55}

Those algorithms should always be integrated with a detailed clinical assessment and 12-lead ECG and repeat blood sampling is mandatory in case of ongoing or recurrent chest pain (Table 5, see Web addenda).

Table 5 (see Web addenda) Characteristics of the 0 h/3 h and 0 h/1 h algorithms

The negative predictive value for MI in patients assigned ‘rule-out’ exceeded 98% in several large validation cohorts.^{30–34,36,39,51–55} Used in conjunction with clinical and ECG findings, the 0 h/1 h algorithm may allow the identification of candidates for early discharge and outpatient management. The positive predictive value for MI in those patients meeting the ‘rule-in’ criteria was 75–80%.^{30–34,39,53–55} Most of the ‘rule-in’ patients with diagnoses other than MI did have conditions that usually require inpatient coronary angiography for accurate diagnosis, including Tako–Tsubo cardiomyopathy and myocarditis.^{39,53–55} Patients who do not qualify for ‘rule-out’ or ‘rule-in’ represent a heterogeneous group that may require further investigations if no alternative explanation for the cardiac troponin elevation is identified. A large proportion of these patients may require a further high-sensitivity cardiac troponin assessment (e.g. at 3 h). Coronary angiography should be considered in patients for whom there is a high degree of clinical suspicion of NSTEMI-ACS, while in patients with low to intermediate likelihood for this condition, computed tomography (CT) coronary angiography should be considered. No further diagnostic testing in the emergency department is indicated when alternative conditions such as rapid ventricular rate response to atrial fibrillation or hypertensive emergency have been identified.

For rapid rule-out, two alternative approaches to the 0 h/1 h or 0 h/3 h algorithms have been adequately validated and may be considered. First, a 2 h rule-out protocol combining the Thrombolysis in Myocardial Infarction (TIMI) risk score with ECG and high-sensitivity cardiac troponin at presentation allowed a safe rule-out in up to 40% of patients.^{56–58} Second, a dual-marker strategy combining normal levels of cardiac troponin together with low levels of copeptin (<10 pmol/L) at presentation showed very high negative predictive value for MI, obviating the need for serial testing in selected patients.^{44–50} When using any algorithm, three main caveats apply: (i) algorithms should only be used in conjunction with all available clinical information, including detailed assessment of chest pain characteristics and ECG; (ii) in patients presenting very early (e.g. within 1 h from chest pain onset), the second cardiac troponin level should be obtained at 3 h, due to the time dependency of troponin release; (iii) as late increases in cardiac troponin have been described in ~1% of patients, serial cardiac troponin testing should be pursued if the clinical suspicion remains high or whenever the patient develops recurrent chest pain.^{52,54} High-sensitivity cardiac troponin assays also maintain high diagnostic accuracy in patients with renal dysfunction. To ensure the best possible clinical use, assay-specific optimal cut-off levels, which are higher in patients with renal dysfunction, should be used.⁵⁹

3.3.4 Non-invasive imaging

3.3.4.1 Functional evaluation

Transthoracic echocardiography should be routinely available in emergency rooms and chest pain units and performed/interpreted

by trained physicians in all patients during hospitalization for NSTEMI-ACS. This imaging modality is useful to identify abnormalities suggestive of myocardial ischaemia or necrosis (i.e. segmental hypokinesia or akinesia). In the absence of significant wall motion abnormalities, impaired myocardial perfusion detected by contrast echocardiography or reduced regional function using strain and strain rate imaging might improve the diagnostic and prognostic value of conventional echocardiography.^{60,61} Moreover, echocardiography can help in detecting alternative pathologies associated with chest pain, such as acute aortic dissection, pericardial effusion, aortic valve stenosis, hypertrophic cardiomyopathy or right ventricular dilatation suggestive of acute pulmonary embolism. Similarly, echocardiography is the diagnostic tool of choice for patients with haemodynamic instability of suspected cardiac origin.⁶² Evaluation of left ventricular (LV) systolic function, at the latest by the time of hospital discharge, is important to estimate prognosis, and echocardiography (as well as other imaging modalities) can provide this information.

In patients without ischaemic changes on 12-lead ECGs and negative cardiac troponins (preferably high-sensitivity) who are free of chest pain for several hours, stress imaging can be performed during admission or shortly after discharge. Stress imaging is preferred over exercise ECG due to its greater diagnostic accuracy.⁶³ Various studies have shown that normal exercise, dobutamine or dipyridamole stress echocardiograms have high negative predictive value for ischaemia and are associated with excellent patient outcomes.^{64,65} Moreover, stress echocardiography demonstrated superior prognostic value over exercise ECG.^{64,66} The addition of contrast may improve endocardial border detection, which may facilitate detection of ischaemia.⁶⁷

Cardiac magnetic resonance (CMR) can assess both perfusion and wall motion abnormalities, and patients presenting with acute chest pain with a normal stress CMR have an excellent short- and midterm prognosis.⁶⁸ CMR also permits detection of scar tissue (using late gadolinium enhancement) and can differentiate this from recent infarction (using T2-weighted imaging to delineate myocardial oedema).^{69,70} Moreover, CMR can facilitate the differential diagnosis between infarction and myocarditis or Tako–Tsubo cardiomyopathy.⁷¹ Similarly, nuclear myocardial perfusion imaging has been shown to be useful for risk stratification of patients with acute chest pain suggestive for ACS. Resting myocardial scintigraphy, by detecting fixed perfusion defects suggestive of myocardial necrosis, can be helpful for initial triage of patients presenting with chest pain without ECG changes or elevated cardiac troponins.⁷² Combined stress–rest imaging may further enhance assessment of ischaemia, while a normal study is associated with excellent outcome.^{73,74} Stress–rest imaging modalities are usually not widely available on 24 h service.

3.3.4.2 Anatomical evaluation

Multidetector computed tomography (MDCT) allows for visualization of the coronary arteries and a normal scan excludes CAD. A meta-analysis of nine studies ($n = 1349$ patients) has reported overall high negative predictive values to exclude ACS (by excluding CAD) and excellent outcome in patients presenting to the emergency department with low to intermediate pre-test probability for ACS and a normal coronary CT angiogram.⁷⁵ Four randomized controlled trials (RCTs) have tested MDCT ($n = 1869$ patients) vs.

usual care ($n = 1397$) in the triage of low- to intermediate-risk patients presenting with acute chest pain to emergency departments without signs of ischaemia on ECG and/or inconclusive cardiac troponins.^{76–79} At a follow-up of 1–6 months, there were no deaths, and a meta-analysis demonstrated comparable outcomes with the two approaches (i.e. no difference in the incidence of MI, post-discharge emergency department visits or rehospitalizations) and showed that MDCT was associated with a reduction in emergency department costs and length of stay.⁸⁰ However, none of these studies used high-sensitivity cardiac troponin assays, which also may reduce hospital stay. It was also noted that MDCT was associated with an increase in the use of invasive angiography {8.4% vs. 6.3%; odds ratio [OR] 1.36 [95% confidence interval (CI) 1.03, 1.80], $P = 0.030$ }.⁸⁰ Accordingly, MDCT coronary angiography can be used to exclude CAD (and MDCT is thus not useful in patients with known CAD). Other factors limiting MDCT coronary angiography include severe calcifications (high calcium score) and elevated or irregular heart rate; in addition, a sufficient level of expertise is needed and 24 h service is currently not widely available. Finally, the use of MDCT coronary angiography in the acute setting in patients with stents or previous CABG has not been validated. Importantly, CT imaging can effectively exclude other causes of acute chest pain that, if untreated, are associated with high mortality, namely pulmonary embolism, aortic dissection and tension pneumothorax.⁸¹

3.4 Differential diagnosis

Among unselected patients presenting with acute chest pain to the emergency department, disease prevalence can be expected to be the following: 5–10% STEMI, 15–20% NSTEMI, 10% unstable angina, 15% other cardiac conditions and 50% non-cardiac diseases.^{48,51,52,56–58} Several cardiac and non-cardiac conditions may mimic NSTEMI-ACS (Table 6).

Conditions that should always be considered in the differential diagnosis of NSTEMI-ACS, because they are potentially life-threatening but also treatable, include aortic dissection, pulmonary embolism and tension pneumothorax. Echocardiography should be performed urgently in all patients with haemodynamic instability of suspected cardiovascular (CV) origin.⁶²

Chest X-ray is recommended in all patients in whom NSTEMI-ACS is considered unlikely in order to detect pneumonia, pneumothorax, rib fractures or other thoracic disorders. Tako-Tsubo cardiomyopathy

and coronary artery spasm are briefly described in section 5.6.4.2, Web addenda. Stroke may be accompanied by ECG changes, myocardial wall motion abnormalities and an increase in cardiac troponin levels.^{2,6} The majority of patients presenting with acute chest pain to the emergency department have non-cardiac conditions causing the chest discomfort. In many instances the pain is musculoskeletal, and therefore benign, self-limiting and does not require hospitalization. Chest pain characteristics help to some extent in the early identification of those patients.²⁴

4. Risk assessment and outcomes

4.1 Clinical presentation, electrocardiogram and biomarkers

4.1.1 Clinical presentation

In addition to some universal clinical markers of risk, such as advanced age, diabetes and renal insufficiency, the initial clinical presentation is highly predictive of early prognosis.⁸² Chest pain at rest carries a worse prognosis than symptoms elicited during physical exertion. In patients with intermittent symptoms, an increasing number of episodes preceding the index event also adversely affects prognosis. Tachycardia, hypotension, heart failure and new mitral regurgitation at presentation predict poor prognosis and call for rapid diagnosis and management.^{25,82–84}

4.1.2 Electrocardiogram

The initial ECG is predictive of early risk.¹⁸ Patients with ST depression have a worse prognosis than patients with a normal ECG.^{85,86} The number of leads showing ST depression and the magnitude of ST depression are indicative of the extent of ischaemia and correlate with prognosis on the one hand, and benefit from an invasive treatment strategy on the other.⁸⁷ ST depression ≥ 0.05 mV in two or more contiguous leads, in the appropriate clinical context, is suggestive of NSTEMI-ACS and linked to adverse prognosis.⁸⁵ ST depression combined with transient ST elevation identifies a high-risk subgroup,⁸⁸ while associated T-wave inversion does not alter the prognostic value of ST depression. While isolated T-wave inversion on admission has not been associated with worse prognosis compared with the absence of ECG abnormalities, it frequently triggers a more rapid diagnosis and treatment.⁸⁶

Table 6 Differential diagnoses of acute coronary syndromes in the setting of acute chest pain

Cardiac	Pulmonary	Vascular	Gastro-intestinal	Orthopaedic	Other
Myopericarditis Cardiomyopathies ^a	Pulmonary embolism	Aortic dissection	Oesophagitis, reflux or spasm	Musculoskeletal disorders	Anxiety disorders
Tachyarrhythmias	(Tension)-Pneumothorax	Symptomatic aortic aneurysm	Peptic ulcer, gastritis	Chest trauma	Herpes zoster
Acute heart failure	Bronchitis, pneumonia	Stroke	Pancreatitis	Muscle injury/ inflammation	Anaemia
Hypertensive emergencies	Pleuritis		Cholecystitis	Costochondritis	
Aortic valve stenosis				Cervical spine pathologies	
Tako-Tsubo cardiomyopathy					
Coronary spasm					
Cardiac trauma					

Bold = common and/or important differential diagnoses.

^aDilated, hypertrophic and restrictive cardiomyopathies may cause angina or chest discomfort.

4.1.3 Biomarkers

Beyond diagnostic utility, cardiac troponin levels add prognostic information in terms of short- and long-term mortality to clinical and ECG variables. While high-sensitivity cardiac troponin T and I seem to have comparable diagnostic accuracy, high-sensitivity cardiac troponin T has greater prognostic accuracy.^{89,90} The higher the high-sensitivity troponin levels at presentation, the greater the risk of death.^{6,8,10,39} Multiple biomarkers have been associated with mortality in NSTEMI-ACS, several of them conferring additive prognostic value to cardiac troponin.^{8,48–50} Serum creatinine and estimated glomerular filtration rate (eGFR) should also be determined in all patients with NSTEMI-ACS because they affect prognosis and are key elements of the Global Registry of Acute Coronary Events (GRACE 2.0) risk calculation (see section 4.2). The extensively validated natriuretic peptides (i.e. B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide and midregional pro-A-type natriuretic peptide) provide prognostic information on top of cardiac troponin.⁹¹ To some extent, the same applies to high-sensitivity C-reactive protein and novel biomarkers such as midregional pro-adrenomedullin, growth differentiation factor 15 and copeptin. However, the assessment of these markers has so far not been shown to improve patient management and their added value in risk assessment on top of the GRACE 2.0 risk calculation seems marginal. Therefore the routine use of these biomarkers for prognostic purposes cannot be recommended at the present time.

4.2 Ischaemic risk assessment

In NSTEMI-ACS, quantitative assessment of ischaemic risk by means of scores is superior to the clinical assessment alone. The GRACE risk score provides the most accurate stratification of risk both on admission and at discharge.^{92,93} The GRACE 2.0 risk calculator (<http://www.gracescore.org/WebSite/default.aspx?ReturnUrl=%2f>) provides a direct estimation, bypassing the calculation of a score, of mortality while in hospital, at 6 months, at 1 year and at 3 years. The combined risk of death or MI at 1 year is also provided.⁹⁴ Variables used in the GRACE 2.0 risk calculation include age, systolic blood pressure, pulse rate, serum creatinine, Killip class at presentation, cardiac arrest at admission, elevated cardiac biomarkers and ST deviation. If the Killip class or serum creatinine values are not available, a modified score can be calculated by adding renal failure and use of diuretics, respectively. The TIMI risk score uses seven variables in an additive scoring system: age ≥ 65 years, three or more CAD risk factors, known CAD, aspirin use in the past 7 days, severe angina (two or more episodes within 24 h), ST change ≥ 0.5 mm and positive cardiac marker (<http://www.timi.org/index.php?page=calculators>).⁸² It is simple to use, but its discriminative accuracy is inferior to that of the GRACE risk score and the GRACE 2.0 risk calculation. While the value of risk scores as prognostic assessment tools is undisputed, the impact of risk score implementation on patient outcomes has not been adequately investigated.^{95,96}

4.2.1 Acute risk assessment

Patients with suspected NSTEMI-ACS must be evaluated rapidly in order to identify individuals with ongoing myocardial ischaemia who are at risk of life-threatening arrhythmias and need close surveillance as well as immediate coronary angiography. Patients with suspected NSTEMI-ACS should be observed in interdisciplinary emergency departments or chest pain units until the diagnosis of MI is confirmed or ruled

out. The greatest challenge is the integration of clinical presentation with information derived from ECG, troponin assessment and imaging modalities into a standardised management strategy.⁹⁷ Assessment of acute risk guides initial evaluation, selection of the site of care (i.e. coronary or intensive care unit, intermediate care unit, inpatient monitored unit or regular unit) and therapy, including antithrombotic treatment and timing of coronary angiography. Risk is highest at the time of presentation and may remain elevated for several days, although rapidly declining over time, depending on clinical presentation, comorbidities, coronary anatomy and revascularization.⁹⁸ The estimated risk should be communicated to the patient and their family.

4.2.2 Cardiac rhythm monitoring

Early revascularization as well as the use of antithrombotic agents and beta-blockers have markedly reduced the incidence of life-threatening arrhythmias in the acute phase to $<3\%$, with most of the arrhythmic events occurring within 12 h of symptom onset.^{99,100} Patients with life-threatening arrhythmias more frequently had prior heart failure, LV ejection fraction (LVEF) $<30\%$ and triple-vessel CAD. A patient with NSTEMI-ACS who presents early after symptom onset, has no or mild to moderate cardiac biomarker elevation, normal LV function and single-vessel CAD successfully treated with PCI may be discharged the next day. At the other end of the spectrum are NSTEMI-ACS patients with multivessel CAD in whom complete revascularization may not be achieved in one session (or at all); these patients may have a complicated course (e.g. heart failure) or prior cardiac disease, major comorbidities, advanced age or recent extensive myocardial necrosis.^{101,102} Cardiac troponin-negative (i.e. unstable angina) patients without recurrent or ongoing symptoms and with normal ECG do not necessarily require rhythm monitoring or hospital admission.

NSTEMI patients at low risk for cardiac arrhythmias require rhythm monitoring for ≤ 24 h or until coronary revascularization (whichever comes first) in an intermediate or coronary care unit, while individuals at intermediate to high risk for cardiac arrhythmia may require rhythm monitoring for >24 h in an intensive or coronary care unit or in an intermediate care unit, depending on the clinical presentation, degree of revascularization and early post-revascularization course (Table 7). It is recommended that personnel adequately equipped and trained to manage life-threatening

Table 7 Recommended unit and duration of monitoring according to clinical presentation after established NSTEMI-ACS diagnosis

Clinical Presentation	Unit	Rhythm monitoring
Unstable angina	Regular ward or discharge	None
NSTEMI at low risk for cardiac arrhythmias ^a	Intermediate care unit or coronary care unit	≤ 24 h
NSTEMI at intermediate to high risk for cardiac arrhythmias ^b	Intensive/coronary care units or intermediate care unit	>24 h

NSTEMI = Non-ST-elevation myocardial infarction.

^aIf none of the following criteria: haemodynamically unstable, major arrhythmias, left ventricular ejection fraction $<40\%$, failed reperfusion, additional critical coronary stenoses of major vessels or complications related to percutaneous revascularization.

^bIf one or more of the above criteria are present.

arrhythmias and cardiac arrest accompany patients who are transferred between facilities during the time window in which they require continuous rhythm monitoring.

4.2.3 Long-term risk

In addition to short-term risk factors, a number of conditions are associated with long-term risk, including a complicated clinical course, LV systolic dysfunction, atrial fibrillation, severity of CAD, revascularization status, evidence of residual ischaemia on non-invasive testing and non-cardiac comorbidities. At 1 year, the rates of death, MI and recurrent ACS in contemporary NSTEMI-ACS registries are >10%. While early events are related to ruptured coronary plaques and associated thrombosis, the majority of later events may be the result of coronary and systemic atherosclerosis progression.^{98,103}

4.3 Bleeding risk assessment

Major bleeding events are associated with increased mortality in NSTEMI-ACS.^{104,105} Bleeding risk scores have been developed from registry or trial cohorts in the setting of ACS and PCI. The Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) bleeding risk score (<http://www.crusadebleedingscore.org>) was developed from a cohort of 71 277 NSTEMI-ACS patients (derivation cohort) and further validated in a cohort of 17 857 patients (validation cohort) from the same registry.¹⁰⁶ The CRUSADE bleeding risk score considered baseline patient characteristics (i.e. female gender, history of diabetes, history of peripheral vascular disease or stroke), admission clinical variables (i.e. heart rate, systolic blood pressure, signs of heart failure) and admission laboratory values (i.e. haematocrit, calculated creatinine clearance) to estimate the patient's likelihood of an in-hospital major bleeding event. However, model performance for the risk score was modest (C-statistic 0.68 in patients treated conservatively and 0.73 in patients undergoing invasive approach).

The Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) bleeding risk score was derived from a pooled cohort of 17 421 patients with ACS (both NSTEMI-ACS and STEMI) recruited in the ACUITY and Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trials.¹⁰⁴ Six independent baseline predictors (i.e. female gender, advanced age, elevated serum creatinine, white blood cell count, anaemia and presentation as NSTEMI or STEMI) and one treatment-related variable [use of unfractionated heparin (UFH) and a glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor rather than bivalirudin alone] were identified. This risk score identified patients at increased risk for non-CABG-related major bleeds at 30 days and subsequent 1 year mortality. However, it has not been validated in an independent cohort, no risk calculator is available and model performance for the risk score is modest (C-statistic 0.74). Changes in interventional practice, such as increasing use of radial access, reduction in the dose of UFH, use of bivalirudin, diminished use of GPIIb/IIIa inhibitors and administration of more effective inhibitors of the platelet adenosine diphosphate (ADP) receptor P2Y₁₂ (P2Y₁₂ inhibitors), may all modify the predictive value of risk scores. Ischaemic and bleeding risks need to be weighed in the individual patient, although many of the predictors of ischaemic events are also associated with bleeding complications.^{104,106} Overall, CRUSADE and ACUITY scores have reasonable predictive value for major bleeding in ACS patients undergoing

coronary angiography, with CRUSADE found to be the most discriminatory.¹⁰⁷ However, in patients medically treated or on oral anticoagulants, the predictive value of these scores is not established. Moreover, the impact on patient outcomes of integrating these scores has not been investigated. Given these limitations, use of the CRUSADE bleeding risk score may be considered in patients undergoing coronary angiography to quantify bleeding risk.

4.4 Recommendations for diagnosis, risk stratification, imaging and rhythm monitoring in patients with suspected non-ST-elevation acute coronary syndromes

Recommendations for diagnosis, risk stratification, imaging and rhythm monitoring in patients with suspected non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
Diagnosis and risk stratification			
It is recommended to base diagnosis and initial short-term ischaemic and bleeding risk stratification on a combination of clinical history, symptoms, vital signs, other physical findings, ECG and laboratory results.	I	A	28, 109–112
It is recommended to obtain a 12-lead ECG within 10 min after first medical contact and to have it immediately interpreted by an experienced physician. It is recommended to obtain an additional 12-lead ECG in case of recurrent symptoms or diagnostic uncertainty.	I	B	28
Additional ECG leads (V _{3R} , V _{4R} , V ₇ –V ₉) are recommended if ongoing ischaemia is suspected when standard leads are inconclusive.	I	C	
It is recommended to measure cardiac troponins with sensitive or high-sensitivity assays and obtain the results within 60 min.	I	A	6, 30–36, 39, 51–59, 108
A rapid rule-out protocol at 0 h and 3 h is recommended if high-sensitivity cardiac troponin tests are available.	I	B	6, 30–36, 39, 51–59, 108
A rapid rule-out and rule-in protocol at 0 h and 1 h is recommended if a high-sensitivity cardiac troponin test with a validated 0 h/1 h algorithm is available. Additional testing after 3–6 h is indicated if the first two troponin measurements are not conclusive and the clinical condition is still suggestive of ACS.	I	B	30–34, 36, 39, 51–55
It is recommended to use established risk scores for prognosis estimation.	I	B	84, 94, 106

The use of the CRUSADE score may be considered in patients undergoing coronary angiography to quantify bleeding risk.	IIb	B	106, 107
Imaging			
In patients with no recurrence of chest pain, normal ECG findings and normal levels of cardiac troponin (preferably high-sensitivity), but suspected ACS, a non-invasive stress test (preferably with imaging) for inducible ischaemia is recommended before deciding on an invasive strategy.	I	A	64,74, 113, 114
Echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses. ^d	I	C	
MDCT coronary angiography should be considered as an alternative to invasive angiography to exclude ACS when there is a low to intermediate likelihood of CAD and when cardiac troponin and/or ECG are inconclusive.	IIa	A	80
Monitoring			
Continuous rhythm monitoring is recommended until the diagnosis of NSTEMI is established or ruled out.	I	C	101
It is recommended to admit NSTEMI patients to a monitored unit.	I	C	99,100
Rhythm monitoring up to 24 h or PCI (whichever comes first) should be considered in NSTEMI patients at low risk for cardiac arrhythmias. ^e	IIa	C	
Rhythm monitoring for >24 h should be considered in NSTEMI patients at intermediate to high-risk for cardiac arrhythmias. ^f	IIa	C	
In the absence of signs or symptoms of ongoing ischaemia, rhythm monitoring in unstable angina may be considered in selected patients (e.g. suspicion of coronary spasm or associated symptoms suggestive of arrhythmic events).	IIb	C	

ACS = acute coronary syndromes; CAD = coronary artery disease; ECG = electrocardiogram; LV = left ventricular; MDCT = multidetector computed tomography; NSTEMI = non-ST-elevation myocardial infarction; PCI = percutaneous coronary intervention. 0 h = time of first blood test; 1 h, 3 h = 1 or 3 h after the first blood test.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

^dDoes not apply to patients discharged the same day in whom NSTEMI has been ruled out.

^eIf none of the following criteria: haemodynamically unstable, major arrhythmias, left ventricular ejection fraction <40%, failed reperfusion, additional critical coronary stenoses of major vessels or complications related to percutaneous revascularization.

^fIf one or more of the above criteria are present.

5. Treatment

5.1 Pharmacological treatment of ischaemia

5.1.1 General supportive measures

The goal of pharmacological anti-ischaemic therapy is to decrease myocardial oxygen demand (secondary to a decrease in heart rate, blood pressure, preload or myocardial contractility) or to increase myocardial oxygen supply (by administration of oxygen or through coronary vasodilation). If, following treatment, the patient does not rapidly become free of ischaemic signs or symptoms, immediate coronary angiography is recommended independently of ECG findings and cardiac troponin levels. While data in NSTEMI-ACS are lacking, a randomized comparison of oxygen vs. air administration in 441 normo-oxygenated patients with STEMI showed no benefit and possibly harm associated with oxygen administration. Oxygen should be administered when blood oxygen saturation is <90% or if the patient is in respiratory distress.¹¹⁵ In patients whose ischaemic symptoms are not relieved by nitrates and beta-blockers, opiate administration is reasonable while waiting for immediate coronary angiography, with the caveat that morphine may slow intestinal absorption of oral platelet inhibitors.

5.1.2 Nitrates

Intravenous nitrates are more effective than sublingual nitrates with regard to symptom relief and regression of ST depression. Under careful blood pressure monitoring, the dose should be titrated upwards until symptoms are relieved, and in hypertensive patients until blood pressure is normalized, unless side effects (notably headache or hypotension) occur. Beyond symptom control, there is no indication for nitrate treatment.¹¹⁶ In patients with recent intake of a phosphodiesterase type 5 inhibitor (i.e. within 24 h for sildenafil or vardenafil and 48 h for tadalafil), nitrates should not be administered due to the risk of severe hypotension.¹¹⁷

5.1.3 Beta-blockers

Beta-blockers competitively inhibit the myocardial effects of circulating catecholamines and reduce myocardial oxygen consumption by lowering heart rate, blood pressure and myocardial contractility. The evidence for the beneficial effects of beta-blockers in NSTEMI-ACS is derived from a meta-analysis of 27 early studies showing that beta-blocker treatment was associated with a significant 13% relative risk reduction (RRR) of mortality in the first week following MI.¹¹⁸ In addition, a later meta-analysis comprising 73 396 patients with ACS showed an 8% RRR ($P = 0.04$) for in-hospital mortality associated with beta-blockade, with no increase in cardiogenic shock.¹¹⁹ A registry study of 21 822 NSTEMI patients found that in patients at risk of developing cardiogenic shock (i.e. age >70 years, heart rate >110 beats/min, systolic blood pressure <120 mmHg) the observed shock or death rate was significantly increased in patients receiving beta-blockers within 24 h of hospital admission.¹²⁰ Therefore early administration of beta-blockers should be avoided in these patients if the ventricular function is unknown. Beta-blockers should not be administered in patients with symptoms possibly related to coronary vasospasm or cocaine use, as they might favour spasm by leaving alpha-mediated vasoconstriction unopposed by beta-mediated vasodilation.

5.1.4 Other drug classes (see Web addenda)

5.1.5 Recommendations for anti-*ischaemic* drugs in the acute phase of non-ST-elevation acute coronary syndromes

Recommendations for anti-*ischaemic* drugs in the acute phase of non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
Early initiation of beta-blocker treatment is recommended in patients with ongoing <i>ischaemic</i> symptoms and without contraindications.	I	B	119
It is recommended to continue chronic beta-blocker therapy, unless the patient is in Killip class III or higher.	I	B	126
Sublingual or i.v. nitrates are recommended to relieve angina; ^d i.v. treatment is recommended in patients with recurrent angina, uncontrolled hypertension or signs of heart failure.	I	C	
In patients with suspected/confirmed vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided.	IIa	B	127

i.v. = intravenous.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

^dShould not be administered in patients with recent intake of sildenafil or vardenafil (<24 h) or tadalafil (<48 h).

5.2 Platelet inhibition

5.2.1 Aspirin

Aspirin (acetylsalicylic acid) irreversibly inactivates the cyclooxygenase (COX) activity of platelet prostaglandin endoperoxide (PGH) synthase 1 (COX-1), thereby suppressing thromboxane A₂ production throughout the platelet lifespan.¹²⁸ Aspirin has been shown to be effective in patients with unstable angina; the incidence of MI or death was consistently reduced in four RCTs in the pre-PCI era.^{129–132} A meta-analysis of these trials suggests that aspirin administration (up to 2 years) is associated with a highly significant 46% odds reduction in major vascular events.¹³³ The Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events—Seventh Organization to Assess Strategies in *Ischaemic* Syndromes (CURRENT-OASIS 7), which enrolled 25 086 ACS (both NSTEMI-ACS and STEMI) patients undergoing invasive strategy, found no difference between higher-dose (300–325 mg/day) and lower-dose (75–100 mg/day) aspirin.¹³⁴ An oral loading dose (150–300 mg) of plain aspirin (non-enteric-coated formulation) is recommended, while the recommended intravenous (i.v.) dose is 150 mg. No monitoring of its effects is required. The mechanisms of action of antiplatelet and anticoagulant agents are described in *Figure 4*.

5.2.2 P2Y₁₂ inhibitors


5.2.2.1 Clopidogrel

Clopidogrel (300–600 mg loading and 75 mg/day maintenance dose) is an inactive prodrug that requires oxidation by the hepatic

cytochrome P450 (CYP) system to generate an active metabolite (*Table 8*). An estimated 85% of the prodrug is hydrolysed by esterases into an inactive form, leaving only 15% of clopidogrel available for transformation to the active metabolite, which selectively and irreversibly inactivates platelet P2Y₁₂ receptors and thus inhibits ADP-induced platelet aggregation.^{135,136} Dual antiplatelet therapy (DAPT) comprising aspirin and clopidogrel has been shown to reduce recurrent *ischaemic* events in the NSTEMI-ACS setting compared with aspirin alone.^{137,138} However, up to 10% of patients treated with the combination of aspirin and clopidogrel will have a recurrent *ischaemic* event in the first year after an ACS, with a rate of stent thrombosis of up to 2%.¹³⁹ This residual risk may be partly explained by suboptimal platelet inhibition due to inadequate response to clopidogrel. Indeed, pharmacodynamic and pharmacokinetic studies have described substantial interindividual variability in the antiplatelet response to this drug and an increased risk of *ischaemic* and bleeding events in clopidogrel hypo- and hyper-responders, respectively.^{140–143} There is evidence that key gene polymorphisms are involved in both the variability of active metabolite generation and clinical efficacy of clopidogrel.^{144–147}

5.2.2.2 Prasugrel

Prasugrel (60 mg loading and 10 mg/day maintenance dose) is a prodrug that irreversibly blocks platelet P2Y₁₂ receptors with a faster onset and a more profound inhibitory effect than clopidogrel (*Table 8*). This compound has been tested against the 300 mg loading and 75 mg/day maintenance dose of clopidogrel in the TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel—Thrombolysis In Myocardial Infarction (TRITON-TIMI 38), in which ACS patients (STEMI and NSTEMI-ACS) scheduled for PCI received the drugs during or after the procedure.¹⁴⁸ In the 10 074 NSTEMI-ACS patients included, recurrent CV events were reduced in prasugrel-treated patients at the 15-month follow-up [from 11.2% to 9.3%; relative risk (RR) 0.82 (95% CI 0.73, 0.93), *P* = 0.002], driven by a significant reduction in MI [from 9.2% to 7.1%; RRR 23.9% (95% CI 12.7, 33.7), *P* < 0.001]. Severe bleeding complications were more common with prasugrel [TIMI non-CABG major bleeds 2.4% vs. 1.8%; hazard ratio (HR) 1.40 (95% CI 1.05, 1.88), *P* = 0.02], due to an increase in spontaneous bleeds [1.6% vs. 1.1%; HR 1.51 (95% CI 1.09, 2.08), *P* = 0.01] and fatal bleeds [0.4% vs. 0.1%; HR 4.19 (95% CI 1.58, 11.11), *P* = 0.002].¹⁴⁹ Bleeding events were increased by more than four-fold in prasugrel-treated patients referred for early CABG. Based on the marked reduction in definite or probable stent thrombosis observed in the TRITON-TIMI 38 overall [1.13% in the prasugrel arm vs. 2.35% in the clopidogrel arm; HR 0.48 (95% CI 0.36, 0.64), *P* < 0.0001] and in patients with drug-eluting stents (DESs) [0.84% vs. 2.31%, respectively; HR 0.36 (95% CI 0.22, 0.58), *P* < 0.0001], prasugrel should be considered in patients who present with stent thrombosis despite compliance with clopidogrel therapy.^{150,151} Prasugrel is contraindicated in patients with prior stroke/transient *ischaemic* attack (TIA) due to evidence of net harm in this group in TRITON-TIMI 38. In addition, the study showed no apparent benefit in patients >75 years of age or with low bodyweight (<60 kg).¹⁴⁸ The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial is discussed in section 5.6.4.1.1.



Downloaded from <http://eurheartj.oxfordjournals.org/> by guest on December 9, 2015

Figure 4 Antithrombotic drugs for non-ST-elevation acute coronary syndromes. The figure depicts the targets of available antithrombotic drugs that can be used to inhibit blood coagulation and platelet aggregation during and after thrombus formation.

5.2.2.3 Ticagrelor

Ticagrelor is an oral, reversibly binding P2Y₁₂ inhibitor with a plasma half-life of 6–12 h. Ticagrelor also inhibits adenosine reuptake via equilibrative nucleoside transporter 1 (ENT1) (Table 8). Like prasugrel, ticagrelor has a more rapid and consistent onset of action compared with clopidogrel, as well as a faster offset of action with more rapid recovery of platelet function.¹⁵² Ticagrelor increases levels of

drugs metabolized through CYP3A, such as simvastatin, while moderate CYP3A inhibitors, such as diltiazem, increase ticagrelor plasma levels and might delay the offset of effect. In the PLATElet inhibition and patient Outcomes (PLATO) trial, 18 624 patients with moderate- to high-risk NSTEMI-ACS (planned for either conservative or invasive management) or STEMI were randomized to either clopidogrel 75 mg/day, with a loading dose of 300–600 mg, or

Table 8 P2Y₁₂ inhibitors

	Clopidogrel	Prasugrel	Ticagrelor	Cangrelor
Chemical class	Thienopyridine	Thienopyridine	Cyclopentyl-triazolopyrimidine	Stabilized ATP analogue
Administration	Oral	Oral	Oral	Intravenous
Dose	300–600 mg orally then 75 mg a day	60 mg orally then 10 mg a day	180 mg orally then 90 mg twice a day	30 µg/kg bolus and 4 µg/kg/min infusion
Dosing in CKD				
• Stage 3 (eGFR 30–59 mL/min/1.73m ²)	No dose adjustment	No dose adjustment	No dose adjustment	No dose adjustment
• Stage 4 (eGFR 15–29 mL/min/1.73m ²)	No dose adjustment	No dose adjustment	No dose adjustment	No dose adjustment
• Stage 5 (eGFR <15 mL/min/1.73m ²)	Use only for selected indications (e.g. stent thrombosis prevention)	Not recommended	Not recommended	No dose adjustment
Binding reversibility	Irreversible	Irreversible	Reversible	Reversible
Activation	Prodrug, with variable liver metabolism	Prodrug, with predictable liver metabolism	Active drug, with additional active metabolite	Active drug
Onset of loading dose effect^a	2–6 hours ^b	30 min ^b	30 min ^b	2 min
Duration of effect	3–10 days	7–10 days	3–5 days	1–2 hours
Withdrawal before surgery	5 days ^c	7 days ^c	5 days ^c	1 hour
Plasma half-life of active P2Y₁₂ inhibitor^d	30–60 min	30–60 min ^e	6–12 hours	5–10 min
Inhibition of adenosine reuptake	No	No	Yes	Yes ('inactive' metabolite only)

ADP = adenosine diphosphate; ATP = adenosine triphosphate; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate.

^a50% inhibition of ADP-induced platelet aggregation.

^bOnset of effect may be delayed if intestinal absorption is delayed (e.g. by opiate).

^cShortening may be considered if indicated by platelet function tests and low bleeding risk.

^dAffecting the response to platelet transfusion.

^eThe distribution phase half-life is reported since it most likely reflects duration of clinically-relevant plasma levels, while the corresponding elimination phase half-life is approximately 7 hours.

ticagrelor 180 mg loading dose followed by 90 mg twice a day.¹⁵³ Patients undergoing PCI were allowed to receive an additional blinded 300 mg loading dose of clopidogrel (total loading dose 600 mg) or its placebo. Treatment was continued for up to 12 months, with a median duration of drug exposure of 9 months.¹⁵³ In the NSTEMI-ACS subgroup ($n = 11\,080$), the primary composite efficacy endpoint (death from CV causes, MI or stroke) was significantly reduced with ticagrelor compared with clopidogrel [10.0% vs. 12.3%; HR 0.83 (95% CI 0.74, 0.93), $P = 0.0013$] with similar reductions for CV death [3.7% vs. 4.9%; HR 0.77 (95% CI 0.64, 0.93), $P = 0.0070$] and all-cause mortality [4.3% vs. 5.8%; HR 0.76 (95% CI 0.64, 0.90), $P = 0.0020$].¹⁵⁴ Differences in bleeding event rates were also similar in the NSTEMI-ACS subgroup compared with the overall study, with increased risk of non-CABG-related PLATO-defined major bleeds with ticagrelor compared with clopidogrel [4.8% vs. 3.8%; HR 1.28 (95% CI 1.05, 1.56), $P = 0.0139$] but no difference in life-threatening or fatal bleeds.¹⁵⁴ The benefits of ticagrelor compared with clopidogrel in NSTEMI-ACS were independent of whether or not revascularization was performed in the first 10 days after randomization.¹⁵⁴ The reduction in definite stent thrombosis with ticagrelor in the NSTEMI-ACS subgroup [1.1% vs. 1.4%; HR 0.71 (95% CI 0.43, 1.17)] was consistent with that seen in the trial overall [1.4% vs. 1.9%; HR 0.67 (95% CI 0.50, 0.90), $P = 0.0091$].¹⁵⁵ In addition to increased rates of minor or non-CABG-related major bleeding events with ticagrelor, adverse effects included dyspnoea (without bronchospasm), increased frequency of asymptomatic ventricular pauses and increases in uric acid.^{153,156}

5.2.2.4 Cangrelor

Cangrelor is an i.v. adenosine triphosphate (ATP) analogue that binds reversibly and with high affinity to the platelet P2Y₁₂ receptor and has a short plasma half-life (<10 min) (Table 8). It produces a highly effective inhibition of ADP-induced platelet aggregation immediately after i.v. bolus administration and allows for restoration of platelet function within 1–2 h of infusion discontinuation in NSTEMI-ACS patients.¹⁵⁷ Cangrelor (30 µg/kg bolus and 4 µg/kg/min infusion) initiated at the commencement of PCI has been examined in three clinical trials including a total of 24 910 patients: one with clopidogrel (600 mg) given at the beginning of PCI [Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION)-PCI], one with clopidogrel (600 mg) initiated at the end of PCI (CHAMPION-PLATFORM), and one with clopidogrel (300 or 600 mg) initiated either before or after PCI based on local clinical practice (CHAMPION-PHOENIX) among patients without prior P2Y₁₂ or GPIIb/IIIa inhibition.^{158–160} A meta-analysis of these studies, in which 69% of patients were undergoing PCI for ACS, observed a 19% RRR in periprocedural death, MI, ischaemia-driven revascularization and stent thrombosis [cangrelor 3.8% vs. clopidogrel 4.7%; OR 0.81 (95% CI 0.71, 0.91), $P = 0.007$], with a 39% RRR in stent thrombosis alone [cangrelor 0.5% vs. clopidogrel 0.8%; OR 0.61 (95% CI 0.43, 0.80), $P = 0.008$].¹⁶¹ The combination of TIMI major and minor bleeds was increased [cangrelor 0.9% vs. clopidogrel 0.6%; OR 1.38 (95% CI 1.03, 1.86), $P = 0.007$], but there was no increase in the rate of transfusions. The European Commission issued marketing authorization for this compound in March 2015.

5.2.3 Timing of P2Y₁₂ inhibitor administration

Initiation of P2Y₁₂ inhibitors soon after the diagnosis of NSTEMI-ACS irrespective of management strategy has been recommended.^{162,163} This implies pretreatment, defined as P2Y₁₂ inhibitor administration before coronary angiography, in patients scheduled for an invasive approach. Subsequently the results of the only RCT on P2Y₁₂ inhibitor pretreatment in NSTEMI-ACS, the Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction (ACCOAST) trial, were published.¹⁶⁴ The ACCOAST study compared pretreatment with prasugrel 30 mg and a further 30 mg dose prior to PCI with a regimen of prasugrel 60 mg after diagnostic angiography but prior to PCI among 4033 patients with NSTEMI scheduled for early invasive strategy. The median duration of pretreatment was 4.3 h. Sixty-nine per cent of the patients underwent PCI, 6% required surgical revascularization and the remainder were treated conservatively.¹⁶⁴ At 7 days, patients randomized to the pretreatment arm experienced no reduction in the primary endpoint (i.e. CV death, recurrent MI, stroke, urgent revascularization and bailout use of GPIIb/IIIa inhibitors) [HR 1.02 (95% CI 0.84, 1.25), $P = 0.81$], and no benefits emerged at 30 days.¹⁶⁴ TIMI major bleeds were significantly increased in the pretreatment group at 7 days [pretreatment 2.6% vs. no pretreatment 1.4%; HR 1.90, (95% CI 1.19, 3.02), $P = 0.006$]. Arguments for and against pretreatment with P2Y₁₂ inhibitors in NSTEMI-ACS patients have been discussed extensively and the topic remains controversial.^{165,166} As the optimal timing of ticagrelor or clopidogrel administration in NSTEMI-ACS patients scheduled for an invasive strategy has not been adequately investigated, no recommendation for or against pretreatment with these agents can be formulated. Based on the ACCOAST results, pretreatment with prasugrel is not recommended. In NSTEMI-ACS patients planned for conservative management, P2Y₁₂ inhibition (preferably with ticagrelor) is recommended, in the absence of contraindications, as soon as the diagnosis is confirmed.

5.2.4 Monitoring of P2Y₁₂ inhibitors (see Web addenda)

5.2.5 Premature discontinuation of oral antiplatelet therapy

Withdrawal of oral antiplatelet therapy may lead to an increased risk of recurrent events, particularly when the recommended course of therapy has not yet been completed.^{176–178} Interruption of DAPT soon after stent implantation increases the risk of stent thrombosis, especially within the first month after cessation.¹⁷⁸ While discontinuation of DAPT prior to cardiac surgery is discussed in section 5.6.6.1 Web addenda and 5.6.6.2, in the case of a non-cardiac surgical procedure that cannot be postponed, a minimum of 1 and 3 months DAPT for bare-metal stents (BMSs) and new-generation DESs, respectively, might be acceptable.¹⁷⁹ In this setting, surgery should be performed in hospitals having continuous catheterization laboratory availability, so as to treat patients immediately in case of perioperative MI.¹⁷⁹ If interruption of DAPT becomes mandatory because of urgent high-risk surgery (e.g. neurosurgery) or in the case of a major bleed that cannot be controlled by local treatment, no alternative therapy can be proposed as a substitute to DAPT to prevent stent thrombosis. Low molecular weight heparin (LMWH) has been advocated, but the proof of efficacy for this indication is lacking.¹⁸⁰ Whenever possible, aspirin should be continued because early discontinuation of both antiplatelet drugs will further increase the risk of stent thrombosis.

In patients undergoing elective non-cardiac surgery, ticagrelor and clopidogrel should be discontinued 5 days before surgery, while the interval should be increased to 7 days in patients on prasugrel, unless the patient is at high risk of stent thrombosis.¹⁷⁹ In the latter case, a multidisciplinary decision is required to determine the best strategy. Longer discontinuation times (e.g. 7 days for ticagrelor and 10 days for clopidogrel or prasugrel) may be appropriate for surgery at extreme risk of bleeding (e.g. some types of neurosurgery). For NSTEMI-ACS patients, the risk of bleeds related to surgery must be balanced against the risk of recurrent ischaemic events related to discontinuation of therapy. The type of surgery, the ischaemic risk and extent of CAD, the time since the acute episode and, for patients who have undergone PCI, the time since the procedure and the type of stent implanted are key elements of the discussion. Selected patients who require non-cardiac surgery after recently implanted stents may benefit from bridging therapy with small molecule GPIIb/IIIa inhibitors (i.e. tirofiban or eptifibatid) after discontinuation of the P2Y₁₂ inhibitor, while cangrelor has so far been tested as bridging therapy to CABG.^{181,182} In patients on DAPT following an episode of NSTEMI-ACS that was treated conservatively, the P2Y₁₂ inhibitor may be discontinued. In surgical procedures with low to moderate bleeding risk, surgeons should be encouraged to operate on patients on DAPT. Adherence to DAPT should be improved through education of patients, relatives and physicians in order to prevent avoidable CV events.

5.2.6 Duration of dual antiplatelet therapy

In patients with NSTEMI-ACS, DAPT with aspirin and clopidogrel has been recommended for 1 year over aspirin alone, irrespective of revascularization strategy and stent type, according to the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study, while the TRITON-TIMI 38 and PLATO studies have demonstrated the superiority of a prasugrel- and ticagrelor-based regimen, respectively, over a clopidogrel-based one.^{138,148,153} A 1-year duration of DAPT with clopidogrel was associated with a 26.9% RRR of death, MI or stroke (8.6% vs. 11.8%; 95% CI 3.9, 44.4; $P = 0.02$) vs. 1-month DAPT in the Clopidogrel for the Reduction of Events During Observation (CREDO) trial, which enrolled 2116 patients.¹⁸³ The study population comprised patients with stable CAD and low-risk NSTEMI-ACS undergoing PCI (each 50%), and no interaction between ACS status and DAPT was observed.

Evidence to support the extension of DAPT after DES beyond 1 year in NSTEMI-ACS patients is limited (*Table 9*, see Web addenda).

Table 9 (see Web addenda) Main features of published randomized studies investigating various durations of dual antiplatelet therapy following percutaneous coronary intervention (PCI)

The DAPT trial randomized patients who did not experience adverse events in the first year after PCI to an additional 18 months of thienopyridine (clopidogrel/prasugrel) or placebo.¹⁸⁴ Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis [0.4% vs. 1.4%; HR 0.29 (95% CI 0.17, 0.48), $P < 0.001$] and major adverse cardiovascular and cerebrovascular events [4.3% vs. 5.9%; HR 0.71 (95% CI 0.59, 0.85), $P < 0.001$]. The rate of MI was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; HR 0.47, $P < 0.001$). The rate of death from any cause was 2.0% in the group that continued thienopyridine

therapy and 1.5% in the placebo group [HR 1.36 (95% CI 1.00, 1.85), $P = 0.05$]. The rate of moderate or severe bleeding was increased with continued thienopyridine treatment [2.5% vs. 1.6%; HR 1.61 (95% CI 1.21, 2.16), $P = 0.001$].¹⁸⁴ A meta-analysis including 32 287 patients enrolled in 10 RCTs compared different DAPT durations.¹⁸⁵ Nearly 50% of the patients had stable CAD. Studies were stratified according to the DAPT duration in the control group in order to avoid having 12-month DAPT duration included in both study arms. As a consequence, it allowed comparison of outcomes of either short-term or extended (i.e. beyond 12 months) DAPT duration vs. 12-month therapy. Compared with 12-month DAPT, a shorter course of treatment was associated with a significant reduction in major bleeds [OR 0.58 (95% CI 0.36, 0.92), $P = 0.02$], while no statistically significant differences in ischaemic outcomes or stent thrombosis risks were observed, although a small to moderate increase could not be excluded. Extended DAPT, compared with 12-month treatment, yielded a significant reduction in MI [OR 0.53 (95% CI 0.42, 0.66), $P < 0.001$] and stent thrombosis [OR 0.33 (95% CI 0.21, 0.51), $P < 0.001$] while more major bleeds occurred [OR 1.62 (95% CI 1.26, 2.09), $P < 0.001$]. In addition, all-cause death was significantly increased in the extended DAPT group [OR 1.30 (95% CI 1.02, 1.66), $P = 0.03$] while CV death did not differ among the groups.¹⁸⁵

The Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial randomized 21 162 patients who had had an MI 1–3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily or placebo.¹⁸⁶ At a median follow-up of 33 months, the study demonstrated a reduced rate of CV death, MI or stroke with ticagrelor [HR 0.85 (95% CI 0.75, 0.96), $P = 0.008$ and HR 0.84 (95% CI 0.74, 0.95), $P = 0.004$ for 90 mg and 60 mg of ticagrelor vs. placebo, respectively] and increased rates of major bleeding events (2.60% with 90 mg, 2.30% with 60 mg and 1.06% with placebo, $P < 0.001$).¹⁸⁶ All-cause mortality did not differ between the groups. Of importance, most patients began treatment with ticagrelor after an interruption in DAPT and all had prior MI (context of secondary prevention in high-risk patients), while patients with a history of ischaemic stroke were excluded. In conclusion, while a 1-year duration of DAPT in NSTEMI-ACS patients is recommended, based on individual patient ischaemic and bleeding risk profiles, DAPT duration may be shortened (i.e. 3–6 months) or extended (i.e. up to 30 months) in selected patients if required.

5.2.7 Glycoprotein IIb/IIIa inhibitors

Intravenous GPIIb/IIIa inhibitors block platelet aggregation by inhibiting fibrinogen binding to a conformationally activated form of the GPIIb/IIIa receptor on two adjacent platelets.¹²⁸ A meta-analysis of six RCTs involving 29 570 NSTEMI-ACS patients, mainly medically managed, showed a 9% RRR in death or non-fatal MI with GPIIb/IIIa inhibitors (10.7% vs. 11.5%, $P = 0.02$) when added to heparin.¹⁹⁶ The greatest benefit was observed in patients undergoing PCI while on these agents [10.5% vs. 13.6%; OR 0.74 (95% CI 0.57, 0.96), $P = 0.02$]. The use of GPIIb/IIIa inhibitors was associated with an increase in major bleeding complications without a significant increase in intracranial haemorrhage. Many of these trials predated the routine use of P2Y₁₂ inhibitors. While

the relative efficacy of prasugrel and ticagrelor in the trials appeared consistent among patients receiving and not receiving GPIIb/IIIa inhibitors, the efficacy and safety of GPIIb/IIIa inhibitors on top of these P2Y₁₂ inhibitors have not been prospectively addressed.^{153,197} In patients treated with prasugrel or ticagrelor, GPIIb/IIIa inhibitors should be limited to bailout situations or thrombotic complications during PCI. Dosing in patients with impaired renal function is reported in Table 10. Additional information on GPIIb/IIIa inhibitors may be found in sections 5.2.7.1–5.2.7.3, while GPIIb/IIIa inhibitor-related thrombocytopenia is described in section 5.8.7.1 (all in the Web addenda).

5.2.7.1 Upstream versus procedural initiation (see Web addenda)

5.2.7.2 Combination with P2Y₁₂ inhibitors (see Web addenda)

5.2.7.3 Adjunctive anticoagulant therapy (see Web addenda)

5.2.8 Vorapaxar (see Web addenda)

5.2.9 Recommendations for platelet inhibition in non-ST-elevation acute coronary syndromes

Recommendations for platelet inhibition in non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
Oral antiplatelet therapy			
Aspirin is recommended for all patients without contraindications at an initial oral loading dose ^d of 150–300 mg (in aspirin-naïve patients) and a maintenance dose of 75–100 mg/day long-term regardless of treatment strategy.	I	A	129–132
A P2Y ₁₂ inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as excessive risk of bleeds.	I	A	137, 148, 153
<ul style="list-style-type: none"> Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindications,^e for all patients at moderate-to-high risk of ischaemic events (e.g. elevated cardiac troponins), regardless of initial treatment strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started). 	I	B	153
<ul style="list-style-type: none"> Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if no contraindication.^e 	I	B	148, 164
<ul style="list-style-type: none"> Clopidogrel (300–600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel or who require oral anticoagulation. 	I	B	137
P2Y ₁₂ inhibitor administration for a shorter duration of 3–6 months after DES implantation may be considered in patients deemed at high bleeding risk.	IIb	A	187–189, 192

It is not recommended to administer prasugrel in patients in whom coronary anatomy is not known.	III	B	164
Intravenous antiplatelet therapy			
GPIIb/IIIa inhibitors during PCI should be considered for bailout situations or thrombotic complications.	IIa	C	
Cangrelor may be considered in P2Y ₁₂ inhibitor-naïve patients undergoing PCI.	IIb	A	158–161
It is not recommended to administer GPIIb/IIIa inhibitors in patients in whom coronary anatomy is not known.	III	A	198, 199
Long-term P2Y₁₂ inhibition			
P2Y ₁₂ inhibitor administration in addition to aspirin beyond 1 year may be considered after careful assessment of the ischaemic and bleeding risks of the patient.	IIb	A	184, 186
General recommendations			
A proton pump inhibitor in combination with DAPT is recommended in patients at higher than average risk of gastrointestinal bleeds (i.e. history of gastrointestinal ulcer/haemorrhage, anticoagulant therapy, chronic NSAID/corticosteroid use or two or more of the following: age ≥65 years, dyspepsia, gastro-oesophageal reflux disease, <i>Helicobacter pylori</i> infection, chronic alcohol use).	I	B	208, 209
In patients on P2Y ₁₂ inhibitors who need to undergo non-emergency major non-cardiac surgery, ^f postponing surgery for at least 5 days after cessation of ticagrelor or clopidogrel, and for 7 days for prasugrel, should be considered if clinically feasible and unless the patient is at high risk of ischaemic events.	IIa	C	
In case of a non-cardiac surgical procedure that cannot be postponed or of a bleeding complication, discontinuation of the P2Y ₁₂ inhibitor may be considered after a minimum of 1 and 3 months from PCI with BMS and new-generation DES, respectively.	IIb	C	

BMS = bare-metal stent; CABG = coronary artery bypass graft; DAPT = dual (oral) antiplatelet therapy; DES = drug-eluting stent; GPIIb/IIIa = glycoprotein IIb/IIIa; NSAID = non-steroidal anti-inflammatory drug; NSTEMI-ACS = non-ST-elevation acute coronary syndromes; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

^dNon-enteric coated formulation; 75–150 mg intravenously if oral ingestion is not possible.

^eContraindications for ticagrelor: previous intracranial haemorrhage or ongoing bleeds. Contraindications for prasugrel: previous intracranial haemorrhage, previous ischaemic stroke or transient ischaemic attack or ongoing bleeds; prasugrel is generally not recommended for patients ≥75 years of age or with a bodyweight <60 kg.

^fRecommendations for cardiac surgery are listed in section 5.6.6.2.

Table 10 Dosing of glycoprotein IIb/IIIa inhibitors in patients with normal and impaired renal function

Drug	Recommendations			
	Normal renal function or stage 1–2 CKD (eGFR ≥60 mL/min/1.73m ²)	Stage 3 CKD (eGFR 30–59 mL/min/1.73m ²)	Stage 4 CKD (eGFR 15–29 mL/min/1.73m ²)	Stage 5 CKD (eGFR <15 mL/min/1.73m ²)
Eptifibatide	Bolus 180 µg/kg i.v., infusion 2 µg/kg/min	No adjustment of bolus, reduce infusion rate to 1 µg/kg/min if eGFR <50 mL/min/1.73m ²	Not recommended	Not recommended
Tirofiban	Bolus 25 µg/kg or 10 µg/kg i.v., infusion 0.15 µg/kg/min	No dose adjustment	No adjustment of bolus, reduce infusion to 0.05 µg/kg/min	Not recommended
Abciximab	Bolus 0.25 mg/kg i.v., infusion 0.125 µg/kg/min (max. 10 µg/min)	No specific recommendations for the use of abciximab, or for dose adjustment in the case of renal failure. Careful evaluation of haemorrhagic risk is needed.		

CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; i.v. = intravenous; kg = kilograms bodyweight.

Recommendations for the use of drugs listed in this table may vary depending on the exact labeling of each drug in the country where it is used.

5.3 Anticoagulation

5.3.1 Anticoagulation during the acute phase

Anticoagulants are used to inhibit thrombin generation and/or activity, thereby reducing thrombus-related events. There is evidence that anticoagulation is effective in reducing ischaemic events in NSTEMI-ACS and that the combination with platelet inhibitors is more effective than either treatment alone.²¹⁰ Several anticoagulants, acting at different levels of the coagulation cascade, have been approved or are under investigation for this indication (Figure 4). Anticoagulant doses in patients with impaired renal function are reported in Table 11.

5.3.1.1 Unfractionated heparin

UFH has a pharmacokinetic profile with large interindividual variability and a narrow therapeutic window. Weight-adjusted i.v. administration with an initial bolus of 60–70 IU/kg up to a maximum of 5000 IU, followed by an infusion of 12–15 IU/kg/h up to a maximum of 1000 IU/h, is recommended. Anticoagulation level is usually monitored in the cardiac catheterization laboratory with activated clotting time (ACT) and elsewhere with the activated partial thromboplastin time (aPTT; therapeutic window is 50–75 s, corresponding to 1.5–2.5 times the upper limit of normal). UFH remains a widely used anticoagulant in NSTEMI-ACS in the context of short delays to coronary angiography and short hospital stays despite consistent evidence for greater bleeding risk compared with other strategies.²¹¹ In the PCI setting, UFH is given as an i.v. bolus either under ACT guidance (in the range of 250–350 s, or 200–250 s if a GPIIb/IIIa inhibitor is given) or in a weight-adjusted manner (usually 70–100 IU/kg, or 50–70 IU/kg in combination with a GPIIb/IIIa inhibitor).^{212,213} UFH should be stopped after PCI unless there is an established indication related to the procedure or to the patient's condition. For heparin-induced thrombocytopenia (HIT) in section 5.8.7.2.

Table 11 Dosing of anticoagulants in patients with normal and impaired renal function

Drug	Recommendations		
	Normal renal function or stage 1–3 CKD (eGFR ≥ 30 mL/min/1.73m ²)	Stage 4 CKD (eGFR 15–29 mL/min/1.73m ²)	Stage 5 CKD (eGFR < 15 mL/min/1.73m ²)
Unfractionated heparin	<ul style="list-style-type: none"> • Prior to coronary angiography: 60–70 IU/kg i.v. (max 5000 IU) and infusion (12–15 IU/kg/h) (max 1000 IU/h), target aPTT 1.5–2.5x control • During PCI: 70–100 IU/kg i.v. (50–70 IU/kg if concomitant with GPIIb/IIIa inhibitors) 	No dose adjustment	No dose adjustment
Enoxaparin	1 mg/kg s.c. twice a day	1 mg/kg s.c. once a day	Not recommended
Fondaparinux	2.5 mg s.c. once a day	Not recommended if eGFR < 20 mL/min/1.73m ²	Not recommended
Bivalirudin	Bolus 0.75 mg/kg i.v., infusion 1.75 mg/kg/h	No adjustment of bolus, reduce infusion rate to 1 mg/kg/h	On dialysis, no adjustment of bolus, reduce infusion rate to 0.25 mg/kg/h

aPTT = activation partial thromboplastin time; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; IU = international units; i.v. = intravenous; kg = kilograms bodyweight; s.c. = subcutaneous. Recommendations for the use of drugs listed in this table may vary depending on the exact labeling of each drug in the country where it is used.

5.3.1.2 Low molecular weight heparin

LMWH has a more predictable dose–effect relationship than UFH and causes HIT less frequently. The most widely used agent in NSTEMI-ACS is enoxaparin, 1 mg/kg administered subcutaneously twice daily, while the dose is reduced to 1 mg/kg once a day if eGFR < 30 mL/min/1.73m². LMWH should not be administered in patients with eGFR < 15 mL/min/1.73m². Monitoring of anti-Xa activity is not necessary except in patients in whom the eGFR is 15–30 mL/min/1.73m² or bodyweight is > 100 kg. In NSTEMI-ACS patients pretreated with enoxaparin, no additional enoxaparin is recommended during PCI if the last subcutaneous (s.c.) enoxaparin injection was administered < 8 h before PCI, whereas an additional 0.3 mg/kg i.v. bolus is recommended if the last s.c. enoxaparin injection was administered ≥ 8 h before PCI.^{214,215} Crossing over to another anticoagulant during PCI is strongly discouraged.²¹⁶ A meta-analysis of all trials testing enoxaparin vs. UFH in ACS showed a marginally significant reduction in the combined endpoint of death or MI at 30 days in favour of enoxaparin [10.0% vs. 11.0%; OR 0.90 (95% CI 0.81, 0.996), $P = 0.043$] but no statistically significant differences in major bleeds [6.3% with enoxaparin vs. 5.4% with UFH; OR 1.13 (95% CI 0.84, 1.54)] at 7 days.²¹⁷ A meta-analysis including 23 trials and 30 966 patients documented the favourable safety and efficacy profile of enoxaparin compared with UFH during PCI, with significant reductions in death [RR 0.66 (95% CI 0.57, 0.76), $P < 0.001$], the composite of death or MI [RR 0.68 (95% CI 0.57, 0.81), $P < 0.001$], complications of MI [RR 0.75 (95% CI 0.6, 0.85), $P < 0.001$] and major bleeds [RR 0.80 (95% CI 0.68, 0.95), $P = 0.009$].²¹¹

5.3.1.3 Fondaparinux

The parenteral selective factor Xa inhibitor fondaparinux is a synthetic pentasaccharide that binds reversibly and non-covalently to

antithrombin with high affinity, thereby preventing thrombin generation (Figure 4). The compound has 100% bioavailability after s.c. injection, with an elimination half-life of 17 h, allowing once-daily dosing. No monitoring of anti-Xa activity and no dose adjustments are required and the compound does not induce HIT. In NSTEMI-ACS, the recommended dose is 2.5 mg/day. Due to its renal elimination, fondaparinux is contraindicated if eGFR is < 20 mL/min/1.73m². In the fifth Organization to Assess Strategies in Acute Ischaemic Syndromes (OASIS-5) study, which enrolled 20 078 patients with NSTEMI-ACS, fondaparinux 2.5 mg s.c. once daily was non-inferior to enoxaparin with respect to ischaemic events [death, MI or refractory ischaemia at 9 days; HR 1.01 (95% CI 0.90, 1.13), $P = 0.007$], but halved in-hospital major bleeds [HR 0.52 (95% CI 0.44, 0.61), $P < 0.001$] and significantly reduced mortality at 30 days [2.9% vs. 3.5%; HR 0.83 (95% CI 0.71, 0.97), $P < 0.02$] and 6 months [5.8% vs. 6.5%; HR 0.89 (95% CI 0.80, 1.00), $P < 0.05$].²¹⁸ In the subgroup of patients who underwent PCI ($n = 6239$), a significantly lower rate of major bleeding complications (including access site complications) was observed at 9 days in the fondaparinux group vs. enoxaparin [2.3% vs. 5.1%; HR 0.45 (95% CI 0.34, 0.59), $P < 0.001$].²⁰³ The rate of major bleeds was not influenced by the timing of the intervention after injection of the last dose of fondaparinux (1.6% vs. 1.3% for < 6 h vs. > 6 h, respectively). Catheter thrombus was observed more frequently with fondaparinux (0.9%) than with enoxaparin (0.4%), but this complication was abolished by injection of an empirically determined bolus of UFH at the time of PCI. Subsequent studies have shown that a standard UFH bolus is recommended at the time of PCI in patients pretreated with fondaparinux.²¹⁹ An analysis exploring the uptake of fondaparinux compared with LMWH among 40 616 NSTEMI patients from a large-scale Scandinavian registry described a reduction in in-hospital mortality [OR 0.75 (95% CI 0.63, 0.89)] and in bleeding events [OR 0.54 (95% CI 0.42, 0.70)] associated with the use of fondaparinux, but the advantage disappeared at 30 days and 6 months, respectively.²²⁰ Overall, fondaparinux is considered to be the parenteral anticoagulant with the most favourable efficacy–safety profile and is recommended regardless of the management strategy, unless the patient is scheduled for immediate coronary angiography.

5.3.1.4 Bivalirudin

Bivalirudin binds directly to thrombin and thereby inhibits the thrombin-induced conversion of fibrinogen to fibrin. It inactivates fibrin-bound as well as fluid-phase thrombin (Figure 4). As the drug does not bind to plasma proteins, its anticoagulant effect is more predictable than that of UFH. Bivalirudin is eliminated by the kidney and has a half-life of 25 min after cessation of the infusion. The anticoagulant activity of bivalirudin correlates well with aPTT and ACT values. In NSTEMI-ACS patients, a bivalirudin dose of 0.1 mg/kg i.v. bolus followed by an infusion of 0.25 mg/kg/h was tested in the ACUITY trial in 13 819 moderate- to high-risk NSTEMI-ACS patients planned for an invasive strategy.²⁰⁵ In patients undergoing PCI, an additional i.v. bolus of 0.5 mg/kg bivalirudin was added before the procedure and the infusion dose was increased to 1.75 mg/kg/h before PCI and stopped at the end of the procedure. Patients were randomized to one of three unblinded treatments: UFH or LMWH plus GPIIb/IIIa inhibitor, bivalirudin plus GPIIb/IIIa inhibitor or bivalirudin with bailout use of GPIIb/IIIa

inhibitor. There was no significant difference between UFH/LMWH plus GIIb/IIIa inhibitor vs. bivalirudin plus GIIb/IIIa inhibitor for the composite ischaemia endpoint at 30 days [death, MI or unplanned revascularization for ischaemia 7.3% vs. 7.7%, respectively; RR 1.07 (95% CI 0.92, 1.23), $P = 0.39$] or for major bleeds [5.7% vs. 5.3%; RR 0.93 (95% CI 0.78, 1.10), $P = 0.38$]. Bivalirudin with bailout use of GIIb/IIIa inhibitor was non-inferior to UFH/LMWH combined with a GIIb/IIIa inhibitor with respect to the composite ischaemia endpoint [7.8% vs. 7.3%; RR 1.08 (95% CI 0.93, 1.24), $P = 0.32$], but with a significantly lower rate of major bleeds [3.0% vs. 5.7%; RR 0.53 (95% CI 0.43, 0.65), $P < 0.001$]. In patients not pretreated with clopidogrel prior to PCI, a significant excess in ischaemic events was observed in bivalirudin-treated patients vs. those receiving UFH/LMWH plus GIIb/IIIa inhibitor [9.1% vs. 7.1%; RR 1.29 (95% CI 1.03, 1.63)].^{221,222} Comparable findings were observed in a trial with a similar design, the Intracoronary Stenting and Anti-thrombotic Regimen–Rapid Early Action for Coronary Treatment (ISAR-REACT) 4 study.²²³ The ISAR-REACT 3 study, the only head-to-head comparison between bivalirudin and UFH alone (140 IU/kg) published so far, was performed in 4570 stable CAD patients as well as biomarker-negative NSTEMI-ACS patients undergoing PCI; the study found comparable rates of death, MI and urgent revascularization at 30 days [5.9% in the bivalirudin arm vs. 5.0% in the UFH arm; OR 1.16 (95% CI 0.91, 1.49), $P = 0.23$] but a reduction in bleeding events [3.1% vs. 4.6%; OR 0.66 (95% CI 0.49, 0.90), $P = 0.008$].²²⁴

5.3.2 Anticoagulation following the acute phase

Two phase III trials have compared non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) (for mode of action, see *Figure 4*) to placebo in patients with recent ACS treated with aspirin and clopidogrel who did not have atrial fibrillation or other indications for oral anticoagulation (OAC). The Apixaban for Prevention of Acute Ischaemic Events (APPRASE) 2 study assessed the effects of the oral factor Xa inhibitor apixaban 5 mg twice daily compared with placebo, in addition to standard-of-care antiplatelet therapy following ACS; it was terminated early (median 8 months) due to a markedly increased risk of severe bleeds, including intracranial haemorrhage, without any apparent benefit in terms of ischaemic events.²²⁵ The study Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin with or without Thienopyridine Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction (ATLAS ACS 2-TIMI 51) has led to the European Medicines Agency's (EMA's) approval of rivaroxaban (2.5 mg twice daily) for NSTEMI and STEMI patients after the acute phase.²²⁶ The trial compared rivaroxaban 2.5 mg or 5 mg twice daily (unlike the 20 mg once-daily dose for atrial fibrillation) with placebo in 15 526 patients following ACS; 50% had NSTEMI-ACS and 93% received clopidogrel in addition to aspirin at randomization. Patients with prior ischaemic stroke/TIA were excluded. At a mean follow-up of 13 months, the primary efficacy endpoint of CV death, MI or stroke was 10.7% with placebo, 9.1% with rivaroxaban 2.5 mg [HR 0.84 (95% CI 0.72, 0.97), $P = 0.02$] and 8.8% with rivaroxaban 5 mg [HR 0.85 (95% CI 0.73, 0.98), $P = 0.03$], with no interaction by ACS subtype. Rates of definite, probable or possible stent thrombosis were 2.2% and 2.3% with 2.5 and 5 mg rivaroxaban, respectively, vs. 2.9% with placebo ($P = 0.02$ and $P = 0.04$, respectively). Rates of CV death were significantly lower with rivaroxaban 2.5 mg compared with placebo [2.7% vs. 4.1%; HR 0.66 (95% CI 0.51, 0.86), $P = 0.002$] but not with

rivaroxaban 5 mg (4.0%). Non-CABG major bleeds occurred in 1.8% and 2.4% with 2.5 and 5 mg rivaroxaban, respectively, compared with 0.6% with placebo [HR 3.46 for rivaroxaban 2.5 mg (95% CI 2.08, 5.77), $P < 0.001$; HR 4.47 for rivaroxaban 5 mg (95% CI 2.71, 7.36), $P < 0.001$]. Intracranial haemorrhage rates were 0.4% with 2.5 mg and 0.7% with 5 mg rivaroxaban vs. 0.2% with placebo [HR 2.83 (95% CI 1.02, 7.86), $P = 0.04$ for 2.5 mg; HR 3.74 (95% CI 1.39, 10.07), $P = 0.005$ for 5 mg].²²⁶ The use of rivaroxaban 2.5 mg twice daily, while not recommended in patients treated with ticagrelor or prasugrel, might be considered in combination with aspirin and clopidogrel if ticagrelor and prasugrel are not available for NSTEMI patients who have high ischaemic and low bleeding risks. It is contraindicated in patients with a prior history of ischaemic stroke/TIA and its use is cautioned in patients >75 years of age or <60 kg bodyweight.

5.3.3 Recommendations for anticoagulation in non-ST-elevation acute coronary syndromes

Recommendations for anticoagulation in non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
Parenteral anticoagulation is recommended at the time of diagnosis according to both ischaemic and bleeding risks.	I	B	227
Fondaparinux (2.5 mg s.c. daily) is recommended as having the most favourable efficacy–safety profile regardless of the management strategy.	I	B	218, 228, 229
Bivalirudin (0.75 mg/kg i.v. bolus, followed by 1.75 mg/kg/h for up to 4 h after the procedure) is recommended as an alternative to UFH plus GIIb/IIIa inhibitors during PCI.	I	A	205, 222, 223
UFH 70–100 IU/kg i.v. (50–70 IU/kg if concomitant with GIIb/IIIa inhibitors) is recommended in patients undergoing PCI who did not receive any anticoagulant.	I	B	219, 229
In patients on fondaparinux (2.5 mg s.c. daily) undergoing PCI, a single i.v. bolus of UFH (70–85 IU/kg, or 50–60 IU/kg in the case of concomitant use of GIIb/IIIa inhibitors) is recommended during the procedure.	I	B	219
Enoxaparin (1 mg/kg s.c. twice daily) or UFH are recommended when fondaparinux is not available.	I	B	218, 230
Enoxaparin should be considered as an anticoagulant for PCI in patients pretreated with s.c. enoxaparin.	IIa	B	211
Additional ACT-guided i.v. boluses of UFH during PCI may be considered following initial UFH treatment.	IIb	B	231
Discontinuation of anticoagulation should be considered after PCI, unless otherwise indicated.	IIa	C	

Crossover between UFH and LMWH is not recommended.	III	B	216
In NSTEMI patients with no prior stroke/TIA and at high ischaemic risk as well as low bleeding risk receiving aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily for approximately 1 year) may be considered after discontinuation of parenteral anticoagulation.	IIb	B	226

ACT = activated clotting time; GPIIb/IIIa = glycoprotein IIb/IIIa; i.v. = intravenous; LMWH = low molecular weight heparin; NSTEMI = non-ST-elevation myocardial infarction; PCI = percutaneous coronary intervention; s.c. = subcutaneous; TIA = transient ischaemic attack; UFH = unfractionated heparin.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

5.4 Managing oral antiplatelet agents in patients requiring long-term oral anticoagulants

5.4.1 Patients undergoing percutaneous coronary intervention

Approximately 6–8% of patients undergoing PCI have an indication for long-term OAC with VKA or NOACs due to various conditions such as atrial fibrillation, mechanical heart valves or venous thromboembolism. In the periprocedural phase it should be considered to perform coronary angiography on OAC, because interruption of OAC and bridging with parenteral anticoagulants may lead to an increase in both thromboembolic episodes and bleeds.^{232–234} The safety of PCI on NOACs without additional parenteral anticoagulation is unknown, while no parenteral anticoagulation is needed if the international normalized ratio (INR) is >2.5 in VKA-treated patients.^{235–237} Strategies to minimise PCI-related complications in patients on oral anticoagulants are listed in *Table 12*.

With respect to long-term antithrombotic treatment after PCI, a cohort study including 82 854 patients with atrial fibrillation showed that long-term exposure of patients to triple therapy, defined as the combination of aspirin, clopidogrel and OAC, was associated with an increased risk of 1-year major [14.3% vs. 6.9%; HR 2.08 (95% CI 1.64, 2.65)] and fatal bleeds [0.9% vs. 0.3%; HR 4.8 (95% CI 1.62, 14.02)] as compared with DAPT.²³⁸ In the setting of NSTEMI-ACS, evidence to guide the management of patients undergoing PCI and requiring long-term OAC is limited.^{234,239} The indication for OAC should be reassessed and treatment continued only if a compelling indication exists {e.g. paroxysmal, persistent or permanent atrial fibrillation with a CHA₂DS₂-VASc [Cardiac failure, Hypertension, Age ≥ 75 (2 points), Diabetes, Stroke (2 points)–Vascular disease, Age 65–74, Sex category] score ≥ 2; mechanical heart valve; recent or a history of recurrent deep venous thrombosis or pulmonary embolism}. Duration of triple therapy should be as limited as possible, depending on the clinical setting as well as the thromboembolic (CHA₂DS₂-VASc score) and bleeding {e.g. based on the HAS-BLED [hypertension,

Table 12 Suggested strategies to reduce bleeding risk related to PCI

- Anticoagulant doses adjusted to bodyweight and renal function, especially in women and elderly patients.
- Radial approach preferred.
- Proton pump inhibitors in patients on DAPT at higher than average risk of gastrointestinal bleeds (i.e. history of gastrointestinal ulcer/haemorrhage, anticoagulant therapy, chronic NSAIDs/corticosteroid use, or two or more among age ≥65 years, dyspepsia, gastrooesophageal reflux disease, *Helicobacter pylori* infection, and chronic alcohol use).
- In patients on OAC
 - PCI performed without interruption of VKAs or NOACs.
 - In patients on VKAs, do not administer UFH if INR value >2.5.
 - In patients on NOACs, regardless of the timing of the last administration of NOACs, add additional low-dose parenteral anticoagulation (e.g. enoxaparin 0.5 mg/kg i.v. or UFH 60 IU/kg).
 - Aspirin indicated but avoid pretreatment with P2Y₁₂ inhibitors.
 - GPIIb/IIIa inhibitors only for bailout of periprocedural complications.

DAPT = dual (oral) antiplatelet therapy; GPIIb/IIIa = glycoprotein IIb/IIIa; INR = international normalised ratio; NOACs = non-vitamin K antagonist oral anticoagulants; NSAIDs = non-steroidal anti-inflammatory drugs; OACs = oral anticoagulants; PCI = percutaneous coronary intervention; UFH = unfractionated heparin; VKAs = vitamin K antagonists.

abnormal renal and liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs and alcohol (1 point each)] score} risks (*Figure 5*).²³⁴ In the absence of safety and efficacy data, the use of prasugrel or ticagrelor as part of triple therapy should be avoided. Gastric protection with a proton pump inhibitor is recommended. The dose intensity of OAC should be carefully monitored with a target INR of 2.0–2.5 in patients treated with VKA (with the exception of individuals with mechanical prosthetic valves in the mitral position); in patients treated with NOACs, the lowest tested dose for stroke prevention should be applied (i.e. dabigatran 110 mg twice a day, rivaroxaban 15 mg once a day, apixaban 2.5 mg twice a day).

The choice of stent type (newer-generation DES vs. BMS) in patients requiring long-term anticoagulation is controversial in the setting of NSTEMI-ACS. In the absence of conclusive data, the decision for the individual patient should also take into account the estimated probability of subsequent target vessel revascularization (TVR) due to restenosis. Although in stable CAD patients DAPT is recommended for at least 1 month after BMS and for 6 months after DES, the risk of stent thrombosis (and other ischaemic complications) during the period beyond 1 month and long-term appears similar with both stent types.^{240–242} Data from the DAPT trial indicate a similar impact of prolonged DAPT administration irrespective of stent type (BMS vs. DES).²⁴³ In addition, analyses on the risk of adverse events among patients with DAPT cessation and patients undergoing non-cardiac surgery indicate no differences between BMS and DES.^{177,244} Until data from RCTs become available, newer-generation DESs are recommended over BMSs in patients requiring OAC at low bleeding risk (HAS-BLED ≤2). For patients at high bleeding risk (HAS-BLED ≥3) undergoing PCI who require OAC, the choice between a BMS and a new-generation DES needs to be individualised.

In the Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) trial, 1606 patients at either high bleeding risk (52%), high thrombotic risk (17%) or low restenosis risk (31%)




Figure 5 Antithrombotic strategies in patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) and non-valvular atrial fibrillation.

were randomized to implantation with either the zotarolimus-eluting stent ($n = 802$; Medtronic Vascular, Santa Rosa, CA, USA) or a BMS ($n = 804$).²⁴⁵ Overall, 4.6% of the population never received DAPT, 43.6% and 62.5% discontinued it at 1 and 2 months, respectively, with 24.7% remaining on DAPT beyond 6 months. At 1 year, major adverse cardiovascular events (MACEs) were lower for those implanted with a zotarolimus-eluting stent compared with a BMS [17.5% vs. 22.1%; HR 0.76 (95% CI 0.61, 0.95), $P = 0.011$], driven by reductions in TVR [5.9% vs. 10.7%; HR 0.53 (95% CI 0.37, 0.75), $P = 0.001$], MI [2.9% vs. 8.1%; HR 0.35 (95% CI 0.22, 0.56), $P < 0.001$] and definite/probable stent thrombosis [2.0% vs. 4.1%; HR 0.48 (95% CI 0.27, 0.88), $P = 0.019$]. The benefit of the zotarolimus-eluting stent over the BMS remained consistent

across all prespecified subgroups and, in particular, in patients at high bleeding risk. While there were no significant differences in any bleeding events between treatment groups, the limited size of the trial does not allow potential differences in major bleeds to be reliably detected. As an additional limitation, the zotarolimus-eluting stent is no longer marketed in Europe. This study suggests that a newer-generation DES may be preferred in patients who cannot tolerate long-term exposure to DAPT, such as those needing chronic OAC.

Omission of aspirin while maintaining clopidogrel has been evaluated in the What is the Optimal antiplatelet and anticoagulant therapy in patients with OAC and coronary StenTing (WOEST) trial, which randomized 573 patients to dual therapy with OAC and

clopidogrel (75 mg/day) or to triple therapy with OAC, clopidogrel and aspirin 80 mg/day.²⁴⁶ Treatment was continued for 1 month after BMS placement (35% of patients) and for 1 year after DES placement (65% of patients); follow-up was for 1 year.²⁴⁶ PCI was performed on VKA in half of the patients and one-third of them presented with NSTEMI-ACS. The primary endpoint of any TIMI bleeds was significantly reduced in the dual-therapy arm [19.5% vs. 44.9%; HR 0.36 (95% CI 0.26, 0.50), $P < 0.001$], while no significant differences in major bleeds were observed. The rates of MI, stroke, TVR or stent thrombosis did not differ significantly, but all-cause mortality was lower in the dual group (2.5% vs. 6.4%, $P = 0.027$) at 1 year. Femoral access was used in the majority of patients (74%). While the trial was too small to reliably assess ischaemic outcomes and potential differences in major bleeds, dual therapy with clopidogrel and OAC may be considered as an alternative to triple therapy in patients at high bleeding risk. In the Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation (ISAR-TRIPLE) trial, 614 patients (one-third with ACS) undergoing stenting and requiring OAC were randomly assigned to receive either 6-week or 6-month clopidogrel therapy in addition to aspirin and VKA. The primary endpoint of death, MI, stent thrombosis, ischaemic stroke or TIMI major bleeding at 9 months did not differ between the 6-week and 6-month triple therapy [9.8% vs. 8.8%; HR 1.14 (95% CI 0.68, 1.91), $P = 0.63$]; the same was true for the combined incidence of death, MI, stent thrombosis and ischaemic stroke [4.0% vs. 4.3%; HR 0.93 (95% CI 0.43, 2.05), $P = 0.87$]. Furthermore, no difference in TIMI major bleeding [5.3% vs. 4.0%; HR 1.35 (95% CI 0.64, 2.84), $P = 0.44$] was observed.²⁴⁷ Finally, there are no data on the timing of cessation of any antiplatelet agents in stented patients requiring chronic OAC. Specifically, it is not known whether there are differences according to the type of OAC (NOACs versus VKA) or stent platform. In accordance with a joint consensus document, discontinuation of any antiplatelet agent at 1 year is encouraged in this patient population irrespective of stent type, while dual therapy with oral anticoagulation and one antiplatelet agent (aspirin or clopidogrel) may be considered in patients at very high risk of coronary events (Figure 5).²³⁴

5.4.2 Patients medically managed or requiring coronary artery bypass surgery

With respect to NSTEMI-ACS patients who are medically managed, in an analysis of the nationwide Danish registry, 90-day bleeding risk was increased on triple therapy compared with OAC plus a single antiplatelet agent [HR 1.47 (95% CI 1.04, 2.08)], with a non-significant increase at 360 days [HR 1.36 (95% CI 0.95, 1.95)], without differences in ischaemic events [HR 1.15 (95% CI 0.95, 1.40)].²⁴⁸ The same registry suggests that warfarin plus clopidogrel resulted in a non-significant reduction in major bleeds [HR 0.78 (95% CI 0.55, 1.12)] compared with triple therapy, with a non-significant reduction in MI or coronary death [HR 0.69 (95% CI 0.55, 1.12)].²⁴⁹

Coronary surgery in fully anticoagulated patients is associated with an increased bleeding risk, thus interruption of VKA prior to CABG is

recommended in non-emergent cases. In emergency surgery, a combination of prothrombin complex concentrate of four inactivated factors (25 IU/kg) and oral vitamin K is required to obtain fast and sustained restoration of haemostasis at the time of surgery.¹⁸⁰ While experience with urgent major surgery in patients treated with NOACs is limited, it has been suggested to use prothrombin complex concentrate of activated factors to restore haemostasis.²⁵⁰ In the setting of planned CABG, a 48 h interruption of NOACs is recommended. In ACS patients with an established indication for OAC, the antiplatelet agent (commonly aspirin) and then anticoagulation should be resumed after CABG as soon as the bleeding is controlled, while triple therapy should be avoided. For antithrombotic therapy and CABG see section 5.6.6.1 and 5.6.6.2).

5.4.3 Recommendations for combining antiplatelet agents and anticoagulants in non-ST-elevation acute coronary syndrome patients requiring chronic oral anticoagulation

Recommendations for combining antiplatelet agents and anticoagulants in non-ST-elevation acute coronary syndrome patients requiring chronic oral anticoagulation

Recommendations	Class ^a	Level ^b	Ref. ^c
In patients with a firm indication for OAC (e.g. atrial fibrillation with a CHA ₂ DS ₂ -VASc score ≥ 2 , recent venous thromboembolism, LV thrombus or mechanical valve prosthesis), OAC is recommended in addition to antiplatelet therapy.	I	C	
An early invasive coronary angiography (within 24 h) should be considered in moderate- to high-risk patients, ^d irrespective of OAC exposure, to expedite treatment allocation (medical vs. PCI vs. CABG) and to determine the optimal antithrombotic regimen.	IIa	C	
Initial dual antiplatelet therapy with aspirin plus a P2Y ₁₂ inhibitor in addition to OAC before coronary angiography is not recommended.	III	C	
Patients undergoing coronary stenting			
Anticoagulation			
During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all NOACs and if INR is < 2.5 in VKA-treated patients.	I	C	
Uninterrupted therapeutic anticoagulation with VKA or NOACs should be considered during the periprocedural phase.	IIa	C	

Antiplatelet treatment			
Following coronary stenting, DAPT including new P2Y ₁₂ inhibitors should be considered as an alternative to triple therapy for patients with NSTEMI-ACS and atrial fibrillation with a CHA ₂ DS ₂ -VASc score of 1 (in males) or 2 (in females).	IIa	C	
If at low bleeding risk (HAS-BLED ≤2), triple therapy with OAC, aspirin (75–100 mg/day) and clopidogrel 75 mg/day should be considered for 6 months, followed by OAC and aspirin 75–100 mg/day or clopidogrel (75 mg/day) continued up to 12 months.	IIa	C	
If at high bleeding risk (HAS-BLED ≥3), triple therapy with OAC, aspirin (75–100 mg/day) and clopidogrel 75 mg/day should be considered for a duration of 1 month, followed by OAC and aspirin 75–100 mg/day or clopidogrel (75 mg/day) continued up to 12 months irrespective of the stent type (BMS or new-generation DES).	IIa	C	
Dual therapy with OAC and clopidogrel 75 mg/day may be considered as an alternative to triple antithrombotic therapy in selected patients (HAS-BLED ≥3 and low risk of stent thrombosis).	IIb	B	246, 248
The use of ticagrelor or prasugrel as part of triple therapy is not recommended.	III	C	
Vascular access and stent type			
Radial over femoral access is recommended for coronary angiography and PCI.	I	A	251
The use of new-generation DES over BMS should be considered among patients requiring OAC.	IIa	B	245, 252
Medically managed patients			
One antiplatelet agent in addition to OAC should be considered for up to 1 year.	IIa	C	

ACS = acute coronary syndromes; BMS = bare-metal stent; CHA₂DS₂-VASc = Cardiac failure, Hypertension, Age ≥ 75 (2 points), Diabetes, Stroke (2 points) – Vascular disease, Age 65–74, Sex category; DAPT = dual (oral) antiplatelet therapy; DES = drug-eluting stent; INR = international normalized ratio; LV = left ventricular; NOAC = non-vitamin K antagonist oral anticoagulant; NSTEMI-ACS = non-ST-elevation acute coronary syndromes; OAC = oral anticoagulant/anticoagulation (it refers to both vitamin K and non-vitamin K antagonist oral anticoagulants); PCI = percutaneous coronary intervention; VKA = vitamin K antagonist.

Triple therapy refers to aspirin, clopidogrel and OAC. HAS-BLED bleeding score includes hypertension, abnormal renal and liver function, stroke, bleeding history or predisposition, labile INR (international normalized ratio), elderly (>65 years) and drugs increasing bleeding risk or alcohol abuse. When NOACs are combined with antiplatelet drugs, they should be used at the lowest dose approved (i.e. dabigatran 2 × 110 mg, rivaroxaban 1 × 15 mg and apixaban 2 × 2.5 mg). When VKAs are combined with antiplatelet drugs, INR should not exceed 2.5.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

^dRisk criteria are listed in Table 13.

5.5 Management of acute bleeding events (see Web addenda)

5.5.1 General supportive measures (see Web addenda)

5.5.2 Bleeding events on antiplatelet agents (see Web addenda)

5.5.3 Bleeding events on vitamin K antagonists (see Web addenda)

5.5.4 Bleeding events on non-vitamin K antagonist oral anticoagulants (see Web addenda)

5.5.5 Non-access-related bleeding events (see Web addenda)

5.5.6 Bleeding events related to percutaneous coronary intervention (see Web addenda)

5.5.7 Bleeding events related to coronary artery bypass surgery (see Web addenda)

5.5.8 Transfusion therapy (see Web addenda)

5.5.9 Recommendations for bleeding management and blood transfusion in non-ST-elevation acute coronary syndromes

Recommendations for bleeding management and blood transfusion in non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
In patients with VKA-associated life-threatening bleeding events, rapid reversal of anticoagulation with four-factor prothrombin complex concentrate rather than with fresh frozen plasma or recombinant activated factor VII should be considered. In addition, repetitive 10 mg i.v. doses of vitamin K should be administered by slow injection.	IIa	C	
In patients with NOAC-associated ongoing life-threatening bleeds, the administration of prothrombin complex concentrate or activated prothrombin complex concentrates should be considered.	IIa	C	
In patients with anaemia and no evidence of active bleed, blood transfusion may be considered in the case of compromised haemodynamic status or haematocrit <25% or haemoglobin level <7 g/dL.	IIb	C	

i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; NSTEMI-ACS = non-ST-elevation acute coronary syndromes; VKA = vitamin K antagonist.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

Table 13 Risk criteria mandating invasive strategy in NSTEMI-ACS

Very-high-risk criteria
• Haemodynamic instability or cardiogenic shock
• Recurrent or ongoing chest pain refractory to medical treatment
• Life-threatening arrhythmias or cardiac arrest
• Mechanical complications of MI
• Acute heart failure
• Recurrent dynamic ST-T wave changes, particularly with intermittent ST-elevation
High-risk criteria
• Rise or fall in cardiac troponin compatible with MI
• Dynamic ST- or T-wave changes (symptomatic or silent)
• GRACE score >140
Intermediate-risk criteria
• Diabetes mellitus
• Renal insufficiency (eGFR <60 mL/min/1.73 m ²)
• LVEF <40% or congestive heart failure
• Early post-infarction angina
• Prior PCI
• Prior CABG
• GRACE risk score >109 and <140
Low-risk criteria
• Any characteristics not mentioned above

CABG = coronary artery bypass graft; eGFR = estimated glomerular filtration rate; GRACE = Global Registry of Acute Coronary Events; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; MI = myocardial infarction.

5.6 Invasive coronary angiography and revascularization

Invasive coronary angiography, followed if indicated by coronary revascularization, is performed in the majority of patients hospitalised with NSTEMI-ACS in regions with well-developed healthcare systems. The decision for an invasive strategy should carefully weigh the risks of invasive diagnostics and the benefits in terms of diagnostic accuracy, risk stratification and assessment of the risks related to revascularization. The decision for revascularization takes into account the risk in terms of morbidity and mortality associated with the proposed modality (PCI or CABG) and the benefits in terms of short- and long-term prognosis, symptom relief, quality of life and duration of hospital stay. The indication for an invasive approach, the timing for myocardial revascularization and the selection of the revascularization modality depend on numerous factors, including clinical presentation, comorbidities, risk stratification (as outlined in section 4), presence of high-risk features specific for a revascularization modality, frailty, cognitive status, estimated life expectancy and functional and anatomic severity as well as pattern of CAD.

5.6.1 Invasive coronary angiography

Invasive coronary angiography maintains its central role in the management of patients with NSTEMI-ACS. In the vast majority of cases it allows clinicians to

- confirm the diagnosis of ACS related to obstructive epicardial CAD (or to rule out a coronary origin of chest pain) and, as a consequence, to guide antithrombotic treatment and avoid unnecessary exposure to antithrombotic agents;
- identify the culprit lesion(s);
- establish the indication for coronary revascularization and assess the suitability of coronary anatomy for PCI and CABG and
- stratify the patient's short- and long-term risk.

5.6.1.1 Pattern of coronary artery disease

Angiographic patterns of CAD in NSTEMI-ACS patients are diverse, ranging from normal epicardial coronary arteries to a severely and diffusely diseased coronary artery tree. Up to 20% of patients with NSTEMI-ACS have no lesions or non-obstructive lesions of epicardial coronary arteries, while among patients with obstructive CAD, 40–80% have multivessel disease.^{164,224,303,304} Bypass graft failures and left main coronary artery disease may be the underlying condition in 5% and up to 10% of patients presenting with NSTEMI-ACS, respectively. The left anterior descending coronary artery is the most frequent culprit vessel in both STEMI and NSTEMI-ACS (in up to 40% of patients).^{164,224,303–306} Regarding the distribution within the infarct-related artery, culprit lesions in NSTEMI-ACS are more often located within the proximal and mid segments, with approximately the same frequency in the two segments.^{305,306}

5.6.1.2 Identification of the culprit lesion

In order to characterize a coronary lesion as culprit on angiography, at least two of the following morphological features suggestive of acute plaque rupture should be present:^{306–308} intraluminal filling defects consistent with thrombus (i.e. acute occlusion abruptly ending with a squared-off or convex upstream termination or an intraluminal filling defect in a patent vessel within or adjacent to a stenotic region with surrounding homogeneous contrast opacification), plaque ulceration (i.e. presence of contrast and hazy contour beyond the vessel lumen), plaque irregularity (i.e. irregular margins or overhanging edges), dissection or impaired flow. Pathological and intracoronary imaging studies have documented the simultaneous occurrence of multiple vulnerable plaques, mostly as thin-cap fibroatheroma.^{309–311} Angiographic studies have confirmed these findings, showing that in up to 40% of NSTEMI-ACS patients with obstructive CAD, multiple complex plaques fulfilling the criteria of a culprit lesion may be observed.^{306,308,312,313} Nearly one-quarter of NSTEMI patients present with an acute occluded coronary artery and two-thirds of the occlusions are already collateralised at the time of angiographic examination.^{223,310} As a consequence, differentiation between an acute/subacute and chronic occlusion may sometimes be challenging and identification of the culprit lesion based solely on angiography may not be possible.

Diffuse precordial ST depression more pronounced in leads V₄–V₆ may indicate a culprit lesion located in the mid left anterior descending coronary artery, while changes more evident in leads V₂–V₃ may be more suggestive of a culprit lesion located in the left circumflex artery.³¹⁴ Diffuse ST depression including both precordial and

extremity leads associated with ST-elevation ≥ 1 mm in lead aVR may indicate either left main coronary artery as the culprit lesion or proximal occlusion of the left anterior descending coronary artery in the presence of severe three-vessel CAD.^{315,316} The correlation of ECG changes with the culprit lesion is weakened in the presence of left coronary artery dominance, multivessel disease and distal location of the culprit lesion.³¹⁷ Echocardiography or left ventriculography may also help to identify the culprit lesion corresponding to a regional wall motion abnormality. Finally, approximately 25% of NSTEMI patients have angiographically normal epicardial coronary arteries or non-obstructive CAD.^{164,303,304} A provocative test, such as with acetylcholine or ergonovine, and newer intracoronary imaging methods (i.e. optical coherence tomography) may sometimes help to identify the culprit lesion or the underlying pathology, such as medial thickness due to abnormal media contraction in coronary spasm or superficial erosions of non-obstructive thin-cap fibroatheroma.^{318–320}

5.6.1.3 Fractional flow reserve

The achievement of maximal hyperaemia may be unpredictable in NSTEMI because of the dynamic nature of coronary lesions and the associated acute microvascular dysfunction. As a result, fractional flow reserve (FFR) may be overestimated and the haemodynamic relevance of a coronary stenosis underestimated.³²⁰ So far, the value of FFR-guided PCI in this setting has not been properly addressed.

5.6.2 Routine invasive vs. selective invasive approach

While PCI associated with antithrombotic therapy results in culprit lesion stabilization, thereby reducing the risk of target lesion-associated (re)infarction, CABG provides protection against complications (i.e. occlusion/subocclusion, but possibly not distal embolization) originating from culprit lesions as well as from disease progression in the vessel segments proximal to the anastomotic sites.³²¹ Compared with a selective invasive strategy, a routine invasive strategy in NSTEMI-ACS has been shown to improve clinical outcomes and reduce recurrent ACS episodes, subsequent rehospitalization and revascularization. A meta-analysis of seven RCTs in 8375 NSTEMI-ACS patients with frequent use of thienopyridines, GPIIb/IIIa inhibitors and stents showed that a routine invasive strategy was associated with a lower risk of death [4.9% vs. 6.5%; RR 0.75 (95% CI 0.63, 0.90), $P = 0.001$], MI [7.6% vs. 9.1%; RR 0.83 (95% CI 0.72, 0.96), $P = 0.012$] and rehospitalization for recurrent ACS [19.9% vs. 28.7%; RR 0.69 (95% CI 0.65, 0.74), $P < 0.0001$] at a mean follow-up of 2 years.³²² A meta-analysis of eight RCTs in 10 150 NSTEMI-ACS patients showed that the benefit in favour of a routine invasive strategy for the composite endpoint of death or MI was confined to biomarker-positive patients [OR 0.68 (95% CI 0.56, 0.82) vs. OR 1.01 (95% CI 0.79, 1.28) in biomarker-negative patients, interaction $P = 0.03$].³²³ An individual patient data meta-analysis of three RCTs with long-term follow-up data throughout 5 years in 5467 NSTEMI-ACS patients reported a lower risk of CV death or MI [14.7% vs. 17.9%; HR 0.81 (95% CI 0.71, 0.93), $P = 0.002$] in favour of a routine over a selective invasive strategy; the most pronounced difference was observed in high-risk patients (according to a risk score developed by the authors based on clinical characteristics), with an absolute risk reduction of 2.0%, 3.8% and 11.1% among low-, intermediate- and high-risk patients, respectively.³²⁴ Of note, the benefit of revascularization in the RCT was likely

underestimated because revascularization was allowed when patients deteriorated while on medical therapy (crossover), the trials did not include consecutive patients and excluded those with very-high-risk features and advances in percutaneous treatment such as single-stent strategy for bifurcation lesions, radial approach, new-generation DES as well as more effective P2Y₁₂ inhibitors were not available or broadly implemented in the trials. Despite these limitations, the results of RCTs and their meta-analyses support the broad implementation of a routine invasive strategy and highlight the role of risk stratification in the decision process. Specific subgroups of high-risk patients that, while benefiting from an early invasive management, pose additional challenges in terms of treatment (e.g. diabetic patients, the elderly, frail patients or those with renal insufficiency) are discussed in their respective sections.

5.6.3 Timing of invasive strategy

5.6.3.1 Immediate invasive strategy (<2 h)

Very-high-risk NSTEMI-ACS patients (i.e. with at least one very-high-risk criterion according to Table 13) have been generally excluded from RCTs. Owing to a poor short- and long-term prognosis if left untreated, an immediate (i.e. <2 h from hospital admission, analogous to STEMI management) invasive strategy with intent to perform revascularization is recommended, irrespective of ECG or biomarker findings. Centres without STEMI programmes should transfer the patient immediately (Figure 6). The management of patients with out-of-hospital cardiac arrest and no ST elevation on ECG needs to be individualized and requires multidisciplinary consultation in the emergency department. While conscious survivors should undergo immediate coronary angiography, comatose survivors should first be investigated for non-coronary conditions, if appropriate, and coronary angiography should be performed directly after in the absence of an obvious non-coronary cause of the cardiac arrest.³²⁵

5.6.3.2 Early invasive strategy (<24 h)

Early invasive strategy is defined as coronary angiography performed within 24 h of hospital admission. The optimal timing of invasive coronary angiography and revascularization in NSTEMI-ACS patients has been investigated in multiple RCTs and meta-analyses. A meta-analysis of four RCTs with 4013 NSTEMI-ACS patients compared an early (i.e. time to angiography 1.16–14 h) with a delayed (i.e. time to angiography 20.8–86 h) invasive strategy. While there were no significant differences in terms of death or MI, the early invasive strategy was associated with a statistically significant lower risk of recurrent ischaemia [RR 0.59 (95% CI 0.38, 0.92), $P = 0.02$] and shorter duration of hospital stay [by 28% (95% CI 22, 35), $P < 0.001$] and a trend towards fewer major bleeds [RR 0.78 (95% CI 0.57, 1.07), $P = 0.13$] and major adverse cardiac events [RR 0.91 (95% CI 0.82, 1.01), $P = 0.09$].³²⁶ An updated meta-analysis of seven RCTs in 5370 NSTEMI-ACS patients and of four observational studies in 77 499 patients compared an early (<24 h) with a delayed invasive strategy.³²⁷ The results of the pooled analysis of RCTs showed no significant benefit for death [3.9% vs. 4.7%; OR 0.83 (95% CI 0.64, 1.09), $P = 0.18$], MI [7.5% vs. 7.8%; OR 1.15 (95% CI 0.65, 2.01), $P = 0.63$] or major bleeds [2.8% vs. 3.7%; OR 0.76 (95% CI 0.56, 1.04), $P = 0.09$], and similar outcomes were reported in the observational studies. Yet an early invasive strategy was associated with a lower risk of refractory ischaemia [3.8% vs. 7.3%; OR 0.55 (95% CI 0.35, 0.86), $P = 0.008$].




Figure 6 Selection of non-ST-elevation acute coronary syndrome (NSTEMI-ACS) treatment strategy and timing according to initial risk stratification.

Three of the trials included in the mentioned meta-analyses compared a strategy of immediate (e.g. primary PCI-like approach) vs. early and/or delayed intervention in NSTEMI-ACS patients.^{304,328,329} There were no differences with respect to the primary endpoints based on biomarker elevation after intervention or with respect to secondary clinical outcomes (except for a higher rate of MI in the immediate invasive approach in one of the studies).³²⁸ However, the design and interpretation of these studies is challenging from a methodological point of view, because in cases of early intervention, biomarkers had not returned to normal values or were still in the ascending phase of the curve. Therefore it may be difficult, if not impossible, to differentiate between the evolution of the index MI and an ischaemic complication of the revascularization procedure.

There is evidence to suggest a benefit of an early invasive strategy in patients with a high-risk profile. The largest individual RCT to date, Timing of Intervention in Acute Coronary Syndromes (TIMACS), randomly assigned 3031 NSTEMI-ACS patients to an early (<24 h, median time 14 h) or delayed (median time 50 h) intervention. At 6 months, the primary composite endpoint of death, MI or stroke was not different between the early and delayed invasive strategy [9.6% vs. 11.3%; HR 0.85 (95% CI 0.68, 1.06), $P = 0.15$]. The secondary endpoint of death, MI, stroke or refractory ischaemia was reduced by 28% in favour

of the early invasive strategy [9.5% vs. 12.9%; HR 0.72 (95% CI 0.58, 0.89), $P = 0.003$]. In the pre-specified analysis of high-risk patients (i.e. one-third of patients with a GRACE risk score > 140), an early invasive strategy lowered the risk of death, MI or stroke [13.9% vs. 21.0%; HR 0.65 (95% CI 0.48, 0.89), $P = 0.006$], whereas the difference was not significant for patients with a GRACE risk score ≤ 140 [7.6% vs. 6.7%; HR 1.12 (95% CI 0.81, 1.56), $P = 0.48$; $P = 0.01$ for heterogeneity].³⁰³ Importantly, an early invasive strategy did not trigger any safety issue in this trial. In a post hoc analysis of the AUCITY trial, a delay to PCI > 24 h was an independent predictor of 30-day and 1-year mortality.³³⁰ The excess of ischaemic events associated with the PCI > 24 h strategy was most apparent among moderate- and high-risk patients (according to the TIMI risk score). Overall, an early invasive strategy is recommended in patients with at least one high-risk criterion (Table 13). This implies timely transfer for patients admitted to hospitals without onsite catheterization facilities (Figure 6).

5.6.3.3 Invasive strategy (< 72 h)

This is the recommended maximal delay for angiography in patients without recurrence of symptoms but at least one intermediate risk criterion.^{324,327} Even if hospital transfer is required, the 72 h window for coronary angiography should be complied with.

5.6.3.4 Selective invasive strategy

Patients with no recurrence of symptoms and none of the criteria listed in Table 13 are to be considered at low risk of ischaemic events. In these patients, a non-invasive stress test (preferably with imaging) for inducible ischaemia is recommended before deciding on an invasive strategy.³³¹

In summary, available data indicate that an early as opposed to a delayed invasive strategy is safe and associated with a lower risk of refractory ischaemia and a shorter duration of hospital stay. The selection of the optimal timing of invasive coronary angiography and revascularization should be guided by individual risk stratification. It is recommended that patients at very high risk (i.e. with at least one very-high-risk criterion) undergo an immediate invasive strategy (<2 h). In patients at high risk (i.e. with at least one high-risk criterion), an early invasive strategy (<24 h) is recommended. In patients with at least one intermediate-risk criterion, the invasive strategy may be delayed but a maximum 72 h window from admission to coronary angiography is recommended. In low-risk patients, a non-invasive stress test (preferably with imaging) for inducible ischaemia is recommended before deciding on an invasive strategy.

5.6.4 Conservative treatment

5.6.4.1 In patients with coronary artery disease

5.6.4.1.1 Non-obstructive CAD. A pooled data analysis from eight NSTEMI-ACS RCTs showed that 9.6% of the patients had non-obstructive CAD. Compared with patients with obstructive CAD, those individuals were younger and more often female, while fewer had diabetes mellitus, previous MI or prior PCI. Thirty-day death or MI was less frequent among patients with non-obstructive CAD (2.2%) vs. obstructive CAD (13.3%) [adjusted OR 0.15 (95% CI 0.11, 0.20)]. Thirty-day death or MI and 6-month mortality were also lower among patients with non-obstructive CAD [adjusted OR 0.19 (95% CI 0.14, 0.25) and adjusted OR 0.37 (95% CI 0.28, 0.49), respectively].³³² While invasive evaluation and, if appropriate and feasible, revascularization are indicated in patients at high ischaemic risk, in a proportion of them this strategy is not offered because of the perception that patients might not benefit in terms of event reduction—due to the estimated increased risk related to coronary angiography and/or revascularization—or quality of life. Patients in whom an invasive strategy may be withheld by the treating physicians may include very elderly or frail patients (section 5.8.1); patients with comorbidities such as dementia, severe chronic renal insufficiency (section 5.8.3) or cancer and patients at high risk of bleeding complications (section 4.3). Usually these patient categories have been excluded from RCTs.

With respect to oral antiplatelet therapy in the context of medically managed NSTEMI-ACS, the CURE study randomized 12 562 patients to clopidogrel or placebo in addition to aspirin for 3–12 months (mean duration of treatment 9 months). The majority of patients were treated conservatively, while <40% underwent coronary revascularization during the study period. The primary outcome, a composite of death from CV causes, non-fatal MI or stroke at 1 year, occurred in 9.3% of the patients in the clopidogrel group and 11.4% of the patients in the placebo group [RR 0.80 (95% CI 0.72, 0.90), $P < 0.001$]. There were significantly more patients with major bleeds in the clopidogrel group than in the placebo group [3.7% vs. 2.7%; RR 1.38 (95% CI 1.13, 1.67), $P = 0.001$].¹³⁷ A registry looked at the comparative effectiveness of clopidogrel vs. no clopidogrel in 16 365 medically managed patients with unstable angina and

NSTEMI.³³³ In 36% of the patients, clopidogrel was prescribed within 7 days of discharge. In 8562 propensity score–matched patients, patients who were prescribed clopidogrel had lower rates of all-cause mortality [8.3% vs. 13.0%; adjusted HR 0.63 (95% CI 0.54, 0.72), $P < 0.01$] and the composite of death or MI [13.5% vs. 17.4%; HR 0.74 (95% CI 0.66, 0.84), $P < 0.01$], but not MI alone [6.7% vs. 7.2%; HR 0.93 (95% CI 0.78, 1.11), $P = 0.30$], compared with non-users of clopidogrel. The association between clopidogrel use and the composite of death or MI was significant among patients presenting with NSTEMI [HR 0.67 (95% CI 0.59, 0.76)] compared with those presenting with unstable angina [HR 1.25 (95% CI 0.94, 1.67), P for interaction <0.01].

The TRILOGY ACS trial randomized 7243 patients with NSTEMI-ACS <75 years of age selected for medical management to clopidogrel or prasugrel for a median duration of 17 months.³³⁴ Allocation to prasugrel was not associated with a statistically significant reduction in the primary endpoint of death from CV causes, MI or stroke [13.9% in the prasugrel group and 16.0% in the clopidogrel group; HR 0.91 (95% CI 0.79, 1.05), $P = 0.21$]. While non-CABG TIMI major bleeding rates did not differ among the groups, TIMI major and minor bleeding events were more frequent in the prasugrel group [1.9% vs. 1.3%; HR 1.54 (95% CI 1.06, 2.23), $P = 0.02$]. In the PLATO study, 5216 patients (28% of the total PLATO population) admitted to hospital for ACS were specified as planned for non-invasive management, although by the end of follow-up, 3143 (60.3%) patients had been managed non-invasively. In the population intended for non-invasive management, the incidence of the primary endpoint, a composite of CV death, MI and stroke, was lower with ticagrelor than with clopidogrel [12.0% vs. 14.3%; HR 0.85 (95% CI 0.73, 1.00), $P = 0.04$]. Overall mortality was also lower [6.1% vs. 8.2%; HR 0.75 (95% CI 0.61, 0.93), $P = 0.01$]. The incidence of non-CABG TIMI major bleeds was numerically higher in the ticagrelor-treated patients [2.8% vs. 2.2%; HR 1.33 (95% CI 0.91, 1.94), $P = 0.142$].³³⁵

5.6.4.1.2 CAD not amenable to revascularization. Data regarding patients with ACS who are not amenable to revascularization due to severe/diffuse CAD are sparse. The available observational studies included mainly patients with stable CAD and refractory angina.^{336,337} Although the prognosis differs according to patient characteristics (e.g. age, prior CABG or PCI, LV dysfunction, congestive heart failure), overall, patients not amenable to revascularization have higher mortality compared with patients who are revascularized.³³⁶ The main objective of pharmacological treatment is relief from refractory angina, as detailed in the 2013 ESC guidelines on the management of stable CAD.⁶³

5.6.4.2 In patients with normal coronary angiogram (see Web addenda). Tako-Tsubo cardiomyopathy, non-CAD-associated coronary thromboembolism, vasospasm and microvascular disease may all cause NSTEMI-ACS. While these conditions have been extensively covered in the 2013 ESC guidelines on the management of stable CAD, the most relevant features are summarised in the Web addenda.⁶³

5.6.5 Percutaneous coronary intervention

5.6.5.1 Technical aspects and challenges

Although suspected or confirmed NSTEMI-ACS represents the most frequent indication for coronary angiography and PCI worldwide, few studies focus on the technical aspects of PCI in this setting. Hence information on PCI techniques and outcomes has to be derived largely from PCI studies or from trials and registries encompassing ACS

patients. As for all other manifestations of CAD, stent implantation in the setting of NSTEMI-ACS helps to reduce abrupt vessel closure and restenosis associated with balloon angioplasty and it should be considered the standard treatment strategy. Based on at least comparable safety and superior efficacy (i.e. prevention of restenosis and need for repeat revascularization), new-generation DESs are recommended over BMSs in NSTEMI-ACS.^{345–347} DAPT is recommended for 12 months irrespective of stent type, while in patients at high ischaemic risk not experiencing bleeding events, DAPT may be extended (see section 5.2.6). The benefit of thrombectomy has not been assessed prospectively in NSTEMI-ACS but cannot be recommended, considering the lack of benefit observed in STEMI.³⁴⁸ While FFR is considered the invasive gold standard for the functional assessment of lesion severity in stable CAD, its role in NSTEMI-ACS still needs to be defined. Strategies to reduce bleeding risk related to PCI are listed in Table 12.

5.6.5.2 Vascular access

The Radial Vs femoral access for coronary intervention (RIVAL) trial randomized 7021 ACS patients (both STEMI and NSTEMI-ACS) to radial or femoral artery access.³⁴⁹ The primary outcome, a composite of death, MI, stroke or non-CABG-related major bleeds at 30 days, occurred in 3.7% of patients in the radial access group compared with 4.0% of patients in the femoral access group [HR 0.92 (95% CI 0.72, 1.17), $P = 0.50$]. The Study of Access Site for Enhancement of PCI for Women (SAFE-PCI) trial randomized women undergoing coronary angiography, and if required PCI, to radial or femoral access. The study was stopped early due to a lower than expected event rate. Among the 1787 patients enrolled (>50% presented with NSTEMI-ACS), 691 underwent PCI. There was no significant difference in the primary efficacy endpoint of bleeding or vascular complications between radial and femoral access among women undergoing PCI [radial 1.2% vs. 2.9% femoral; OR 0.39 (95% CI 0.12, 1.27), $P = 0.12$], while in the overall cohort of women undergoing coronary angiography a benefit was detected [0.6% in the radial group vs. 1.7% in the femoral group; OR 0.32 (95% CI 0.12, 0.90), $P = 0.03$].³⁵⁰ In the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of angioX (MATRIX) trial, 8404 ACS patients were randomly allocated to radial or femoral access. The first co-primary outcome of 30-day MACE, defined as death, MI or stroke, occurred in 8.8% of patients with radial access and 10.3% of patients with femoral access [RR 0.85 (95% CI 0.74, 0.99), two-sided $P = 0.031$; formally non-significant at the pre-specified α of 0.025].²⁵¹ The second co-primary outcome of 30-day net adverse clinical events [MACE or non-CABG Bleeding Academic Research Consortium (BARC) major bleeding] was experienced in 9.8% and 11.7% of patients [RR 0.83 (95% CI 0.73, 0.96), $P = 0.009$]. Radial access was associated with a lower risk of all-cause mortality [1.6% vs. 2.2%; RR 0.72 (95% CI 0.53, 0.99), $P = 0.045$], while the rates of cardiac mortality, MI and stroke were not significantly different. The two groups had similar rates of urgent TVR and stent thrombosis. Major BARC 3 or 5 bleeding was significantly reduced in the radial group [1.6% vs. 2.3%; RR 0.67 (95% CI 0.49, 0.92), $P = 0.013$]. Radial access was associated with significantly lower rates of surgical access site repair or transfusion of blood products. An updated meta-analysis including MATRIX found a significant reduction in major bleeds; death, MI or stroke and in all-cause mortality associated with radial as compared with femoral access.²⁵¹ Radial access, performed by experienced operators, is recommended over the

transfemoral access in ACS. It is recommended that centres treating ACS patients implement a transition from transfemoral to transradial access. However, proficiency in the femoral approach should be maintained, as this access is indispensable in a variety of procedures, including intra-aortic balloon counterpulsation implantation, structural heart disease interventions and peripheral revascularization procedures. A consensus document has proposed a stepwise approach to favour the transition from a femoral to a radial approach.³⁵¹

5.6.5.3 Revascularization strategies and outcomes

There is a lack of prospective randomized investigations addressing the type (i.e. complete vs. incomplete) and timing (i.e. simultaneous vs. staged) of revascularization in NSTEMI-ACS. A complete revascularization strategy of significant lesions should be pursued in multivessel disease patients with NSTEMI-ACS based on two considerations. First, several studies showing the benefit of early intervention when compared with the conservative approach in patients with NSTEMI-ACS mandated a complete revascularization strategy, irrespective of the possibility to identify and/or treat the culprit lesion.^{352–354} Second, multiple PCI and NSTEMI-ACS trials have shown a detrimental prognostic effect of incomplete revascularization. Accordingly, a residual SYnergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) score >8 has been shown to be independently associated with a poor 30-day and 1-year prognosis, including higher mortality after PCI in patients with moderate- and high-risk ACS.^{355,356} However, the presence of important unmeasured confounding factors in retrospective studies showing worse outcomes in patients who did not receive complete revascularization cannot be excluded. Since pursuing completeness of revascularization for some patients with complex coronary anatomy may mean increasing the risk of PCI (e.g. in the presence of complex chronic total occlusions) or requiring CABG, it is reasonable, in the absence of compelling clinical data, to tailor the need for complete revascularization to age, general patient condition and comorbidities. The decision to treat all the significant lesions in the same setting or to stage the procedures should be based on clinical presentation, comorbidities, complexity of coronary anatomy, ventricular function, revascularization modality and patient preference.

With respect to outcomes, periprocedural complications of PCI as well as the long-term ischaemic risk remain higher in NSTEMI-ACS than in stable patients, despite contemporary management. Accordingly, the risk of CV death, MI or stroke in NSTEMI-ACS patients in recent trials was approximately 10% and 15% at 1 and 2 years follow-up, respectively.^{154,206} For ACS patients who underwent PCI, revascularization procedures represent the most frequent, most costly and earliest cause for rehospitalization.^{357,358} This reflects both planned (i.e. staged) as well as unplanned revascularization procedures due to symptoms or CV event recurrence.^{357,358}

5.6.6 Coronary artery bypass surgery

Approximately 10% of NSTEMI-ACS patients may require CABG during their index hospitalization.³⁵⁹ A Danish nationwide cohort study showed that the proportion of patients undergoing CABG for NSTEMI-ACS decreased from 2001 to 2009, while the proportion of patients undergoing coronary angiography and PCI markedly increased.³⁶⁰ NSTEMI-ACS patients requiring CABG represent a challenging group of patients, mainly because of the difficulties in balancing ischaemic and bleeding risks in relation to the timing of surgery and perioperative antithrombotic therapy. In addition, NSTEMI-ACS

patients present with a higher proportion of surgical high-risk characteristics, including older age, female gender, left main coronary disease and LV dysfunction compared with patients undergoing elective CABG.³⁶¹ In the absence of randomized data, optimal timing for non-emergent CABG in NSTEMI-ACS patients should be determined individually, as detailed in section 5.6.6.1, Web addenda.

5.6.6.1 *Timing of surgery and antithrombotic drug discontinuation (see Web addenda)*

5.6.6.2 *Recommendations for perioperative management of antiplatelet therapy in non-ST-elevation acute coronary syndrome patients requiring coronary artery bypass surgery*

Recommendations for perioperative management of antiplatelet therapy in non-ST-elevation acute coronary syndrome patients requiring coronary artery bypass surgery

Recommendations	Class ^a	Level ^b	Ref. ^c
Irrespective of the revascularization strategy, a P2Y ₁₂ inhibitor is recommended in addition to aspirin and maintained over 12 months unless there are contraindications such as excessive risk of bleeding events.	I	A	137, 148, 153
It is recommended that the Heart Team estimate the individual bleeding and ischaemic risks and guide the timing of CABG as well as management of DAPT.	I	C	
It is recommended to perform CABG without delay in patients with haemodynamic instability, ongoing myocardial ischaemia or very-high-risk coronary anatomy, regardless of antiplatelet treatment.	I	C	
Aspirin is recommended 6–24 h post-CABG in the absence of ongoing bleeding events.	I	A	365, 366
It is recommended to continue low-dose aspirin until CABG.	I	B	367–369
In stabilised patients requiring CABG who are on DAPT, discontinuation of ticagrelor and clopidogrel 5 days before and prasugrel 7 days prior to surgery should be considered.	IIa	B	285, 370, 371
After CABG, resuming P2Y ₁₂ inhibitor therapy should be considered as soon as deemed safe.	IIa	C	
Platelet function testing may be considered in shortening the time window to CABG following P2Y ₁₂ inhibitor discontinuation.	IIb	B	372

ACS = acute coronary syndromes; CABG = coronary artery bypass graft; DAPT = dual (oral) antiplatelet therapy.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

5.6.6.3 *Technical aspects and outcomes (see Web addenda)*

5.6.7 Percutaneous coronary intervention vs. coronary artery bypass surgery

While the main advantages of PCI in the setting of NSTEMI-ACS are faster revascularization of the culprit lesion, a lower risk of stroke and the absence of deleterious effects of cardiopulmonary bypass on the ischaemic myocardium, CABG may more frequently offer complete revascularization in advanced multivessel CAD. However, no contemporary RCT comparing PCI with CABG in patients with NSTEMI-ACS and multivessel CAD is available. Accordingly, in nearly all trials comparing an early with a delayed invasive strategy, or a routine invasive with a selective invasive strategy, the decision to perform PCI or CABG was left to the discretion of the investigator. A post hoc analysis of 5627 NSTEMI-ACS patients with multivessel CAD included in the ACUITY trial showed that 78% underwent PCI while the remaining patients were treated surgically.³⁷⁴ After propensity-score matching, there were no differences among 1056 patients in mortality at 1 month (CABG 2.5% vs. PCI 2.1%; $P = 0.69$) and 1 year (CABG 4.4% vs. PCI 5.7%; $P = 0.58$). PCI-treated patients experienced lower rates of stroke (0% vs. 1.1%; $P = 0.03$), MI (8.8% vs. 13.3%; $P = 0.03$), major bleeds (9.1% vs. 45.5%; $P < 0.001$) and renal injury (14.2% vs. 31.7%; $P < 0.001$), but had significantly higher rates of unplanned revascularization than CABG (3.1% vs. 0.2%; $P < 0.001$) during the periprocedural period. At 1 year, the risk of stroke remained lower among PCI-treated patients (0% vs. 1.1%; $P = 0.03$), whereas unplanned revascularization (12% vs. 0.2%; $P < 0.001$) and MACE tended to be more common (25.0% vs. 19.2%; $P = 0.053$). A subgroup analysis of an individual patient data meta-analysis of 10 RCTs comparing CABG and PCI reported similar mortality after a median follow-up of 5.9 years among 2653 stabilised NSTEMI-ACS patients with multivessel CAD [9.6% in the CABG group vs. 11.1% in the PCI group; HR 0.95 (95% CI 0.80, 1.12)].³⁷⁷

As both the SYNERGY Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) and Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trials compared PCI and CABG in patients with multivessel CAD and included up to one-third of patients with unstable angina or NSTEMI-ACS, it is reasonable to use the criteria applied in patients with stable CAD to guide the choice of revascularization modality among stabilised patients with NSTEMI-ACS.^{378–380} While the majority of patients with single-vessel CAD should undergo ad hoc PCI of the culprit lesion, the revascularization strategy in an individual NSTEMI-ACS patient with multivessel CAD should be discussed in the context of a Heart Team and be based on the clinical status as well as the severity and distribution of the CAD and the lesion characteristics. The SYNTAX score was found to be useful in the prediction of death, MI and revascularization among NSTEMI-ACS patients undergoing PCI and may help guide the choice between revascularization strategies.³⁸¹ PCI of the culprit lesion does not require a case-by-case review by the Heart Team when an ad hoc intervention is indicated based on clinical or angiographic grounds, such as ongoing ischaemia, haemodynamic instability, pulmonary oedema, recurrent ventricular arrhythmias or total occlusion of the culprit coronary artery requiring urgent revascularization. Following PCI of the culprit lesion, stabilised NSTEMI-ACS patients with multivessel

CAD may be discussed within the Heart Team if delayed CABG of the non-culprit vessels is an option.

5.6.8 Management of patients with cardiogenic shock

Cardiogenic shock may develop in up to 3% of NSTEMI-ACS patients during hospitalization and has become the most frequent cause of in-hospital mortality in this setting.^{382–384} One or more partial or complete vessel occlusions may result in severe heart failure, especially in cases of pre-existing LV dysfunction, reduced cardiac output and ineffective peripheral organ perfusion. More than two-thirds of patients have three-vessel CAD. Cardiogenic shock may also be related to mechanical complications of NSTEMI, including mitral regurgitation related to papillary muscle dysfunction or rupture and ventricular septal or free wall rupture. In patients with cardiogenic shock, immediate coronary angiography is indicated and PCI is the most frequently used revascularization modality. If the coronary anatomy is not suitable for PCI, patients should undergo emergent CABG. The value of intra-aortic balloon counterpulsation in MI complicated by cardiogenic shock has been challenged.³⁸⁵ Extracorporeal membrane oxygenation and/or implantable LV assist devices may be considered in selected patients.

5.6.9 Recommendations for invasive coronary angiography and revascularization in non-ST-elevation acute coronary syndromes

Recommendations for invasive coronary angiography and revascularization in non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
<p>An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very-high-risk criteria:</p> <ul style="list-style-type: none"> – haemodynamic instability or cardiogenic shock – recurrent or ongoing chest pain refractory to medical treatment – life-threatening arrhythmias or cardiac arrest – mechanical complications of MI – acute heart failure with refractory angina or ST deviation – recurrent dynamic ST- or T-wave changes, particularly with intermittent ST-elevation. 	I	C	
<p>An early invasive strategy (<24 h) is recommended in patients with at least one of the following high-risk criteria:</p> <ul style="list-style-type: none"> – rise or fall in cardiac troponin compatible with MI – dynamic ST- or T-wave changes (symptomatic or silent) – GRACE score >140. 	I	A	303, 326, 327

<p>An invasive strategy (<72 h) is recommended in patients with at least one of the following intermediate-risk criteria:</p> <ul style="list-style-type: none"> – diabetes mellitus – renal insufficiency (eGFR < 60 mL/min/1.73 m²) – LVEF < 40% or congestive heart failure – early post-infarction angina – recent PCI – prior CABG – GRACE risk score > 109 and < 140, <p>or recurrent symptoms or ischaemia on non-invasive testing.</p>	I	A	322, 324
<p>In patients with none of the above mentioned risk criteria and no recurrent symptoms, non-invasive testing for ischaemia (preferably with imaging) is recommended before deciding on an invasive evaluation.</p>	I	A	113, 114
<p>In centres experienced with radial access, a radial approach is recommended for coronary angiography and PCI.</p>	I	A	251
<p>In patients undergoing PCI, new-generation DESs are recommended.</p>	I	A	242, 252, 386–390
<p>In patients with multivessel CAD, it is recommended to base the revascularization strategy (e.g. ad hoc culprit-lesion PCI, multivessel PCI, CABG) on the clinical status and comorbidities as well as the disease severity (including distribution, angiographic lesion characteristics, SYNTAX score), according to the local Heart Team protocol.</p>	I	C	
<p>In patients in whom a short DAPT duration (30 days) is planned because of an increased bleeding risk, a new-generation DES may be considered over a BMS.</p>	IIb	B	245

BMS = bare-metal stent; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DAPT = dual (oral) antiplatelet therapy; DES = drug-eluting stent; eGFR = estimated glomerular filtration rate; GRACE = Global Registry of Acute Coronary Events; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NSTEMI-ACS = non-ST-elevation acute coronary syndromes; PCI = percutaneous coronary intervention; SYNTAX = SYnergy between percutaneous coronary intervention with TAXus and cardiac surgery.

Timing to coronary angiography is calculated from hospital admission.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

5.7 Gender specificities (see Web addenda)

5.8 Special populations and conditions (see Web addenda)

5.8.1 The elderly and frail patients (see Web addenda)

5.8.1.1 Recommendations for the management of elderly patients with non-ST-elevation acute coronary syndromes

Recommendations for the management of elderly patients with non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
It is recommended to tailor antithrombotic treatment according to bodyweight and renal function.	I	C	
Elderly patients should be considered for an invasive strategy and, if appropriate, revascularization after careful evaluation of potential risks and benefits, estimated life expectancy, comorbidities, quality of life, frailty and patient values and preferences.	IIa	A	408, 414–418
Adjusted dosing regimens of beta-blockers, ACE inhibitors, ARBs and statins should be considered to prevent side effects.	IIa	C	

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; NSTEMI-ACS = non-ST-elevation acute coronary syndromes.
^aClass of recommendation.
^bLevel of evidence.
^cReferences supporting level of evidence.

5.8.2 Diabetes mellitus (see Web addenda)

5.8.2.1 Recommendations for the management of diabetic patients with non-ST-elevation acute coronary syndromes

Recommendations for the management of diabetic patients with non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
Blood glucose control			
It is recommended to screen all patients with NSTEMI-ACS for diabetes and to monitor blood glucose levels frequently in patients with known diabetes or admission hyperglycaemia.	I	C	

Glucose-lowering therapy should be considered in ACS patients with blood glucose >10 mmol/L (>180 mg/dL), with the target adapted to comorbidities, while episodes of hypoglycaemia should be avoided.	IIa	C	
Less stringent glucose control should be considered both in the acute phase and at follow-up in patients with more advanced cardiovascular disease, older age, longer diabetes duration and more comorbidities.	IIa	C	
Antithrombotic treatment and invasive strategy			
It is recommended to administer the same antithrombotic treatment in diabetic and non-diabetic patients.	I	C	
An invasive strategy is recommended over non-invasive management.	I	A	352, 441, 442
It is recommended to monitor renal function for 2–3 days after coronary angiography or PCI in patients with baseline renal impairment or on metformin.	I	C	
In patients undergoing PCI, new-generation DESs are recommended over BMSs.	I	A	240, 241, 443
In patients with stabilised multivessel CAD and an acceptable surgical risk, CABG is recommended over PCI.	I	A	379, 436, 444
In patients with stabilised multivessel CAD and a SYNTAX score ≤22, PCI should be considered as an alternative to CABG.	IIa	B	435, 445

ACS = acute coronary syndromes; BMS = bare-metal stent; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES = drug-eluting stent; NSTEMI-ACS = non-ST-elevation acute coronary syndromes; PCI = percutaneous coronary intervention; SYNTAX = SYnergy between percutaneous coronary intervention with TAXus and cardiac surgery.
^aClass of recommendation.
^bLevel of evidence.
^cReferences supporting level of evidence.

5.8.3 Chronic kidney disease (see Web addenda)

5.8.3.1 Dose adjustment of antithrombotic agents (see Web addenda)

5.8.3.2 Recommendations for the management of patients with chronic kidney disease and non-ST-elevation acute coronary syndromes

Recommendations for the management of patients with chronic kidney disease and non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
It is recommended to assess kidney function by eGFR in all patients.	I	C	
It is recommended to administer the same first-line antithrombotic treatment as in patients with normal kidney function, with appropriate dose adjustment if indicated.	I	B	453, 454
Depending on the degree of renal dysfunction, it is recommended to switch parenteral anticoagulation to UFH or to adjust the doses of fondaparinux, enoxaparin and bivalirudin, as well as the dose of small molecule GPIIb/IIIa inhibitors.	I	B	453, 454
It is recommended to switch s.c. or i.v. anticoagulation to UFH infusion adjusted to the aPTT when eGFR is <30 mL/min/1.73 m ² (for fondaparinux, when eGFR is <20 mL/min/1.73 m ²).	I	C	
In patients undergoing an invasive strategy, hydration with isotonic saline and low- or iso-osmolar contrast media (at lowest possible volume) are recommended.	I	A	455–460
Coronary angiography and, if needed, revascularization are recommended after careful assessment of the risk–benefit ratio, in particular with respect to the severity of renal dysfunction.	I	B	448
In patients undergoing PCI, new-generation DESs are recommended over BMSs.	I	B	461, 462
CABG should be considered over PCI in patients with multivessel CAD whose surgical risk profile is acceptable and life expectancy is >1 year.	IIa	B	463, 464
PCI should be considered over CABG in patients with multivessel CAD whose surgical risk profile is high or life expectancy is <1 year.	IIa	B	465, 466

^aPTT = activated partial thromboplastin time; BMS = bare metal stent; CABG = coronary artery bypass graft; CAD = coronary artery disease; CKD = chronic kidney disease; DES = drug-eluting stent; eGFR = estimated glomerular filtration rate; GP = glycoprotein; i.v. = intravenous; PCI = percutaneous coronary intervention; s.c. = subcutaneous; UFH = unfractionated heparin.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

5.8.4 Left ventricular dysfunction and heart failure (see Web addenda)

5.8.4.1 Recommendations for the management of patients with acute heart failure in the setting of non-ST-elevation acute coronary syndromes

Recommendations for the management of patients with acute heart failure in the setting of non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
It is recommended to perform emergency echocardiography to assess LV and valvular function and exclude mechanical complications.	I	C	
Immediate coronary angiography is recommended in patients with acute heart failure with refractory angina, ST deviation or cardiogenic shock.	I	B	1, 475, 476
Immediate PCI is recommended for patients with cardiogenic shock if coronary anatomy is suitable.	I	B	475
Emergency CABG is recommended for patients with cardiogenic shock if the coronary anatomy is not amenable to PCI.	I	B	475
It is recommended that patients with mechanical complications of NSTEMI-ACS are immediately discussed by the Heart Team.	I	C	
IABP insertion should be considered in patients with haemodynamic instability/cardiogenic shock due to mechanical complications.	IIa	C	
Short-term mechanical circulatory support in patients with cardiogenic shock may be considered.	IIb	C	
Routine use of IABP in patients with cardiogenic shock is not recommended.	III	B	477

CABG = coronary artery bypass grafting; IABP = intra-aortic balloon pump; LV = left ventricular; NSTEMI-ACS = non-ST-elevation acute coronary syndromes; PCI = percutaneous coronary intervention.

With respect to detailed medical management of acute heart failure, we refer the reader to dedicated guidelines.⁴⁶⁹

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

5.8.4.2 Recommendations for the management of patients with heart failure following non-ST-elevation acute coronary syndromes

Recommendations for the management of patients with heart failure following non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
An ACE inhibitor (or ARB, if an ACE inhibitor is not tolerated) is recommended in patients with LVEF ≤40% after stabilization, to reduce the risk of death, recurrent MI and hospitalization for heart failure.	I	A	469, 478–481
A beta-blocker is recommended in patients with an LVEF ≤40% after stabilization, to reduce the risk of death, recurrent MI and hospitalization for heart failure.	I	A	469, 482–486
Mineralocorticoid receptor antagonists are recommended to reduce the risk of heart failure hospitalization and death in all patients with persistent symptoms (NYHA class II–IV) and LVEF ≤35% despite treatment with an ACE inhibitor (or an ARB, if an ACE inhibitor is not tolerated) and a beta-blocker.	I	A	487, 488
Mineralocorticoid receptor antagonists, preferably eplerenone, are recommended to reduce the risk of cardiovascular hospitalization and death in patients with LVEF ≤40%.	I	B	469, 525
Device therapy (CRT-D or ICD, depending on QRS duration) is recommended in symptomatic patients with severe LV dysfunction (LVEF ≤35%) despite optimal medical therapy >40 days after the acute event and without options of revascularization. Patients should be expected to survive >1 year with good functional status.	I	A	489, 490
In patients with CAD and LVEF ≤35%, testing for residual ischaemia and subsequent revascularization should be considered prior to primary prophylactic ICD/CRT-D implantation. After revascularization, assessment of reverse LV remodelling up to 6 months should be considered prior to primary prophylactic ICD/CRT-D implantation.	IIa	B	491, 492

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CAD = coronary artery disease; CRT-D = cardiac resynchronization therapy defibrillator; ICD = implantable cardioverter defibrillator; LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NYHA = New York Heart Association.
^aClass of recommendation.
^bLevel of evidence.
^cReferences supporting level of evidence.

5.8.5 Atrial fibrillation (see Web addenda)

5.8.5.1 Recommendations for the management of atrial fibrillation in patients with non-ST-elevation acute coronary syndromes

Recommendations for the management of atrial fibrillation in patients with non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
In the absence of contraindications, it is recommended to administer anticoagulant drugs to all patients at presentation.	I	A	497
Investigations to detect ischaemia should be considered in patients with atrial fibrillation and elevated cardiac troponin levels.	IIa	C	
Patients with rapid ventricular rate			
Electrical cardioversion is recommended in haemodynamically unstable patients.	I	C	
Electrical or pharmacological cardioversion with amiodarone is recommended in patients when a decision is made to restore sinus rhythm non-urgently (rhythm control strategy). This strategy should only be employed in patients with the first episode of atrial fibrillation of <48 h duration (or in patients with no evidence of left atrial appendage thrombus on TOE) or if the patient was anticoagulated in the therapeutic range for at least 3 weeks.	I	C	
Intravenous beta-blockers are recommended to slow the rapid ventricular response to atrial fibrillation in haemodynamically stable patients.	I	C	
Intravenous administration of cardiac glycosides may be considered for ventricular rate control if the response to beta-blockers is not sufficient.	IIb	C	
Intravenous administration of non-dihydropyridine calcium antagonists (verapamil, diltiazem) may be considered to slow a rapid ventricular response to atrial fibrillation in patients not on beta-blockers and with no signs of heart failure.	IIb	C	
Administration of class I antiarrhythmic agents (e.g. encainide, flecainide) is not recommended.	III	B	498
Vernakalant is not recommended.	III	C	493

TOE = transoesophageal echocardiography.
^aClass of recommendation.
^bLevel of evidence.
^cReferences supporting level of evidence.

5.8.6 Anaemia (see Web addenda)

5.8.7 Thrombocytopenia

5.8.7.1 *Thrombocytopenia related to GPIIb/IIIa inhibitors (Web addenda)*

5.8.7.2 *Heparin-induced thrombocytopenia (Web addenda)*

5.8.7.3 *Recommendations for the management of thrombocytopenia in non-ST-elevation acute coronary syndromes*

Recommendations for the management of thrombocytopenia in non-ST-elevation acute coronary syndromes

Recommendations	Class ^a	Level ^b	Ref. ^c
Immediate interruption of GPIIb/IIIa inhibitor and/or heparin (UFH, LMWH, other heparin products) is recommended in case of thrombocytopenia <100 000/ μ L (or >50% relative drop from baseline platelet count) occurring during treatment.	I	C	
In patients treated with GP IIb/IIIa inhibitors, platelet transfusion is recommended in case of major active bleeding events or in the presence of severe (<10 000/ μ L) asymptomatic thrombocytopenia.	I	C	
Treatment with a non-heparin anticoagulant is recommended in case of documented or suspected HIT.	I	C	
Use of anticoagulants with low or no risk of HIT or brief administration of UFH or LMWH, when these are chosen, are recommended to prevent the occurrence of HIT.	I	C	

GP = glycoprotein; HIT = heparin-induced thrombocytopenia; LMWH = low molecular weight heparin; UFH = unfractionated heparin.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

5.8.8 Patients requiring chronic analgesic or anti-inflammatory treatment (see Web addenda)

5.8.9 Non-cardiac surgery (see Web addenda)

5.9 Long-term management

5.9.1 Medical therapy for secondary prevention

Secondary prevention of CV events, including optimal medical therapy, other strategies for risk factor modification and lifestyle changes such as diet, exercise and smoking cessation, is of paramount importance because after an ACS episode, patients remain at high risk for recurrent ischaemic events.⁵²¹ Secondary prevention has been shown to have a major impact on long-term outcome in these patients.^{478,479,482,521–526}

5.9.1.1 Lipid-lowering treatment

It is recommended to initiate high-intensity statin therapy [i.e. statin regimens that reduce low-density lipoprotein (LDL) cholesterol by ~50%] as early as possible after admission in all NSTEMI-ACS patients (in the absence of contraindications). The intensity of statin therapy

should be increased in those receiving a low- or moderate-intensity statin treatment at presentation, unless they have a history of intolerance to high-intensity statin therapy or other characteristics that may influence safety.^{522,527,528} In this regard, the IMPROVED Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) randomized a total of 18 144 patients with recent ACS (NSTEMI 47%, STEMI 29% and unstable angina 24%) and LDL cholesterol <125 mg/dL (<2.5 mmol/L) to either ezetimibe 10 mg/simvastatin 40 mg or simvastatin 40 mg (simvastatin was up-titrated to 80 mg if LDL cholesterol was >79 mg/dL or 2.04 mmol/L). Over a period of 7 years, the composite primary endpoint of CV death, MI, hospital admission for unstable angina, coronary revascularization or stroke was significantly lower in the combined treatment arm compared with the statin-only arm [32.7% vs. 34.7%; HR 0.94 (95% CI 0.89, 0.99), $P = 0.016$].⁵²⁹ IMPROVE-IT was the first study powered for clinical outcomes to show a modest benefit with a non-statin agent added to a statin. As a limitation, not all patients in the control arm were on a high-intensity statin regimen. Based on the results of the trial, further LDL cholesterol lowering with a non-statin agent should be considered in patients with LDL cholesterol ≥ 70 mg/dL (≥ 1.8 mmol/L) after NSTEMI-ACS despite a maximally tolerated dose of statin. At the time of finalizing the guidelines, this recommendation applies only to ezetimibe.

5.9.1.2 Antithrombotic therapy

Duration of antiplatelet treatment and anticoagulation during the chronic phase are discussed in sections 5.2.6 and 5.3.2, respectively.

5.9.1.3 ACE inhibition

ACE inhibitors are recommended in patients with systolic LV dysfunction or heart failure, hypertension or diabetes (agents and doses of proven efficacy should be employed). ARBs are indicated in patients who are intolerant of ACE inhibitors.^{478–480,530,531}

5.9.1.4 Beta-blockers

Beta-blockers are recommended, in the absence of contraindications, in patients with reduced systolic LV function (LVEF $\leq 40\%$). Agents and doses of proven efficacy should be administered.^{482–486} Beta-blocker therapy has not been investigated in contemporary RCTs in patients after NSTEMI-ACS and no reduced LV function or heart failure. In a large-scale observational propensity-matched study in patients with known prior MI, beta-blocker use was not associated with a lower risk of CV events or mortality.⁵³²

5.9.1.5 Mineralocorticoid receptor antagonist therapy

Aldosterone antagonist therapy is recommended in patients with LV dysfunction (LVEF $\leq 40\%$) and heart failure or diabetes after NSTEMI-ACS. Eplerenone therapy has been shown to reduce morbidity and mortality in these patients after ACS.^{487,488,525}

5.9.1.6 Antihypertensive therapy

Antihypertensive therapy (blood pressure goal <140/90 mmHg) is recommended according to the European Society of Hypertension/ESC guidelines on the management of arterial hypertension.⁵³³

5.9.1.7 Glucose-lowering therapy in diabetic patients

This topic is beyond the scope of the present document and was discussed in recent guidelines.⁴³³ As a general rule, the more advanced

the CV disease, the older the patient, the longer the diabetes duration and the more comorbidities that are present, the less stringent the glucose control should be.

Core components and goals of cardiac rehabilitation, including physical activity counselling, diet/nutrition counselling, smoking cessation, weight control and goals for lipid and blood pressure management should be stated in the discharge letter.⁵³⁴

5.9.2 Lifestyle changes and cardiac rehabilitation

Enrolment in a well-structured cardiac rehabilitation/secondary prevention programme after NSTEMI-ACS should be considered, as it can enhance patient compliance with the medical regimen and promote lifestyle changes, including regular physical exercise and smoking cessation, and allows for dietary counselling.^{521,535} Aerobic exercise training within a cardiac rehabilitation programme should be offered to patients after NSTEMI-ACS, with the need for an evaluation of both exercise capacity and exercise-associated risk. If feasible, regular exercise training three or more times a week and 30 min per session is recommended. Sedentary patients should be strongly encouraged to start light-intensity exercise programmes after adequate exercise-related risk stratification. Smoking cessation is a highly effective measure to reduce morbidity and mortality in patients after ACS.^{521,536}

5.9.3 Recommendations for long-term management after non-ST-elevation acute coronary syndromes

Recommendations for long-term management after non-ST-elevation acute coronary syndromes

Recommendations (for the recommendations on antithrombotic treatment, see sections 5.2.9 and 5.3.3)	Class ^a	Level ^b	Ref. ^c
It is recommended to advise all patients on lifestyle changes (including smoking cessation, regular physical activity and a healthy diet).	I	A	536, 537
It is recommended to start high-intensity statin therapy as early as possible, unless contraindicated, and maintain it long term.	I	A	522, 527, 528
An ACE inhibitor is recommended in patients with LVEF ≤40% or heart failure, hypertension or diabetes, unless contraindicated. An ARB provides an alternative, particularly if ACE inhibitors are not tolerated.	I	A	478–481, 530, 531, 538
Beta-blocker therapy is recommended in patients with LVEF ≤40%, unless contraindicated.	I	A	482–486
Mineralocorticoid receptor antagonists, preferably eplerenone, are recommended in patients with LVEF ≤35% and either heart failure or diabetes after NSTEMI-ACS but no significant renal dysfunction or hyperkalaemia. ^d	I	A	487, 488, 525
A diastolic blood pressure goal of <90 mmHg is recommended (<85 mmHg in diabetic patients).	I	A	539, 540

Participation in a well-structured cardiac rehabilitation programme to modify lifestyle habits and increase adherence to treatment should be considered.	IIa	A	535, 541–546
In patients with LDL cholesterol ≥70 mg/dL (≥1.8 mmol/L) despite a maximally tolerated statin dose, further reduction in LDL cholesterol with a non-statin agent ^e should be considered.	IIa	B	529
A systolic blood pressure goal of <140 mmHg should be considered.	IIa	B	547–549

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; LDL = low-density lipoprotein; LVEF = left ventricular ejection fraction; NSTEMI-ACS = non-ST-elevation acute coronary syndromes.

^aClass of recommendation.

^bLevel of evidence.

^cReferences supporting level of evidence.

^dSerum creatinine <221 μmol/L (2.5 mg/dL) for men and <177 μmol/L (2.0 mg/dL) for women; serum potassium concentration <5.0 mmol/L.

^eAt the time of finalizing the guidelines, this recommendation applies only to ezetimibe.

6. Performance measures

Variations in the application of evidence-based strategies are associated with significant differences in outcome. Several large registries have shown deficiencies in the treatment of NSTEMI-ACS patients when compared with recommendations from contemporary guidelines. Underutilization of evidence-based treatments is common. Adherence to guidelines has been correlated with improvements in patient outcomes in ACS, including reduced mortality.^{550,551} Thus priority needs to be given to improving the utilization of evidence-based guidelines. Continuous monitoring of performance indicators is strongly encouraged to enhance the quality of treatment and minimize unwarranted variations in evidence-based care. Consistent application of therapies based on

Table 14 Performance measures in NSTEMI-ACS patients

• Use of aspirin
• Use of ticagrelor/prasugrel/clopidogrel
• Use of fondaparinux/bivalirudin/UFH/enoxaparin
• Use of beta-blocker at discharge in patients with LV dysfunction
• Use of statins
• Use of ACE-inhibitor or ARB in patients with systolic LV dysfunction or heart failure, hypertension or diabetes
• Use of early invasive procedures in intermediate- to high-risk patients
• Smoking cessation advice/counselling
• Enrolment in a secondary prevention/ cardiac rehabilitation programme
• Development of regional and/or national programmes to measure performance indicators systematically and provide feedback to individual hospitals

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; LV = left ventricular; NSTEMI = non-ST-elevation myocardial infarction; UFH = unfractionated heparin.

robust evidence may have larger effects on real-life CV health than those seen in selected trial populations, especially with the combined implementation of several effective treatment modalities. Such programmes have been implemented successfully in several countries, including Sweden [the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)], the UK [Myocardial Infarction National Audit Project (MINAP) registry], Germany, Italy and Israel on a regional basis, or in intermittent programmes in many other countries. These performance measure programmes are also proposed and developed by the ESC through the continuous ACS Registry within the Euro Heart Survey Program. The most useful performance indicators for monitoring and improving the standards of care in NSTEMI are listed in *Table 14*.

7. Summary of management strategy

This section summarises the diagnostic and therapeutic steps discussed in the previous sections. The goal is to outline the most important steps in the management of patients with NSTEMI-ACS. In each individual patient, decision making should take into account the patient's history (e.g. age, comorbidities), clinical presentation (e.g. ongoing myocardial ischaemia, haemodynamic or electrical instability), findings obtained during the initial assessment (i.e. ECG, cardiac troponin), timing and expected risk–benefit ratio of available therapies (i.e. pharmacological, invasive assessment, revascularization).

Step 1: Initial evaluation and pathway

Chest pain or other atypical symptoms prompt the patient to seek medical attention. All patients with suspected NSTEMI-ACS must be admitted to an emergency department and evaluated rapidly by a qualified physician. The delay between first medical contact and ECG should be ≤ 10 min. The cardiac rhythm of the patient should be monitored (*Table 7*).

The working diagnosis of NSTEMI-ACS and the initial management should be based on the following parameters:

- Chest pain characteristics, duration and persistence as well as a symptom-oriented physical examination (e.g. systolic blood pressure, heart rate, cardiopulmonary auscultation, Killip classification)
- Assessment of the probability of CAD based on chest pain characteristics, age, gender, CV risk factors, known CAD and non-cardiac manifestations of atherosclerosis
- 12-lead ECG (to detect ST deviation or other abnormalities suggestive of myocardial ischaemia or necrosis)

On the basis of these findings, the patient can be assigned to one of four working diagnoses:

- STEMI
- NSTEMI-ACS with ongoing ischaemia or haemodynamic instability
- NSTEMI-ACS without ongoing ischaemia or haemodynamic instability
- NSTEMI-ACS unlikely

The treatment of patients with STEMI is covered in the respective ESC guidelines.¹ The assignment to the category 'unlikely' must be done with caution, especially in patients with a specific condition, such as the elderly and those with diabetes mellitus, and only when another explanation is obvious. The initial treatment measure should include nitrates (sublingual or i.v.) if there is persisting chest

pain, hypertension or heart failure. Oxygen therapy should be applied in the presence of a blood oxygen saturation $< 90\%$ or respiratory distress. Morphine (i.v. or s.c.) or alternative opiates are reserved for patients with persisting severe chest pain. In patients with ongoing chest pain and inconclusive ECG, consider immediate echocardiography to exclude alternative diagnoses (if appropriate in conjunction with CT angiography) such as pulmonary embolism, pericarditis or aortic dissection and at the same time to reinforce the suspicion of NSTEMI-ACS (i.e. by identifying a focal wall motion abnormality). In the setting of ongoing myocardial ischaemia or haemodynamic compromise (the clinical suspicion should be corroborated by the echocardiographic finding of regional wall motion abnormality) the patient should undergo immediate coronary angiography irrespective of ECG or biomarker findings to prevent life-threatening ventricular arrhythmias and limit myocardial necrosis. Blood work on admission should include at least (preferably high-sensitivity) cardiac troponin T or I, serum creatinine, haemoglobin, haematocrit, platelet count, blood glucose and INR in patients on VKA. The results of the troponin measurements should be available within 60 min and troponin measurement should be repeated at 1–3 h if high-sensitivity troponin assays are used. Vital signs should be assessed on a regular basis. In case of hospital admission, guidance in the choice of the unit is described in *Table 7*. Patients with suspected NSTEMI-ACS should be observed in interdisciplinary emergency departments or chest pain units until the diagnosis of MI is confirmed or ruled out. If the diagnosis of NSTEMI-ACS is confirmed, the lipid profile should be assessed in the early phase of admission. In case of ongoing ischaemia, defibrillator patches should be placed until urgent revascularization is performed. It is recommended that medical and paramedical personnel caring for suspected NSTEMI-ACS patients have access to defibrillator equipment and are trained in advanced cardiac life support.

Step 2: Diagnosis validation, risk assessment and rhythm monitoring

Once the initial clinical assessment, complemented by the 12-lead ECG and the first cardiac troponin measurement, has substantiated the diagnosis of NSTEMI-ACS, antithrombotic treatment (as described in step 3) as well as anti-anginal treatment (i.e. beta-blockers and nitrates) should be started. Further management of the patient is based on responsiveness to anti-anginal treatment and risk assessment, as quantified by the GRACE 2.0 risk score (<http://www.gracescore.org/WebSite/default.aspx?ReturnUrl=%2f>), as well as on results of the subsequent troponin measurement (at 1–3 h, if high-sensitivity assays are used). Echocardiography is useful to identify abnormalities suggestive of myocardial ischaemia or necrosis (i.e. segmental hypokinesia or akinesia) and should be performed immediately in patients with haemodynamic instability of suspected CV origin. If aortic dissection or pulmonary embolism is suspected, echocardiography, D-dimer assessment and CT angiography should be implemented according to the respective ESC guidelines.^{42,43} Rhythm monitoring up to 24 hours or PCI (whichever comes first) should be considered in NSTEMI patients at low risk for cardiac arrhythmias (i.e. with none of the following criteria: haemodynamically unstable, major arrhythmias, LVEF $< 40\%$, failed reperfusion, additional critical coronary stenoses or complications related to PCI). Rhythm monitoring for > 24 hours should be considered in NSTEMI patients at intermediate to high-risk for cardiac arrhythmias (i.e. if one or more of the above criteria are present).

Step 3: Antithrombotic treatment

The choice of the antithrombotic regimen in NSTEMI-ACS should be based on the selected management strategy (i.e. conservative vs. invasive) as well as the chosen revascularization modality (PCI vs. CABG). Dosing of antithrombotic agents (Tables 8, 10 and 11) should take into account patient age and renal function. Aspirin and parenteral anticoagulation are recommended. In patients intended for a conservative treatment and not at high bleeding risk, ticagrelor (preferred over clopidogrel) is recommended once the NSTEMI diagnosis is established. In patients intended for an invasive strategy, the optimal timing of the administration of ticagrelor (preferred over clopidogrel) has not been adequately investigated, while prasugrel is recommended only after coronary angiography prior to PCI.

Step 4: Invasive strategy

Radial access for coronary angiography and, if needed, revascularization is recommended. Strategies to reduce bleeding complications related to PCI are summarised in Table 12. The timing of angiography (calculated from first medical contact) can be classified into four categories based on the risk profile of the individual patient according to Table 13 and Figure 6.

- **Immediate invasive strategy (<2 h).** Paralleling the STEMI pathway, this strategy should be undertaken for patients with ongoing ischaemia, characterized by at least one very-high-risk criterion. Centres without ongoing STEMI programmes should transfer the patient immediately.
- **Early invasive strategy (<24 h).** Most patients in this category respond to the initial pharmacological treatment but are at increased risk and need early angiography followed by revascularization. Patients qualify if they have at least one high-risk criterion. This implies timely transfer for patients admitted to hospitals without onsite catheterization facilities.
- **Invasive strategy (<72 h).** This is the recommended maximal delay for coronary angiography in patients without recurrence of symptoms but with at least one intermediate-risk criterion. Urgent transfer to a hospital with onsite catheterization facilities is not necessary, but the 72 h window for coronary angiography should be complied with.
- **Selective invasive strategy.** Patients with no recurrence of chest pain, no signs of heart failure, no abnormalities in the initial or subsequent ECG and no increase in (preferably high-sensitivity) cardiac troponin level are at low risk of subsequent CV events. In this setting, a non-invasive stress test (preferably with imaging) for inducible ischaemia is recommended before deciding on an invasive strategy.

Step 5: Revascularization modalities

In the absence of dedicated trials, recommendations for PCI and CABG in stabilised NSTEMI-ACS are similar to those for stable CAD. In patients with single-vessel disease, PCI with stenting of the culprit lesion is the first choice. In patients with multivessel disease, the decision for PCI or CABG should be individualized through consultation with the Heart Team. A sequential approach, consisting of treating the culprit lesion with PCI followed by elective CABG with proof of ischaemia and/or FFR of the non-culprit lesions, may be advantageous in selected patients. In patients on a single antiplatelet agent (aspirin) undergoing PCI, the addition of a P2Y₁₂ inhibitor (prasugrel or ticagrelor preferred over clopidogrel) is recommended. The anticoagulant should be selected based on both the ischaemic and bleeding risks

and should not be changed during PCI. In patients pretreated with fondaparinux, UFH must be added before PCI. In anticoagulant-naive patients, consider bivalirudin. If CABG is planned and the patient is on a P2Y₁₂ inhibitor, this should be stopped and surgery deferred if the clinical condition and the angiographic findings permit. If coronary angiography shows no options for revascularization, owing to the extent of the lesions and/or poor distal run-off, freedom from angina should be aimed for by intensifying medical therapy.

Step 6: Hospital discharge and post-discharge management

Although in NSTEMI-ACS most adverse events occur in the early phase, the risk for MI or death remains elevated over several months. Intense risk factor modification and lifestyle changes are warranted in all patients following NSTEMI-ACS, and enrolment in a cardiac rehabilitation programme after discharge can enhance patient adherence to the medical regimen, may be supportive of risk factor modification and is associated with improved outcomes.

8. Gaps in evidence

- The role of genetic testing to individualize treatment and ultimately improve patient outcomes remains to be established.
- While both sensitive and high-sensitivity cardiac troponin assays show superior diagnostic accuracy compared with conventional assays, it is unknown whether high-sensitivity assays provide a clinically meaningful advantage over sensitive assays and whether there are clinically relevant differences among various high-sensitivity assays. The incremental value of copeptin over high-sensitivity cardiac troponin assays remains to be fully elucidated.
- The performance of the 1 h algorithm to rule in and rule out acute MI in patients presenting with chest pain to the emergency department has not been tested within an RCT. The best management of patients assigned to the 'observational zone' according to the 1 h algorithm remains to be defined.
- The role of CT angiography as a rule-out tool for acute MI in the emergency department needs to be reassessed in the context of high-sensitivity cardiac troponin assays.
- The development of a single clinical risk score that assesses both ischaemic and bleeding risks would be desirable.
- The role of beta-blockers during and after an NSTEMI-ACS episode in patients with normal or mildly depressed LV function needs to be investigated.
- The optimal timing of ticagrelor administration in patients intended for an invasive strategy needs to be defined.
- Additional data are necessary to establish the optimal duration of dual antiplatelet therapy following stent implantation.
- The development of antidotes to normalise haemostasis in patients with ongoing major bleeding events while on P2Y₁₂ inhibitors or NOACs should be accelerated.
- The safety, effectiveness and optimal duration of combined oral anticoagulant and antiplatelet therapy in patients requiring chronic oral anticoagulation deserves further investigation.
- While several RCTs have compared CABG and PCI in populations comprising mainly stable CAD patients with multivessel disease, contemporary comparative investigations in the NSTEMI-ACS setting are lacking.
- The value of FFR-guided PCI in NSTEMI-ACS requires adequate investigation.

- The burden of late CV events despite optimal pharmacological treatment, including effective P2Y₁₂ inhibitors and statins, calls for reappraisal of the pathophysiology of these adverse outcomes and innovative preventive strategies.
- Clinical trials are under way to examine whether a profound LDL cholesterol-lowering or immune-modulating therapy (e.g. PCSK-9 inhibition, intense CETP inhibition, methotrexate or monoclonal anti-IL-1β antibodies) in addition to maximally tolerated statin treatment may improve long-term prognosis.
- The optimal haemoglobin/haematocrit threshold that should trigger blood transfusion in anaemic patients with NSTEMI-ACS needs to be determined.

9. To do and not to do messages from the guidelines

	Recommendations	Class ^a	Level ^b
Diagnosis			
1	Similarly to the 0 h and 3 h protocol, a rapid rule-out and rule-in protocol at 0 h and 1 h is recommended if a high-sensitivity cardiac troponin test with a validated 0 h/1 h algorithm is available. Additional testing after 3–6 h is indicated if the first two troponin measurements are not conclusive and the clinical condition is still suggestive of ACS.	I	B
2	Echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.	I	C
Antiplatelet treatment			
3	A P2Y ₁₂ inhibitor is recommended, in addition to aspirin, for 12 months unless there are contraindications such as excessive risk of bleeds.	I	A
	<ul style="list-style-type: none"> • Ticagrelor (180 mg loading dose, 90 mg twice daily) is recommended, in the absence of contraindications,^c for all patients at moderate to high risk of ischaemic events (e.g. elevated cardiac troponins), regardless of initial treatment strategy and including those pretreated with clopidogrel (which should be discontinued when ticagrelor is started). 	I	B
	<ul style="list-style-type: none"> • Prasugrel (60 mg loading dose, 10 mg daily dose) is recommended in patients who are proceeding to PCI if there are no contraindications.^c 	I	B
	<ul style="list-style-type: none"> • Clopidogrel (300–600 mg loading dose, 75 mg daily dose) is recommended for patients who cannot receive ticagrelor or prasugrel or who require oral anticoagulation. 	I	B
4	It is not recommended to administer prasugrel in patients in whom the coronary anatomy is not known.	III	B

Invasive strategy			
5	An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very-high-risk criteria: haemodynamic instability or cardiogenic shock; recurrent or ongoing chest pain refractory to medical treatment; life-threatening arrhythmias or cardiac arrest; mechanical complications of MI; acute heart failure with refractory angina or ST deviation; recurrent dynamic ST- or T-wave changes, particularly with intermittent ST elevation.	I	C
6	An early invasive strategy (<24 h) is recommended in patients with at least one of the following high-risk criteria: rise or fall in cardiac troponin compatible with MI; dynamic ST- or T-wave changes (symptomatic or silent); GRACE score >140.	I	A
7	An invasive strategy (<72 h) is recommended in patients with at least one of the following intermediate-risk criteria: <ul style="list-style-type: none"> ○ diabetes mellitus ○ renal insufficiency (eGFR <60 mL/min/1.73 m²) ○ LVEF <40% or congestive heart failure ○ early post-infarction angina ○ recent PCI ○ prior CABG ○ GRACE risk score >109 and <140 	I	A
Coronary revascularization			
8	In centres experienced with radial access, a radial approach is recommended for coronary angiography and PCI.	I	A
9	In patients with multivessel CAD, it is recommended to base the revascularization strategy (e.g. ad hoc culprit-lesion PCI, multivessel PCI, CABG) on the clinical status and comorbidities as well as the disease severity (including distribution, angiographic lesion characteristics, SYNTAX score) according to the local Heart Team protocol.	I	C
Secondary cardiovascular prevention			
10	It is recommended to start high-intensity statin therapy as early as possible, unless contraindicated, and maintain it long term.	I	A

ACS = acute coronary syndromes; CABG = coronary artery bypass graft; CAD = coronary artery disease; eGFR = estimated glomerular filtration rate; GRACE = Global Registry of Acute Coronary Events; LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI = percutaneous coronary intervention; SYNTAX = SYnergy between percutaneous coronary intervention with TAXus and cardiac surgery.

^aClass of recommendation.

^bLevel of evidence.

^cContraindications for ticagrelor: previous intracranial haemorrhage or ongoing bleeds. Contraindications for prasugrel: previous intracranial haemorrhage, previous ischaemic stroke or transient ischaemic attack or ongoing bleeds; prasugrel is generally not recommended for patients ≥75 years of age or with a bodyweight <60 kg.

10. Web addenda and companion documents

All Web figures and Web tables are available in the online addenda at: <http://www.escardio.org/Guidelines-&-Education/Clinical-Practice-Guidelines/Acute-Coronary-Syndromes-ACS-in-patients-presenting-without-persistent-ST-segm>

Questions and answers companion manuscripts of these guidelines are available via this same link.

11. Acknowledgements

We are indebted to Veronica Dean, Nathalie Cameron, Catherine Despres and the entire ESC Practice Guidelines Staff for their invaluable support throughout the project.

12. Appendix

ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon (Spain), Gonzalo Barón-Esquivias (Spain), Helmut Baumgartner (Germany), Jeroen J. Bax (The Netherlands), Héctor Bueno (Spain), Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey), Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Paulus Kirchhof (UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellotti (Belgium), Gregory Y.H. Lip (UK), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marco Roffi (Switzerland), Adam Torbicki (Poland), Antonio Vaz Carneiro (Portugal), Stephan Windecker (Switzerland).

ESC National Cardiac Societies actively involved in the review process of the 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation:

Armenia: Armenian Cardiologists Association, Aram Chilingaryan; **Austria:** Austrian Society of Cardiology, Franz Weidinger; **Azerbaijan:** Azerbaijan Society of Cardiology, Ruslan Najafov; **Belgium:** Belgian Society of Cardiology, Peter R. Sinnaeve; **Bosnia & Herzegovina:** Association of Cardiologists of Bosnia & Herzegovina, Ibrahim Terzić; **Bulgaria:** Bulgarian Society of Cardiology, Arman Postadzhiyan; **Croatia:** Croatian Cardiac Society, Davor Miličić; **Cyprus:** Cyprus Society of Cardiology, Christos Eftychiou; **Czech Republic:** Czech Society of Cardiology, Petr Widimsky; **Denmark:** Danish Society of

Cardiology, Lia Bang; **Egypt:** Egyptian Society of Cardiology, Adel El Etriby; **Estonia:** Estonian Society of Cardiology, Toomas Marandi; **Finland:** Finnish Cardiac Society, Mikko Pietilä; **Former Yugoslav Republic of Macedonia:** Macedonian Society of Cardiology, Sasko Kedev; **France:** French Society of Cardiology, René Koning; **Georgia:** Georgian Society of Cardiology, Alexander Aladashvili; **Germany:** German Cardiac Society, Franz-Josef Neumann; **Greece:** Hellenic Cardiological Society, Kostantinos Tsioufis; **Hungary:** Hungarian Society of Cardiology, Dávid Becker; **Iceland:** Icelandic Society of Cardiology, Thorarinn Guðnason; **Israel:** Israel Heart Society, Shlomi Matetzky; **Italy:** Italian Federation of Cardiology, Leonardo Bolognese; **Kazakhstan:** Association of Cardiologists of Kazakhstan, Aisulu Mussagalieva; **Kyrgyzstan:** Kyrgyz Society of Cardiology, Medet Beishenkulov; **Latvia:** Latvian Society of Cardiology, Gustavs Latkovskis; **Lithuania:** Lithuanian Society of Cardiology, Pranas Serpytis; **Luxembourg:** Luxembourg Society of Cardiology, Bruno Pereira; **Malta:** Maltese Cardiac Society, Caroline Jane Magri; **Moldova:** Moldavian Society of Cardiology, Aurel Grosu; **Morocco:** Moroccan Society of Cardiology, Saadia Abir-Khalil; **Norway:** Norwegian Society of Cardiology, Alf Inge Larsen; **Poland:** Polish Cardiac Society, Andrzej Budaj; **Portugal:** Portuguese Society of Cardiology, Jorge M. Vieira Mimoso; **Romania:** Romanian Society of Cardiology, Carmen Gingham; **Russia:** Russian Society of Cardiology, Oleg Averkov; **Serbia:** Cardiology Society of Serbia, Milan A. Nedeljkovic; **Slovakia:** Slovak Society of Cardiology, Martin Studenčan; **Spain:** Spanish Society of Cardiology, José A. Barrabés; **Sweden:** Swedish Society of Cardiology, Claes Held; **Switzerland:** Swiss Society of Cardiology, Hans Rickli; **The Netherlands:** Netherlands Society of Cardiology, Ron J.G. Peters; **Tunisia:** Tunisian Society of Cardiology and Cardio-Vascular Surgery, Mohamed Sami Mourali; **Turkey:** Turkish Society of Cardiology, Enver Atalar; **UK:** British Cardiovascular Society, Neil Swanson; **Ukraine:** Ukrainian Association of Cardiology, Alexander Parkhomenko.

†Section Coordinators affiliations: Jean-Philippe Collet, ACTION study Group, Institut de Cardiologie, INSERM_UMRS 1166, Pitié-Salpêtrière Hospital (AP-HP), Sorbonne Universités UPMC (Paris 6), F-75013 Paris, France, Tel: +33 1 42 16 30 13, Fax: +33 1 42 16 29 31, Email: jean-philippe.collet@psl.aphp.fr

Christian Mueller, Department of Cardiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland, Tel: +41 61 265 25 25, Fax: +41 61 265 53 53, Email: christian.mueller@usb.ch

Marco Valgimigli: Thoraxcenter, Erasmus MC, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands, Tel: +31 10 7033938, Fax: +31 10 7035258, Email: m.valgimigli@erasmusmc.nl

The CME text '2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation' is accredited by the European Board for Accreditation in Cardiology (EBAC). EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). In compliance with EBAC/EACCME Guidelines, all authors participating in this programme have disclosed any potential conflicts of interest that might cause a bias in the article. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the programme are declared to the participants prior to the CME activities.

CME questions for this article are available at: European Heart Journal <http://www.oxford-learning.com/eurheartj> and European Society of Cardiology <http://www.escardio.org/guidelines>.

References

1. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;**33**:2569–2619.
2. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA,

Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Januzzi JL, Nieminen MS, Gheorghide M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. *Eur Heart J* 2012;**33**:2551–2567.

3. Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery



- disease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial investigators. *Circulation* 2000;**102**: 1101–1106.
4. Reynolds HR, Srichai MB, Iqbal SN, Slater JN, Mancini GB, Feit F, Pena-Sing I, Axel L, Attubato MJ, Yatskar L, Kalhorn RT, Wood DA, Lobach IV, Hochman JS. Mechanisms of myocardial infarction in women without angiographically obstructive coronary artery disease. *Circulation* 2011;**124**: 1414–1425.
 5. Larsen AI, Galbraith PD, Ghali WA, Norris CM, Graham MM, Knudtson ML. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. *Am J Cardiol* 2005;**95**:261–263.
 6. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS. How to use high-sensitivity cardiac troponins in acute cardiac care. *Eur Heart J* 2012;**33**:2252–2257.
 7. Braunwald E, Morrow DA. Unstable angina: is it time for a requiem? *Circulation* 2013;**127**:2452–2457.
 8. Mueller C. Biomarkers and acute coronary syndromes: an update. *Eur Heart J* 2014;**35**:552–556.
 9. Reichlin T, Twerenbold R, Maushart C, Reiter M, Moehring B, Schaub N, Balmelli C, Rubini Gimenez M, Hoeller R, Sakarikos K, Drexler B, Haaf P, Osswald S, Mueller C. Risk stratification in patients with unstable angina using absolute serial changes of 3 high-sensitive troponin assays. *Am Heart J* 2013;**165**: 371–378, e373.
 10. Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti S, Balmelli C, Winkler K, Kurz S, Stelzig C, Freese M, Drexler B, Haaf P, Zellweger C, Osswald S, Mueller C. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. *Am J Med* 2012;**125**:1205–1213, e1201.
 11. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLuca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. *JAMA* 2001;**286**: 2405–2412.
 12. Bugiardini R, Manfrini O, De Ferrari GM. Unanswered questions for management of acute coronary syndrome: risk stratification of patients with minimal disease or normal findings on coronary angiography. *Arch Intern Med* 2006;**166**:1391–1395.
 13. Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. *Circulation* 2014;**129**:293–303.
 14. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. *N Engl J Med* 2013;**368**:2004–2013.
 15. Badimon L, Padro T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. *Eur Heart J Acute Cardiovasc Care* 2012;**1**:60–74.
 16. Davi G, Patrono C. Platelet activation and atherothrombosis. *N Engl J Med* 2007;**357**:2482–2494.
 17. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. *Am J Med* 2011;**124**:40–47.
 18. Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafrici A, Cavallini C, Melandri G, Thompson TD, Vahanian A, Ohman EM, Califf RM, Van de Werf F, Topol EJ. Prognostic value of the admission electrocardiogram in acute coronary syndromes. *JAMA* 1999;**281**:707–713.
 19. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, Gitt A, Hasdai D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Behar S. The Second Euro Heart Survey on Acute Coronary Syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean basin in 2004. *Eur Heart J* 2006;**27**:2285–2293.
 20. Terkelsen CJ, Lassen JF, Norgaard BL, Gerdes JC, Jensen T, Gotzsche LB, Nielsen TT, Andersen HR. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. *Eur Heart J* 2005;**26**:18–26.
 21. Campeau L. Letter: grading of angina pectoris. *Circulation* 1976;**54**:522–523.
 22. Canto JG, Fincher C, Kiefe CI, Allison JJ, Li Q, Funkhouser E, Centor RM, Selker HP, Weissman NW. Atypical presentations among Medicare beneficiaries with unstable angina pectoris. *Am J Cardiol* 2002;**90**:248–253.
 23. Mackay MH, Ratner PA, Johnson JL, Humphries KH, Buller CE. Gender differences in symptoms of myocardial ischaemia. *Eur Heart J* 2011;**32**:3107–3114.
 24. Rubini Gimenez M, Reiter M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Wicki K, Zellweger C, Hoeller R, Moehring B, Sou SM, Mueller M, Denhaerynck K, Meller B, Stallone F, Henseler S, Bassetti S, Geigy N, Osswald S, Mueller C. Sex-specific chest pain characteristics in the early diagnosis of acute myocardial infarction. *JAMA Intern Med* 2014;**174**:241–249.
 25. Persson A, Hartford M, Herlitz J, Karlsson T, Omland T, Caidahl K. Long-term prognostic value of mitral regurgitation in acute coronary syndromes. *Heart* 2010;**96**:1803–1808.
 26. Grani C, Senn O, Bischof M, Cippa PE, Hauffe T, Zimmerli L, Battegay E, Franzen D. Diagnostic performance of reproducible chest wall tenderness to rule out acute coronary syndrome in acute chest pain: a prospective diagnostic study. *BMJ Open* 2015;**5**:e007442.
 27. Devon HA, Rosenfeld A, Steffen AD, Daya M. Sensitivity, specificity, and sex differences in symptoms reported on the 13-item acute coronary syndrome checklist. *J Am Heart Assoc* 2014;**3**:e000586.
 28. Diercks DB, Peacock WF, Hiestand BC, Chen AY, Pollack CV Jr, Kirk JD, Smith SC Jr, Gibler WB, Ohman EM, Blomkalns AL, Newby LK, Hochman JS, Peterson ED, Roe MT. Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE initiative). *Am J Cardiol* 2006;**97**: 437–442.
 29. Okamoto K, Takano M, Sakai S, Ishibashi F, Uemura R, Takano T, Mizuno K. Elevated troponin T levels and lesion characteristics in non-ST-elevation acute coronary syndromes. *Circulation* 2004;**109**:465–470.
 30. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidhardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *N Engl J Med* 2009;**361**:858–867.
 31. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Munzel TF, Blankenberg S. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. *N Engl J Med* 2009;**361**:868–877.
 32. Keller T, Zeller T, Ojeda F, Tzikas S, Lillpopp L, Sinning C, Wild P, Genth-Zotz S, Warnholtz A, Giannitsis E, Mockel M, Bickel C, Peetz D, Lackner K, Baldus S, Munzel T, Blankenberg S. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. *JAMA* 2011;**306**:2684–2693.
 33. Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus HA. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. *Clin Chem* 2010;**56**:642–650.
 34. Haaf P, Drexler B, Reichlin T, Twerenbold R, Reiter M, Meissner J, Schaub N, Stelzig C, Freese M, Heinzelmann A, Meune C, Balmelli C, Freidank H, Winkler K, Denhaerynck K, Hochholzer W, Osswald S, Mueller C. High-sensitivity cardiac troponin in the distinction of acute myocardial infarction from acute cardiac noncoronary artery disease. *Circulation* 2012;**126**:31–40.
 35. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. *Clin Chem* 2009;**55**:1303–1306.
 36. Rubini Gimenez M, Hoeller R, Reichlin T, Zellweger C, Twerenbold R, Reiter M, Moehring B, Wildi K, Mosimann T, Mueller M, Meller B, Hochgruber T, Ziller R, Sou SM, Murray K, Sakarikos K, Ernst S, Gea J, Campodarve I, Vilaplana C, Haaf P, Steuer S, Minners J, Osswald S, Mueller C. Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. *Int J Cardiol* 2013;**168**:3896–3901.
 37. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. non-coronary disease. *Eur Heart J* 2011;**32**:404–411.
 38. Goodacre SW, Bradburn M, Cross E, Collinson P, Gray A, Hall AS. The Randomised Assessment of Treatment Using Panel Assay of Cardiac Markers (RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. *Heart* 2011;**97**:190–196.
 39. Reichlin T, Schindler C, Drexler B, Twerenbold R, Reiter M, Zellweger C, Moehring B, Ziller R, Hoeller R, Rubini Gimenez M, Haaf P, Potocki M, Wildi K, Balmelli C, Freese M, Stelzig C, Freidank H, Osswald S, Mueller C. One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. *Arch Intern Med* 2012;**172**:1211–1218.
 40. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, Bassetti S, Steuer S, Winkler K, Peter F, Meissner J, Haaf P, Potocki M, Drexler B, Osswald S, Mueller C. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. *Circulation* 2011;**124**:136–145.
 41. Irfan A, Twerenbold R, Reiter M, Reichlin T, Stelzig C, Freese M, Haaf P, Hochholzer W, Steuer S, Bassetti S, Zellweger C, Freidank H, Peter F, Campodarve I, Meune C, Mueller C. Determinants of high-sensitivity troponin T among patients with a noncardiac cause of chest pain. *Am J Med* 2012;**125**: 491–498, e491.
 42. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH,

- Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J* 2014;**35**:3033–3069, 3069a–3069k.
43. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2014;**35**:2873–2926.
 44. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C. Incremental value of copeptin for rapid rule out of acute myocardial infarction. *J Am Coll Cardiol* 2009;**54**:60–68.
 45. Keller T, Tzikas S, Zeller T, Czyz E, Lillpop L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF, Blankenberg S. Copeptin improves early diagnosis of acute myocardial infarction. *J Am Coll Cardiol* 2010;**55**:2096–2106.
 46. Raskovalova T, Twerenbold R, Collinson PO, Keller T, Bouvaist H, Folli C, Giavarina D, Lotze U, Eggers KM, Dupuy AM, Chenevier-Gobeaux C, Meune C, Maisel A, Mueller C, Labarere J. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. *Eur Heart J Acute Cardiovasc Care* 2014;**3**:18–27.
 47. Lipinski MJ, Escarcega RO, D'Ascenzo F, Magalhaes MA, Baker NC, Torguson R, Chen F, Epstein SE, Miro O, Llorens P, Giannitsis E, Lotze U, Lefebvre S, Sebbane M, Cristol JP, Chenevier-Gobeaux C, Meune C, Eggers KM, Charpentier S, Twerenbold R, Mueller C, Biondi-Zoccai G, Waksman R. A systematic review and collaborative meta-analysis to determine the incremental value of copeptin for rapid rule-out of acute myocardial infarction. *Am J Cardiol* 2014;**113**:1581–1591.
 48. Mockel M, Searle J, Hamm C, Slagman A, Blankenberg S, Huber K, Katus H, Liebetrau C, Muller C, Muller R, Peitsmeyer P, von Recum J, Tajsic M, Vollert JO, Giannitsis E. Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. *Eur Heart J* 2015;**36**:369–376.
 49. Maisel A, Mueller C, Neath SX, Christenson RH, Morgenthaler NG, McCord J, Nowak RM, Vilke G, Daniels LB, Hollander JE, Apple FS, Cannon C, Nagurny JT, Schreiber D, deFilippi C, Hogan C, Diercks DB, Stein JC, Headden G, Limkakeng AT Jr, Anand I, Wu AH, Papassotiropoulos J, Hartmann O, Ebmeyer S, Clopton P, Jaffe A, Peacock WF. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial IN-farction). *J Am Coll Cardiol* 2013;**62**:150–160.
 50. Balmelli C, Meune C, Twerenbold R, Reichlin T, Rieder S, Drexler B, Rubini MG, Mosimann T, Reiter M, Haaf P, Mueller M, Ernst S, Ballarino P, Alaffay AA, Zellweger C, Wildi K, Moehring B, Vilaplana C, Bernhard D, Merk S, Ebmeyer S, Freidank H, Osswald S, Mueller C. Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men. *Am Heart J* 2013;**166**:30–37.
 51. Body R, Carley S, McDowell G, Jaffe AS, France M, Cruickshank K, Wibberley C, Nuttall M, Mackway-Jones K. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. *J Am Coll Cardiol* 2011;**58**:1332–1339.
 52. Bandstein N, Ljung R, Johansson M, Holzmann MJ. Undetectable high-sensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. *J Am Coll Cardiol* 2014;**63**:2569–2578.
 53. Zhelev Z, Hyde C, Youngman E, Rogers M, Fleming S, Slade T, Coelho H, Jones-Hughes T, Nikolaou V. Diagnostic accuracy of single baseline measurement of Elecsys troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis. *BMJ* 2015;**350**:h15.
 54. Reichlin T, Twerenbold R, Wildi K, Gimenez MR, Bergsma N, Haaf P, Druey S, Puelacher C, Moehring B, Freese M, Stelzig C, Krivoshei L, Hillinger P, Jager C, Herrmann T, Kreutzinger P, Radosavac M, Weidmann ZM, Pershyna K, Honegger U, Wagener M, Vuillomenet T, Campodarve I, Bingisser R, Miro O, Rentsch K, Bassetti S, Osswald S, Mueller C. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. *CMAJ* 2015;**187**:E243–E252.
 55. Rubini Gimenez M, Twerenbold R, Jaeger C, Schindler C, Puelacher C, Wildi K, Reichlin T, Haaf P, Merk S, Honegger U, Wagener M, Druey S, Schumacher C, Krivoshei L, Hillinger P, Herrmann T, Campodarve I, Rentsch K, Bassetti S, Osswald S, Mueller C. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. *Am J Med* 2015;**128**:861–870.e4.
 56. Than M, Cullen L, Reid CM, Lim SH, Aldous S, Ardagh MW, Peacock WF, Parsonage WA, Ho HF, Ko HF, Kasliwal RR, Bansal M, Soerianata S, Hu D, Ding R, Hua Q, Seok-Min K, Sritara P, Sae-Lee R, Chiu TF, Tsai KC, Chu FY, Chen WK, Chang WH, Flaws DF, George PM, Richards AM. A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. *Lancet* 2011;**377**:1077–1084.
 57. Than M, Cullen L, Aldous S, Parsonage WA, Reid CM, Greenslade J, Flaws D, Hammett CJ, Beam DM, Ardagh MW, Troughton R, Brown AF, George P, Florkowski CM, Kline JA, Peacock WF, Maisel AS, Lim SH, Lamanna A, Richards AM. 2-hour accelerated diagnostic protocol to assess patients with chest pain symptoms using contemporary troponins as the only biomarker: the ADAPT trial. *J Am Coll Cardiol* 2012;**59**:2091–2098.
 58. Cullen L, Mueller C, Parsonage WA, Wildi K, Greenslade JH, Twerenbold R, Aldous S, Meller B, Tate JR, Reichlin T, Hammett CJ, Zellweger C, Ungerer JP, Rubini Gimenez M, Troughton R, Murray K, Brown AF, Mueller M, George P, Mosimann T, Flaws DF, Reiter M, Lamanna A, Haaf P, Pemberton CJ, Richards AM, Chu K, Reid CM, Peacock WF, Jaffe AS, Florkowski C, Deely JM, Than M. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. *J Am Coll Cardiol* 2013;**62**:1242–1249.
 59. Twerenbold R, Wildi K, Jaeger C, Gimenez MR, Reiter M, Reichlin T, Walukiewicz A, Gugala M, Krivoshei L, Marti N, Moreno Weidmann Z, Hillinger P, Puelacher C, Rentsch K, Honegger U, Schumacher C, Zurbriggen F, Freese M, Stelzig C, Campodarve I, Bassetti S, Osswald S, Mueller C. Optimal cut-off levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. *Circulation* 2015;**131**:2041–2050.
 60. Tong KL, Kaul S, Wang XQ, Rinkevich D, Kalvaitis S, Belcik T, Lepper W, Foster WA, Wei K. Myocardial contrast echocardiography versus thrombolysis in myocardial infarction score in patients presenting to the emergency department with chest pain and a nondiagnostic electrocardiogram. *J Am Coll Cardiol* 2005;**46**:920–927.
 61. Grenne B, Eek C, Sjolvi B, Dahlslett T, Uchto M, Hol PK, Skulstad H, Smiseth OA, Edvardsen T, Brunvand H. Acute coronary occlusion in non-ST-elevation acute coronary syndrome: outcome and early identification by strain echocardiography. *Heart* 2010;**96**:1550–1556.
 62. Lancellotti P, Price S, Edvardsen T, Cosyns B, Neskovic AN, Dulgheru R, Flachskampf FA, Hassager C, Pasquet A, Gargani L, Galderisi M, Cardim N, Haugaa KH, Ancion A, Zamorano JL, Donal E, Bueno H, Habib G. The use of echocardiography in acute cardiovascular care: recommendations of the European Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. *Eur Heart J Acute Cardiovasc Care* 2015;**4**:3–5.
 63. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, Zamorano JL, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tenders M, Torbicki A, Wijns W, Windecker S, Valgimigli M, Claeys MJ, Donner-Banzhoff N, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Husted S, James SK, Kervinen K, Kristensen SD, Maggioni AP, Pries AR, Romeo F, Ryden L, Simoons ML, Steg PG, Timmis A, Yildirim A. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology. *Eur Heart J* 2013;**34**:2949–3003.
 64. Shah BN, Balaji G, Alhajiri A, Ramzy IS, Ahmadvazir S, Senior R. Incremental diagnostic and prognostic value of contemporary stress echocardiography in a chest pain unit: mortality and morbidity outcomes from a real-world setting. *Circ Cardiovasc Imaging* 2013;**6**:202–209.
 65. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D, Voigt JU, Zamorano JL. Stress echocardiography expert consensus statement—executive summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). *Eur Heart J* 2009;**30**:278–289.
 66. Gaibazzi N, Reverberi C, Badano L. Usefulness of contrast stress-echocardiography or exercise-electrocardiography to predict long-term acute coronary syndromes in patients presenting with chest pain without electrocardiographic abnormalities or 12-hour troponin elevation. *Am J Cardiol* 2011;**107**:161–167.
 67. Gaibazzi N, Squeri A, Reverberi C, Molinaro S, Lorenzoni V, Sartorio D, Senior R. Contrast stress-echocardiography predicts cardiac events in patients with

- suspected acute coronary syndrome but nondiagnostic electrocardiogram and normal 12-hour troponin. *J Am Soc Echocardiogr* 2011;**24**:1333–1341.
68. Ingkanisorn WP, Kwong RY, Bohme NS, Geller NL, Rhoads KL, Dyke CK, Paterson DI, Syed MA, Aletras AH, Arai AE. Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest pain. *J Am Coll Cardiol* 2006;**47**:1427–1432.
 69. Kwong RY, Schussheim AE, Rekhraj S, Aletras AH, Geller N, Davis J, Christian TF, Balaban RS, Arai AE. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. *Circulation* 2003;**107**:531–537.
 70. Cury RC, Shash K, Nagurney JT, Rosito G, Shapiro MD, Nomura CH, Abbasa S, Bamberg F, Ferencik M, Schmidt EJ, Brown DF, Hoffmann U, Brady TJ. Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. *Circulation* 2008;**118**:837–844.
 71. Lockie T, Nagel E, Redwood S, Plein S. Use of cardiovascular magnetic resonance imaging in acute coronary syndromes. *Circulation* 2009;**119**:1671–1681.
 72. Udelson JE, Beshansky JR, Ballin DS, Feldman JA, Griffith JL, Handler J, Heller GV, Hendel RC, Pope JH, Ruthazer R, Spiegler EJ, Woolard RH, Selker HP. Myocardial perfusion imaging for evaluation and triage of patients with suspected acute cardiac ischemia: a randomized controlled trial. *JAMA* 2002;**288**:2693–2700.
 73. Lim SH, Anantharaman V, Sundram F, Chan ES, Ang ES, Yo SL, Jacob E, Goh A, Tan SB, Chua T. Stress myocardial perfusion imaging for the evaluation and triage of chest pain in the emergency department: a randomized controlled trial. *J Nucl Cardiol* 2013;**20**:1002–1012.
 74. Nabi F, Chang SM, Xu J, Gigliotti E, Mahmarian JJ. Assessing risk in acute chest pain: the value of stress myocardial perfusion imaging in patients admitted through the emergency department. *J Nucl Cardiol* 2012;**19**:233–243.
 75. Samad Z, Hakeem A, Mahmood SS, Pieper K, Patel MR, Simel DL, Douglas PS. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. *J Nucl Cardiol* 2012;**19**:364–376.
 76. Goldstein JA, Gallagher MJ, O'Neill WW, Ross MA, O'Neil BJ, Raff GL. A randomized controlled trial of multi-slice coronary computed tomography for evaluation of acute chest pain. *J Am Coll Cardiol* 2007;**49**:863–871.
 77. Goldstein JA, Chinnaiyan KM, Abidov A, Achenbach S, Berman DS, Hayes SW, Hoffmann U, Lesser JR, Mikati IA, O'Neil BJ, Shaw LJ, Shen MY, Valeti US, Raff GL. The CT-STAT (coronary computed tomographic angiography for systematic triage of acute chest pain patients to treatment) trial. *J Am Coll Cardiol* 2011;**58**:1414–1422.
 78. Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney JT, Pope JH, Hauser TH, White CS, Weiner SG, Kalanjan S, Mullins ME, Mikati I, Peacock WF, Zakrofsky P, Hayden D, Goehler A, Lee H, Gazelle GS, Wiviott SD, Fleg JL, Udelson JE. Coronary CT angiography versus standard evaluation in acute chest pain. *N Engl J Med* 2012;**367**:299–308.
 79. Litt HL, Gatsonis C, Snyder B, Singh H, Miller CD, Entrikin DW, Leaming JM, Gavin LJ, Pacella CB, Hollander JE. CT angiography for safe discharge of patients with possible acute coronary syndromes. *N Engl J Med* 2012;**366**:1393–1403.
 80. Hulten E, Pickett C, Bittencourt MS, Villines TC, Petrillo S, Di Carli MF, Blankstein R. Outcomes after coronary computed tomography angiography in the emergency department: a systematic review and meta-analysis of randomized, controlled trials. *J Am Coll Cardiol* 2013;**61**:880–892.
 81. Ayaram D, Bellolio MF, Murad MH, Laack TA, Sadosty AT, Erwin PJ, Hollander JE, Montori VM, Stiell IG, Hess EP. Triple rule-out computed tomographic angiography for chest pain: a diagnostic systematic review and meta-analysis. *Acad Emerg Med* 2013;**20**:861–871.
 82. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. *JAMA* 2000;**284**:835–842.
 83. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van de Werf F, Avezum A, Goodman SG, Flather MD, Fox KA. Predictors of hospital mortality in the global registry of acute coronary events. *Arch Intern Med* 2003;**163**:2345–2353.
 84. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson FA Jr, Granger CB. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). *BMJ* 2006;**333**:1091.
 85. Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIB. *PARAGON-A and GUSTO IIB Investigators. Platelet IIB/IIIa antagonism for the reduction of acute global organization network. J Am Coll Cardiol* 2001;**38**:64–71.
 86. Mueller C, Neumann FJ, Perach W, Perruchoud AP, Buettner HJ. Prognostic value of the admission electrocardiogram in patients with unstable angina/non-ST-segment elevation myocardial infarction treated with very early revascularization. *Am J Med* 2004;**117**:145–150.
 87. Holmvang L, Clemmensen P, Lindahl B, Lagerqvist B, Venge P, Wagner G, Wallentin L, Grande P. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. *J Am Coll Cardiol* 2003;**41**:905–915.
 88. Tan NS, Goodman SG, Yan RT, Elbarouni B, Budaj A, Fox KA, Gore JM, Brieger D, Lopez-Sendon J, Langer A, van de Werf F, Steg PG, Yan AT. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2013;**166**:290–297.
 89. Rubini Gimenez M, Twerenbold R, Reichlin T, Wildi K, Haaf P, Schaefer M, Zellweger C, Moehring B, Stallone F, Sou SM, Mueller M, Denhaerynck K, Mosimann T, Reiter M, Meller B, Freese M, Stelzig C, Klimmeck I, Voegele J, Hartmann B, Rentsch K, Osswald S, Mueller C. Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. *Eur Heart J* 2014;**35**:2303–2311.
 90. Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger C, Moehring B, Fischer C, Meller B, Wildi K, Freese M, Stelzig C, Mosimann T, Reiter M, Mueller M, Hochgruber T, Sou SM, Murray K, Minners J, Freidank H, Osswald S, Mueller C. Risk stratification in patients with acute chest pain using three high-sensitivity cardiac troponin assays. *Eur Heart J* 2014;**35**:365–375.
 91. Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, Hasin Y, Biasucci LM, Giannitsis E, Lindahl B, Koenig W, Tubaro M, Collinson P, Katus H, Galvani M, Venge P, Alpert JS, Hamm C, Jaffe AS. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the study group on biomarkers in cardiology of the ESC working group on acute cardiac care. *Eur Heart J* 2012;**33**:2001–2006.
 92. Aragam KG, Tamhane UU, Kline-Rogers E, Li J, Fox KA, Goodman SG, Eagle KA, Gurm HS. Does simplicity compromise accuracy in ACS risk prediction? A retrospective analysis of the TIMI and GRACE risk scores. *PLoS One* 2009;**4**:e7947.
 93. de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. *Eur Heart J* 2005;**26**:865–872.
 94. Fox KA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, Coste P, Monsegu J, Gabriel Steg P, Danchin N, Anderson F. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. *BMJ Open* 2014;**4**:e004425.
 95. Fox KA, Anderson FA Jr, Dabbous OH, Steg PG, Lopez-Sendon J, Van de Werf F, Budaj A, Gurfinkel EP, Goodman SG, Brieger D. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). *Heart* 2007;**93**:177–182.
 96. Bawamia B, Mehran R, Qiu W, Kunadian V. Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review. *Am Heart J* 2013;**165**:441–450.
 97. Scirica BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. *J Am Coll Cardiol* 2010;**55**:1403–1415.
 98. Chang WC, Boersma E, Granger CB, Harrington RA, Califf RM, Simoons ML, Kleiman NS, Armstrong PW. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIB and PURSUIT. *Am Heart J* 2004;**148**:62–71.
 99. Rahimi K, Watzlawek S, Thiele H, Secknus MA, Hayerizadeh BF, Niebauer J, Schuler G. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment. *Eur Heart J* 2006;**27**:1706–1711.
 100. Piccini JP, White JA, Mehta RH, Likhnygina Y, Al-Khatib SM, Tricoci P, Pollack CV Jr, Montalescot G, Van de Werf F, Gibson CM, Giugliano RP, Califf RM, Harrington RA, Newby LK. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. *Circulation* 2012;**126**:41–49.
 101. Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, Macfarlane PW, Somargren C, Swiryn S, Van Hare GF. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association scientific statement from the councils on cardiovascular nursing, clinical cardiology, and cardiovascular disease in the young: endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. *Circulation* 2004;**110**:2721–2746.

102. Dressler R, Dryer MM, Coletti C, Mahoney D, Doorey AJ. Altering overuse of cardiac telemetry in non-intensive care unit settings by hardwiring the use of American Heart Association guidelines. *JAMA Intern Med* 2014;**174**:1852–1854.
103. Fox KA, Anderson FA Jr, Goodman SG, Steg PG, Pieper K, Quill A, Gore JM. Time course of events in acute coronary syndromes: implications for clinical practice from the grace registry. *Nat Clin Pract Cardiovasc Med* 2008;**5**:580–589.
104. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. *J Am Coll Cardiol* 2010;**55**:2556–2566.
105. Steg PG, Huber K, Andreotti F, Arnesen H, Atar D, Badimon L, Bassand JP, De Caterina R, Eikelboom JA, Gulba D, Hamon M, Helft G, Fox KA, Kristensen SD, Rao SV, Verheugt FW, Widimsky P, Zeymer U, Collet JP. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the working group on thrombosis of the European Society of Cardiology. *Eur Heart J* 2011;**32**:1854–1864.
106. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, Pollack CV Jr, Peterson ED, Alexander KP. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. *Circulation* 2009;**119**:1873–1882.
107. Abu-Assi E, Raposeiras-Roubin S, Lear P, Cabanas-Grandio P, Gironde M, Rodriguez-Cordero M, Pereira-Lopez E, Romani SG, Gonzalez-Cambeiro C, Alvarez-Alvarez B, Garcia-Acuna JM, Gonzalez-Juanatey JR. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care* 2012;**1**:222–231.
108. Weber M, Bazzino O, Navarro Estrada JL, de Miguel R, Salzberg S, Fuselli JJ, Liebetrau C, Woelken M, Moellmann H, Nef H, Hamm C. Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. *Am Heart J* 2011;**162**:81–88.
109. Akkerhuis KM, Klootwijk PA, Lindeboom W, Umans VA, Meij S, Kint PP, Simoons ML. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. *Eur Heart J* 2001;**22**:1997–2006.
110. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. *N Engl J Med* 1997;**337**:1648–1653.
111. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. *N Engl J Med* 1996;**335**:1342–1349.
112. Scirica BM, Morrow DA, Budaj A, Dalby AJ, Mohanavelu S, Qin J, Aroesty J, Hedgepeth CM, Stone PH, Braunwald E. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36) trial. *J Am Coll Cardiol* 2009;**53**:1411–1421.
113. Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. *The RISC study group. Int J Cardiol* 1993;**39**:131–142.
114. Amsterdam EA, Kirk JD, Diercks DB, Lewis WR, Turnipseed SD. Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain. *J Am Coll Cardiol* 2002;**40**:251–256.
115. Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, Cameron P, Barger B, Ellims AH, Taylor AJ, Meredith IT, Kaye DM. Air versus oxygen in ST-segment-elevation myocardial infarction. *Circulation* 2015;**131**:2143–2150.
116. Borzak S, Cannon CP, Kraft PL, Douthat L, Becker RC, Palmeri ST, Henry T, Hochman JS, Fuchs J, Antman EM, McCabe C, Braunwald E. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. *TIMI 7 Investigators. Thrombin inhibition in myocardial ischemia. Am J Cardiol* 1998;**81**:678–681.
117. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation* 2010;**122**:88–95.
118. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. *Treatments following myocardial infarction. JAMA* 1988;**260**:2088–2093.
119. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, Mukherjee D. Early intravenous beta-blockers in patients with acute coronary syndrome—a meta-analysis of randomized trials. *Int J Cardiol* 2013;**168**:915–921.
120. Kontos MC, Diercks DB, Ho PM, Wang TY, Chen AY, Roe MT. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology's NCDR®. *Am Heart J* 2011;**161**:864–870.
121. Theroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. *J Am Coll Cardiol* 1985;**5**:717–722.
122. Parodi O, Simonetti I, Michelassi C, Carpeggiani C, Biagini A, L'Abbate A, Maseri A. Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit. *Am J Cardiol* 1986;**57**:899–906.
123. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT). *Am J Cardiol* 1987;**60**:18A–25A.
124. Hansen JF. Treatment with verapamil after an acute myocardial infarction. Review of the Danish Studies on Verapamil in Myocardial Infarction (DAVIT I and II). *Drugs* 1991;**42**(Suppl 2):43–53.
125. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, Wolff AA, Skene A, McCabe CH, Braunwald E. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. *JAMA* 2007;**297**:1775–1783.
126. Miller CD, Roe MT, Mulgund J, Hoekstra JW, Santos R, Pollack CV Jr, Ohman EM, Gibler WB, Peterson ED. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. *Am J Med* 2007;**120**:685–692.
127. Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S, Takaoka K, Okumura K. Long-term prognosis for patients with variant angina and influential factors. *Circulation* 1988;**78**:1–9.
128. Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, De Caterina R, Gulba D, Huber K, Husted S, Kristensen SD, Morais J, Neumann FJ, Rasmussen LH, Siegbahn A, Steg PG, Storey RF, van de Werf F, Verheugt F. Antiplatelet agents for the treatment and prevention of atherothrombosis. *Eur Heart J* 2011;**32**:2922–2932.
129. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC group. *Lancet* 1990;**336**:827–830.
130. Leshem YD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE 3rd, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. *Results of a Veterans Administration cooperative study. N Engl J Med* 1983;**309**:396–403.
131. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P, Pelletier GB, Rinzler D, Waters DD. Aspirin, heparin, or both to treat acute unstable angina. *N Engl J Med* 1988;**319**:1105–1111.
132. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG, Sackett DL, Sealey BJ, Tanser PH. Aspirin, sulfinpyrazone, or both in unstable angina. *Results of a Canadian multicenter trial. N Engl J Med* 1985;**313**:1369–1375.
133. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;**324**:71–86.
134. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med* 2010;**363**:930–942.
135. Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2Y₁₂, a new platelet ADP receptor, target of clopidogrel. *Biochem Biophys Res Commun* 2001;**283**:379–383.
136. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y₁₂ adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. *Semin Thromb Hemost* 2005;**31**:174–183.
137. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;**345**:494–502.
138. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. *Lancet* 2001;**358**:527–533.
139. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. *JAMA* 2011;**306**:1215–1223.
140. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. *Circulation* 2004;**109**:3171–3175.

141. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. *J Am Coll Cardiol* 2006;**48**:1742–1750.
142. Sibbing D, Braun S, Morath T, Mehilil J, Vogt W, Schomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. *J Am Coll Cardiol* 2009;**53**:849–856.
143. Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. *Eur Heart J* 2014;**35**:209–215.
144. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. *N Engl J Med* 2009;**360**:363–375.
145. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. *Lancet* 2009;**373**:309–317.
146. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. *J Am Coll Cardiol* 2010;**56**:112–116.
147. Cayla G, Hulot JS, O'Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignolou JB, Huere Y, de la Briolle A, Allanic F, Beygui F, Barthelemy O, Montalescot G, Collet JP. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. *JAMA* 2011;**306**:1765–1774.
148. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2007;**357**:2001–2015.
149. De Servi S, Goedicke J, Schirmer A, Widimsky P. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. *Eur Heart J Acute Cardiovasc Care* 2014;**3**:363–372.
150. Pena A, Collet JP, Hulot JS, Silvain J, Barthelemy O, Beygui F, Funck-Brentano C, Montalescot G. Can we override clopidogrel resistance? *Circulation* 2009;**119**:2854–2857.
151. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. *Lancet* 2008;**371**:1353–1363.
152. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the onset and offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the Onset/Offset study. *Circulation* 2009;**120**:2577–2585.
153. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009;**361**:1045–1057.
154. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. *Eur Heart J* 2014;**35**:2083–2093.
155. Steg PG, Harrington RA, Emanuelsson H, Katus HA, Mahaffey KW, Meier B, Storey RF, Wojdyla DM, Lewis BS, Maurer G, Wallentin L, James SK. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. *Circulation* 2013;**128**:1055–1065.
156. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, Wallentin L. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. *Eur Heart J* 2011;**32**:2945–2953.
157. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2 T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. *Thromb Haemost* 2001;**85**:401–407.
158. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Platelet inhibition with cangrelor in patients undergoing PCI. *N Engl J Med* 2009;**361**:2318–2329.
159. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA. Intravenous platelet blockade with cangrelor during PCI. *N Engl J Med* 2009;**361**:2330–2341.
160. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Genereux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA. Effect of platelet inhibition with cangrelor during PCI on ischemic events. *N Engl J Med* 2013;**368**:1303–1313.
161. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. *Lancet* 2013;**382**:1981–1992.
162. Hamm CV, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011;**32**:2999–3054.
163. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G, Barthelemy O, Collet JP, Montalescot G. New P2Y₁₂ inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. *J Am Coll Cardiol* 2010;**56**:1542–1551.
164. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angiolillo P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. *N Engl J Med* 2013;**369**:999–1010.
165. Collet JP, Silvain J, Bellemain-Appaix A, Montalescot G. Pretreatment with P2Y₁₂ inhibitors in non-ST-segment-elevation acute coronary syndrome: an outdated and harmful strategy. *Circulation* 2014;**130**:1904–1914.
166. Valgimigli M. Pretreatment with P2Y₁₂ inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified. *Circulation* 2014;**130**:1891–1903.
167. Stone GW, Witzensichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. *Lancet* 2013;**382**:614–623.
168. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standardized high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011;**305**:1097–1105.
169. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. *J Am Coll Cardiol* 2012;**59**:2159–2164.
170. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monsegu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthelemy O, Beygui F, Silvain J, Vicaut E, Montalescot G. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. *N Engl J Med* 2012;**367**:2100–2109.
171. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. *Lancet* 2010;**376**:1312–1319.
172. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Buttner HJ, Neumann FJ. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. *J Am Coll Cardiol* 2008;**51**:1925–1934.
173. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. *Circulation* 2009;**119**:2553–2560.

174. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. *Lancet* 2012;**379**: 1705–1711.
175. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. *Eur Heart J* 2013;**34**:1708–1713, 1713a–1713b.
176. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, Krumholz HM, Rumsfeld JS. Impact of medication therapy discontinuation on mortality after myocardial infarction. *Arch Intern Med* 2006;**166**:1842–1847.
177. Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet* 2013; **382**:1714–1722.
178. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. *Circulation* 2007;**115**:813–818.
179. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, Ford I, Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoes A, Huber K, Lung B, Kjeldsen KP, Longrois D, Luscher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management. *Eur Heart J* 2014;**35**:2383–2431.
180. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA. Guideline on antiplatelet and anticoagulation management in cardiac surgery. *Eur J Cardiothorac Surg* 2008;**34**:73–92.
181. Savonitto S, D'Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M, Klugmann S, De Servi S. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. *Br J Anaesth* 2010;**104**: 285–291.
182. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ. Bridging antiplatelet therapy with Cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. *JAMA* 2012;**307**:265–274.
183. Steinhilb SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002;**288**:2411–2420.
184. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med* 2014;**371**: 2155–2166.
185. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. *BMJ* 2015;**350**: h1618.
186. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med* 2015;**372**:1791–1800.
187. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). *J Am Coll Cardiol* 2012;**60**:1340–1348.
188. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Nogueira M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicoleta EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmao M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. *JAMA* 2013;**310**:2510–2522.
189. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of science/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. *Circulation* 2012;**125**:505–513.
190. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fuca G, Kubajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. *Circulation* 2012;**125**:2015–2026.
191. Colombo A, Chieffo A, Frasieri A, Garbo R, Masotti-Centol M, Salvatella N, Oteo Dominguez JF, Steffanon L, Tarantini G, Presbitero P, Menozzi A, Pucci E, Mauri J, Cesana BM, Giustino G, Sardella G. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. *J Am Coll Cardiol* 2014;**64**:2086–2097.
192. Schulz-Schupke S, Byrne RA, ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tolg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hohenberg E, Wohrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Schomig A, Mehilli J, Kastrati A. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. *Eur Heart J* 2015;**36**:1252–1263.
193. Gilard M, Barragan P, Noryani AA, Noor HA, Majwal T, Hovasse T, Castellant P, Schneeberger M, Maillard L, Bressolette E, Wojcik J, Delarche N, Blanchard D, Jouve B, Ormezzano O, Paganelli F, Levy G, Sainsous J, Carrie D, Furber A, Berland J, Darremont O, Le Breton H, Luyycx-Bore A, Gommeaux A, Casset C, Kermarrec A, Cazaux P, Druelles P, Dauphin R, Armengaud J, Dupouy P, Champagnac D, Ohlmann P, Endresen K, Benamer H, Kiss RG, Ungi I, Boschat J, Morice MC. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. *J Am Coll Cardiol* 2015;**65**:777–786.
194. Lee CW, Ahn JM, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Han S, Lee SG, Seong IW, Rha SW, Jeong MH, Lim DS, Yoon JH, Hur SH, Choi YS, Yang JY, Lee NH, Kim HS, Lee BK, Kim KS, Lee SU, Chae JK, Cheong SS, Suh IW, Park HS, Nah DY, Jeon DS, Seung KB, Lee K, Jang JS, Park SJ. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. *Circulation* 2014;**129**:304–312.
195. Collet JP, Silvain J, Barthelemy O, Range G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrie D, Rousseau H, Aubry P, Monsegu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-INTERRUPTION): a randomised trial. *Lancet* 2014;**384**:1577–1585.
196. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heesch C, Hamm CW, Robbins MA, Kleiman NS, Theroux P, White HD, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. *Gradient of benefit related to the revascularization strategy*. *Eur Heart J* 2002;**23**:1441–1448.
197. O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel—Thrombolysis in Myocardial Infarction 38) analysis. *J Am Coll Cardiol* 2009;**54**:678–685.
198. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. *JAMA* 2007;**297**: 591–602.
199. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van 't Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F, Braunwald E, Harrington RA, Califf RM, Newby LK. Early versus delayed, provisional eptifibatid in acute coronary syndromes. *N Engl J Med* 2009;**360**: 2176–2190.
200. Wang TY, White JA, Tricoci P, Giugliano RP, Zeymer U, Harrington RA, Montalescot G, James SK, Van de Werf F, Armstrong PW, Braunwald E, Califf RM, Newby LK. Upstream clopidogrel use and the efficacy and safety of early eptifibatid treatment in patients with acute coronary syndrome: an analysis

- from the early glycoprotein IIb/IIIa inhibition in patients with non-ST-segment elevation acute coronary syndrome (early ACS) trial. *Circulation* 2011;**123**:722–730.
201. Judge HM, Buckland RJ, Holgate CE, Storey RF. Glycoprotein IIb/IIIa and P2Y₁₂ receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40 l release and procoagulant responses. *Platelets* 2005;**16**: 398–407.
 202. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. *JAMA* 2006;**295**:1531–1538.
 203. Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta SR. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. *J Am Coll Cardiol* 2009;**54**:468–476.
 204. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV Jr, Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, Stone GW. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. *J Am Coll Cardiol* 2008;**51**:1734–1741.
 205. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM. Bivalirudin for patients with acute coronary syndromes. *N Engl J Med* 2006;**355**:2203–2216.
 206. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. *N Engl J Med* 2012;**366**:20–33.
 207. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA. Vorapaxar in the secondary prevention of atherothrombotic events. *N Engl J Med* 2012;**366**:1404–1413.
 208. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanus A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without omeprazole in coronary artery disease. *N Engl J Med* 2010;**363**:1909–1917.
 209. Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinical update. *Circulation* 2012;**125**:375–380.
 210. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. *Lancet* 2000;**355**:1936–1942.
 211. Silvain J, Beygui F, Barthelemy O, Pollack C Jr, Cohen M, Zeymer U, Huber K, Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. *BMJ* 2012;**344**:e553.
 212. Lee MS, Wali AU, Menon V, Berkowitz SD, Thompson TD, Califf RM, Topol EJ, Granger CB, Hochman JS. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. *J Thromb Thrombolysis* 2002;**14**:91–101.
 213. Hassan WM, Flaker GC, Feutz C, Petroski GF, Smith D. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: a randomized trial. *J Thromb Thrombolysis* 1995;**2**:245–249.
 214. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. *Circulation* 2001;**103**: 658–663.
 215. Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, Ozoux ML, Pensyl CE, Bigonzi F. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. *Catheter Cardiovasc Interv* 2004;**61**:163–170.
 216. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. *JAMA* 2004;**292**:45–54.
 217. Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. *Eur Heart J* 2007;**28**:2077–2086.
 218. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. *N Engl J Med* 2006;**354**:1464–1476.
 219. Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Budaj A, Diaz R, Avezum A, Widimsky P, Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. *JAMA* 2010;**304**: 1339–1349.
 220. Szummer K, Oldgren J, Lindhagen L, Carrero JJ, Evans M, Spaak J, Edfors R, Jacobson SH, Andell P, Wallentin L, Jernberg T. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. *JAMA* 2015;**313**:707–716.
 221. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. *Lancet* 2007;**369**:907–919.
 222. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. *JAMA* 2007;**298**:2497–2506.
 223. Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schomig A, Berger PB, Mehilli J. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. *N Engl J Med* 2011;**365**:1980–1989.
 224. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Buttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schomig A. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. *N Engl J Med* 2008;**359**: 688–696.
 225. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Gerales M, Lawrence J, Harrington RA, Wallentin L. Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med* 2011;**365**: 699–708.
 226. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruno N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM. Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med* 2012;**366**:9–19.
 227. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. *JAMA* 1996;**276**:811–815.
 228. Simoons ML, Bobbink IW, Boland J, Gardien M, Klootwijk P, Lensing AW, Ruzyllo W, Umans VA, Vahanian A, Van De Werf F, Zeymer U. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the pentasaccharide in unstable angina (PENTUA) study. *J Am Coll Cardiol* 2004;**43**:2183–2190.
 229. Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) pilot trial. *Circulation* 2005;**111**:1390–1397.
 230. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. *JAMA* 2004;**292**:89–96.
 231. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhagic complications:

- analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. *Circulation* 2004;**110**:994–998.
232. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, Finet G, Le Breton H, Bosch J. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTing and oral antiCOagulants [STENTICO]). *Am J Cardiol* 2009;**104**:338–342.
 233. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, Valdes M, Lip GY. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. *J Am Coll Cardiol* 2008;**51**:818–825.
 234. Lip GY, Windecker S, Huber K, Kirchhoff P, Marin F, ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology working group on thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). *Eur Heart J* 2014;**35**:3155–3179.
 235. Beyer-Westendorf J, Gelbricht V, Forster K, Ebertz F, Kohler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. *Eur Heart J* 2014;**35**:1888–1896.
 236. Dewilde WJ, Janssen PW, Kelder JC, Verheugt FW, De Smet BJ, Adriaenssens T, Vrolix M, Brueren GB, Vandendriessche T, Van Mieghem C, Cornelis K, Vos J, Breet NJ, ten Berg JM. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. *EuroIntervention* 2015 Mar 5; **10**(11). pii: 20140202-08. doi:10.4244/EIJY14M06_07. [Epub ahead of print]
 237. Kiviniemi T, Karjalainen P, Pietila M, Ylitalo A, Niemela M, Vikman S, Puurunen M, Biancari F, Airaksinen KE. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. *Am J Cardiol* 2012;**110**:30–35.
 238. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. *Arch Intern Med* 2010;**170**:1433–1441.
 239. Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. *Circ Cardiovasc Interv* 2011;**4**:522–534.
 240. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttrop MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schali MJ, Diem P, Meier B, Windecker S, Juni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. *BMJ* 2008;**337**:t1331.
 241. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Williams DO, Slater J, Cutlip DE, Feit F. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. *BMJ* 2012;**345**:e5170.
 242. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, Bhatt DL, Slater J. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. *Circulation* 2012;**125**:2873–2891.
 243. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. *JAMA* 2015;**313**:1113–1121.
 244. Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, Maddox TM. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. *JAMA* 2013;**310**:1462–1472.
 245. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. *J Am Coll Cardiol* 2015;**65**:805–815.
 246. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijssen JG, van 't Hof AW, ten Berg JM. Use of clopidogrel with or without aspirin in patients taking oral anti-coagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet* 2013;**381**:1107–1115.
 247. Fiedler KA, Maeng M, Mehilli J, Schulz-Schüpke S, Byrne RA, Sibbing D, Hoppmann P, Schneider S, Fusaro M, Ott I, Kristensen SD, Ibrahim T, Massberg S, Schunkert H, Laugwitz K-L, Kastrati A, Saraffo N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPE trial. *J Am Coll Cardiol* 2015;**65**:1619–1629.
 248. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. *Circulation* 2012;**126**:1185–1193.
 249. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Kober L, Torp-Pedersen C, Hansen ML. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. *J Am Coll Cardiol* 2013;**62**:981–989.
 250. Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llaou JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. *Recommendations of the Working Group on Peri-operative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis* 2011;**104**:669–676.
 251. Valgimigli M, Gagnor A, Calabro P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbuhler M, Vranckx P, Juni P. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. *Lancet* 2015;**385**:2465–2476.
 252. Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. *BMJ* 2013;**347**:f6625.
 253. Dutton RP. Haemostatic resuscitation. *Br J Anaesth* 2012;**109**(Suppl 1):i39–i46.
 254. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. *Blood* 1983;**61**:1081–1085.
 255. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ. Normalization of platelet reactivity in clopidogrel-treated subjects. *J Thromb Haemost* 2007;**5**:82–90.
 256. Hansson EC, Shams Hakimi C, Astrom-Olsson K, Hesse C, Wallen H, Dellborg M, Albertsson P, Jeppsson A. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. *Br J Anaesth* 2014;**112**:570–575.
 257. Zafar MU, Santos-Gallego C, Vorchheimer DA, Viles-Gonzalez JF, Elmariah S, Giannarelli C, Sartori S, Small DS, Jakubowski JA, Fuster V, Badimon JJ. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. *J Thromb Haemost* 2013;**11**:100–106.
 258. Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. *Pharmacotherapy* 2000;**20**:1159–1166.
 259. Fondevila CG, Grosso SH, Santarelli MT, Pinto MD. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarin discontinuation. *A prospective, randomized, open study. Blood Coagul Fibrinolysis* 2001;**12**:9–16.
 260. Ageno W, Crowther M, Steidl L, Ultori C, Mera V, Dentali F, Squizzato A, Marchesi C, Venco A. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. *Thromb Haemost* 2002;**88**:48–51.
 261. Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. *J Am Coll Cardiol* 2005;**46**:732–733.
 262. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, Blostein MD, Kahn SR, Vesely SK, Schulman S, Kovacs MJ, Rodger MA, Wells P, Anderson D, Ginsberg J, Selby R, Siragusa S, Silingardi M, Dowd MB, Kearon C. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. *Ann Intern Med* 2009;**150**:293–300.
 263. Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L, Schnurr T, McGinnis J, Gent M, Hirsh J, Ginsberg J. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. *Lancet* 2000;**356**:1551–1553.

264. Ageno W, Garcia D, Aguilar MI, Douketis J, Finazzi G, Imberti D, Iorio A, Key NS, Lim W, Marietta M, Prisco D, Sarode R, Testa S, Tosetto A, Crowther M. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. *Am J Hematol* 2009;**84**:584–588.
265. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012;**141**:e44S–88S.
266. Liesenfeld KH, Staab A, Hartter S, Formella S, Clemens A, Lehr T. Pharmacometric characterization of dabigatran hemodialysis. *Clin Pharmacokinet* 2013;**52**:453–462.
267. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. *Circulation* 2011;**124**:1573–1579.
268. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. *Nat Med* 2013;**19**:446–451.
269. Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. *JACC Cardiovasc Interv* 2011;**4**:191–197.
270. Ndrepepa G, Schulz S, Neumann FJ, Byrne RA, Hoppmann P, Cassese S, Ott I, Fusaro M, Ibrahim T, Tada T, Richardt G, Laugwitz KL, Schunkert H, Kastrati A. Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. *Am Heart J* 2013;**166**:534–540.
271. Vranckx P, Campo G, Anselmi M, Bolognese L, Colangelo S, Biondi-Zoccai G, Moreno R, Piva T, Favero L, Prati F, Nazzaro M, Diaz Fernandez JF, Ferrari R, Valgimigli M. Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. *EuroIntervention* 2012;**8**:71–78.
272. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Morrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L. Bleeding complications with the P2Y₁₂ receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO) trial. *Eur Heart J* 2011;**32**:2933–2944.
273. Lopes RD, Subherwal S, Holmes DN, Thomas L, Wang TY, Rao SV, Magnus Ohman E, Roe MT, Peterson ED, Alexander KP. The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. *Eur Heart J* 2012;**33**:2044–2053.
274. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. *Circulation* 2011;**123**:2736–2747.
275. Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ, Richardt G, Schulz S, Laugwitz KL, Massberg S, Schomig A, Kastrati A. Validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. *Circulation* 2012;**125**:1424–1431.
276. Ndrepepa G, Guerra E, Schulz S, Fusaro M, Cassese S, Kastrati A. Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. *J Thromb Thrombolysis* 2015;**39**:35–42.
277. Baber U, Kovacic J, Kini AS, Sharma SK, Dargas G, Mehran R. How serious a problem is bleeding in patients with acute coronary syndromes? *Curr Cardiol Rep* 2011;**13**:312–319.
278. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, Kastrati A. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. *J Am Coll Cardiol* 2008;**51**:690–697.
279. Moscucci M, Fox KA, Cannon CP, Klein WW, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J* 2003;**24**:1815–1823.
280. Leibundgut G, Pache J, Schulz S, Berger PB, Ferenc M, Gick M, Mehilli J, Kastrati A, Neumann FJ. Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non ST-segment elevation myocardial infarction. *J Interv Cardiol* 2013;**26**:623–629.
281. Ndrepepa G, Neumann FJ, Richardt G, Schulz S, Tolg R, Stoyanov KM, Gick M, Ibrahim T, Fiedler KA, Berger PB, Laugwitz KL, Kastrati A. Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. *Circ Cardiovasc Interv* 2013;**6**:354–361.
282. Marso SP, Amin AP, House JA, Kennedy KF, Spertus JA, Rao SV, Cohen DJ, Messenger JC, Rumsfeld JS. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. *JAMA* 2010;**303**:2156–2164.
283. Schulz-Schupke S, Helde S, Gewalt S, Ibrahim T, Linhardt M, Haas K, Hoppe K, Bottiger C, Groha P, Bradaric C, Schmidt R, Bott-Flugel L, Ott I, Goedel J, Byrne RA, Schneider S, Burgdorf C, Morath T, Kufner S, Joner M, Cassese S, Hoppmann P, Hengstenberg C, Pache J, Fusaro M, Massberg S, Mehilli J, Schunkert H, Laugwitz KL, Kastrati A. Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial. *JAMA* 2014;**312**:1981–1987.
284. Shi J, Ji H, Ren F, Wang G, Xu M, Xue Y, Chen M, Qi J, Li L. Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. *JAMA Surg* 2013;**148**:538–547.
285. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Morrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (PLATElet inhibition and patient Outcomes) trial. *J Am Coll Cardiol* 2011;**57**:672–684.
286. Mehta RH, Sheng S, O'Brien SM, Grover FL, Gammie JS, Ferguson TB, Peterson ED. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. *Circ Cardiovasc Qual Outcomes* 2009;**2**:583–590.
287. Paone G, Likosky DS, Brewer R, Theurer PF, Bell GF, Cogan CM, Prager RL. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality. *Ann Thorac Surg* 2014;**97**:87–93; discussion 93–84.
288. Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB, Mazer CD, Bridges CR, Despotis GJ, Joints R, Clough ER. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. *Ann Thorac Surg* 2012;**94**:1761–1781.
289. Vivacqua A, Koch CG, Yousuf AM, Nowicki ER, Houghtaling PL, Blackstone EH, Sabik JF 3rd. Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? *Ann Thorac Surg* 2011;**91**:1780–1790.
290. Hardy JF, Belisle S, Van der Linden P. Efficacy and safety of activated recombinant factor VII in cardiac surgical patients. *Curr Opin Anaesthesiol* 2009;**22**:95–99.
291. Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, Straka Z, Piegas LS, Akar AR, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC, Novick RJ, Vijayanath P, Reddy S, Tao L, Olavegogeoascoechea PA, Airan B, Sullung TA, Whitlock RP, Ou Y, Ng J, Chrolavicius S, Yusuf S. Off-pump or on-pump coronary-artery bypass grafting at 30 days. *N Engl J Med* 2012;**366**:1489–1497.
292. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. *JAMA* 2004;**292**:1555–1562.
293. Sherwood MW, Wang Y, Curtis JP, Peterson ED, Rao SV. Patterns and outcomes of red blood cell transfusion in patients undergoing percutaneous coronary intervention. *JAMA* 2014;**311**:836–843.
294. Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. *JACC Cardiovasc Interv* 2009;**2**:624–632.
295. Silvain J, Abtan J, Kerneis M, Martin R, Finzi J, Vignallou JB, Barthelemy O, O'Connor SA, Luyt CE, Brechot N, Mercadier A, Brugier D, Galier S, Collet JP, Chastre J, Montalescot G. Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry use and light transmission aggregometry). *J Am Coll Cardiol* 2014;**63**:1289–1296.
296. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev* 2012;**4**:CD002042.
297. Kansagara D, Dyer E, Englander H, Fu R, Freeman M, Kagen D. Treatment of anemia in patients with heart disease: a systematic review. *Ann Intern Med* 2013;**159**:746–757.
298. Chatterjee S, Wetterstev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a

- meta-analysis and diversity-adjusted study sequential analysis. *JAMA Intern Med* 2013;**173**:132–139.
299. Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW, Panza JA. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT randomized pilot study). *Am J Cardiol* 2011;**108**:1108–1111.
 300. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM, Ohman EM, Roe MT, Boden WE, Harrington RA, Peterson ED. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2008;**155**:1047–1053.
 301. Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. *BMJ* 2015;**350**:h1354.
 302. Murphy GJ, Pike K, Rogers CA, Wordsworth S, Stokes EA, Angelini GD, Reeves BC. Liberal or restrictive transfusion after cardiac surgery. *N Engl J Med* 2015;**372**:997–1008.
 303. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Wludimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S. Early versus delayed invasive intervention in acute coronary syndromes. *N Engl J Med* 2009;**360**:2165–2175.
 304. Thiele H, Rach J, Klein N, Pfeiffer D, Hartmann A, Hambrecht R, Sick P, Eitel I, Desch S, Schuler G. Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig immediate versus early and late Percutaneous coronary intervention trial in NSTEMI (LIPSIA-NSTEMI trial). *Eur Heart J* 2012;**33**:2035–2043.
 305. Ndrepepa G, Mehilli J, Schulz S, Iijima R, Keta D, Byrne RA, Pache J, Seyfarth M, Schomig A, Kastrati A. Patterns of presentation and outcomes of patients with acute coronary syndromes. *Cardiology* 2009;**113**:198–206.
 306. Kerensky RA, Wade M, Deedwania P, Boden WE, Pepine CJ. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. *J Am Coll Cardiol* 2002;**39**:1456–1463.
 307. Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris. *J Am Coll Cardiol* 1985;**5**:609–616.
 308. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. *N Engl J Med* 2000;**343**:915–922.
 309. Libby P. Inflammation in atherosclerosis. *Arterioscler Thromb Vasc Biol* 2012;**32**:2045–2051.
 310. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. *J Am Coll Cardiol* 2006;**47**:C13–C18.
 311. Vergallo R, Ren X, Yonetsu T, Kato K, Uemura S, Yu B, Jia H, Abtahian F, Aguirre AD, Tian J, Hu S, Soeda T, Lee H, McNulty I, Park SJ, Jang Y, Prasad A, Lee S, Zhang S, Porto I, Biasucci LM, Crea F, Jang IK. Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: a 3-vessel optical coherence tomography study. *Am Heart J* 2014;**167**:59–67.
 312. Cheruvu PK, Finn AV, Gardner C, Caplan J, Goldstein J, Stone GW, Virmani R, Muller JE. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. *J Am Coll Cardiol* 2007;**50**:940–949.
 313. Shishebor MH, Lauer MS, Singh IM, Chew DP, Karha J, Brenner SJ, Moliterno DJ, Ellis SG, Topol EJ, Bhatt DL. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? *J Am Coll Cardiol* 2007;**49**:849–854.
 314. Sgarbossa EB, Birnbaum Y, Parrillo JE. Electrocardiographic diagnosis of acute myocardial infarction: current concepts for the clinician. *Am Heart J* 2001;**141**:507–517.
 315. Kurisu S, Inoue I, Kawagoe T, Ishihara M, Shimatani Y, Nakamura S, Yoshida M, Mitsuba N, Hata T. Electrocardiographic features in patients with acute myocardial infarction associated with left main coronary artery occlusion. *Heart* 2004;**90**:1059–1060.
 316. de Winter RJ, Verouden NJ, Wellens HJ, Wilde AA. A new ECG sign of proximal LAD occlusion. *N Engl J Med* 2008;**359**:2071–2073.
 317. Tahvanainen M, Nikus KC, Holmvang L, Clemmensen P, Sclarovsky S, Birnbaum Y, Kelbaek H, Huhtala H, Tilsted HH, Eskola MJ. Factors associated with failure to identify the culprit artery by the electrocardiogram in inferior ST-elevation myocardial infarction. *J Electrocardiol* 2011;**44**:495–501.
 318. Tanaka A, Shimada K, Tearney GJ, Kitabata H, Taguchi H, Fukuda S, Kashiwagi M, Kubo T, Takarada S, Hirata K, Mizukoshi M, Yoshikawa J, Bouma BE, Akasaka T. Conformational change in coronary artery structure assessed by optical coherence tomography in patients with vasospastic angina. *J Am Coll Cardiol* 2011;**58**:1608–1613.
 319. Kato M, Dote K, Sasaki S, Kagawa E, Nakano Y, Watanabe Y, Higashi A, Itakura K, Ochiuni Y, Takiguchi Y. Presentations of acute coronary syndrome related to coronary lesion morphologies as assessed by intravascular ultrasound and optical coherence tomography. *Int J Cardiol* 2013;**165**:506–511.
 320. Pijls NH, Tanaka N, Fearon WF. Functional assessment of coronary stenoses: can we live without it? *Eur Heart J* 2013;**34**:1335–1344.
 321. Gersh BJ, Frye RL. Methods of coronary revascularization—things may not be as they seem. *N Engl J Med* 2005;**352**:2235–2237.
 322. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. *J Am Coll Cardiol* 2006;**48**:1319–1325.
 323. O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacke R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. *JAMA* 2008;**300**:71–80.
 324. Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, Lagerqvist B, Wallentin L. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome: a meta-analysis of individual patient data. *J Am Coll Cardiol* 2010;**55**:2435–2445.
 325. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, Windecker S, Spaulding C. Invasive coronary treatment strategies for out-of-hospital cardiac arrest: a consensus statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent For Life (SFL) groups. *EuroIntervention* 2014;**10**:31–37.
 326. Katritsis DG, Siontis GC, Kastrati A, van't Hof AW, Neumann FJ, Siontis KC, Ioannidis JP. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. *Eur Heart J* 2011;**32**:32–40.
 327. Navarese EP, Gurbel PA, Andreotti F, Tantry U, Jeong YH, Kozinski M, Engstrom T, Di Pasquale G, Kochman W, Ardissino D, Kedhi E, Stone GW, Kubica J. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. *Ann Intern Med* 2013;**158**:261–270.
 328. Riezebos RK, Ronner E, Ter Bals E, Slagboom T, Smits PC, ten Berg JM, Kiemeneij F, Amoroso G, Patterson MS, Suttrop MJ, Tijssen JG, Laarman GJ. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. *Heart* 2009;**95**:807–812.
 329. Montalescot G, Cayla G, Collet JP, Elhadad S, Beygui F, Le Breton H, Choussat R, Leclercq F, Silvain J, Duclos F, Aout M, Dubois-Rande JL, Barthelemy O, Ducrocq G, Bellemain-Appaix A, Payot L, Steg PG, Henry P, Spaulding C, Vicaut E. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. *JAMA* 2009;**302**:947–954.
 330. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tcheng JE, Mehran R, Lansky AJ, Grines CL, Stone GW. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. *J Am Coll Cardiol* 2010;**55**:1416–1424.
 331. Amsterdam EA, Kirk JD, Blumek DA, Diercks D, Farkouh ME, Garvey JL, Kontos MC, McCord J, Miller TD, Morise A, Newby LK, Ruberg FL, Scordo KA, Thompson PD. Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. *Circulation* 2010;**122**:1756–1776.
 332. De Ferrari GM, Fox KA, White JA, Giugliano RP, Tricoci P, Reynolds HR, Hochman JS, Gibson CM, Theroux P, Harrington RA, Van de Werf F, White HD, Califf RM, Newby LK. Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. *Eur Heart J Acute Cardiovasc Care* 2014;**3**:37–45.
 333. Solomon MD, Go AS, Shilane D, Boothroyd DB, Leong TK, Kazi DS, Chang TI, Hlatky MA. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2014;**63**:2249–2257.
 334. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon RC, Winters KJ, Brown EB, Likhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRIL-OGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. *N Engl J Med* 2012;**367**:1297–1309.
 335. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATO trial. *BMJ* 2011;**342**:d3527.
 336. Williams B, Menon M, Satran D, Hayward D, Hodges JS, Burke MN, Johnson RK, Poulouse AK, Traverse JH, Henry TD. Patients with coronary artery disease not

- amenable to traditional revascularization: prevalence and 3-year mortality. *Cathet Cardiovasc Interv* 2010;**75**:886–891.
337. Henry TD, Satran D, Hodges JS, Johnson RK, Poulouse AK, Campbell AR, Garberich RF, Bart BA, Olson RE, Boisjolie CR, Harvey KL, Arndt TL, Traverse JH. Long-term survival in patients with refractory angina. *Eur Heart J* 2013;**34**:2683–2688.
 338. Dorfman TA, Iskandrian AE. Takotsubo cardiomyopathy: state-of-the-art review. *J Nucl Cardiol* 2009;**16**:122–134.
 339. Bellandi B, Salvadori C, Parodi G, Ebert AG, Petix N, Del Pace S, Boni A, Pestelli F, Fineschi M, Giomi A, Cresti A, Giuliani G, Venditti F, Querceto L, Gensini GF, Bolognese L, Bovenzi F. [Epidemiology of Tako-Tsubo cardiomyopathy: the Tuscany registry for Tako-Tsubo cardiomyopathy]. *G Ital Cardiol (Rome)* 2012;**13**:59–66.
 340. Sy F, Basraon J, Zheng H, Singh M, Richina J, Ambrose JA. Frequency of takotsubo cardiomyopathy in postmenopausal women presenting with an acute coronary syndrome. *Am J Cardiol* 2013;**112**:479–482.
 341. Jaguszewski M, Osipova J, Ghadri JR, Napp LC, Wiedera C, Franke J, Fijalkowski M, Nowak R, Fijalkowska M, Volkman I, Katus HA, Wollert KC, Bauersachs J, Erne P, Luscher TF, Thum T, Templin C. A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. *Eur Heart J* 2014;**35**:999–1006.
 342. Madhavan M, Prasad A. Proposed Mayo Clinic criteria for the diagnosis of Tako-Tsubo cardiomyopathy and long-term prognosis. *Herz* 2010;**35**:240–243.
 343. Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem U. Coronary artery spasm as a frequent cause of acute coronary syndrome: the CASPAR (Coronary Artery Spasm in Patients with Acute coronary syndrome) study. *J Am Coll Cardiol* 2008;**52**:523–527.
 344. Mohri M, Koyanagi M, Egashira K, Tagawa H, Ichiki T, Shimokawa H, Takeshita A. Angina pectoris caused by coronary microvascular spasm. *Lancet* 1998;**351**:1165–1169.
 345. Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, von Birgelen C, Roffi M, Moschovitis A, Khattab AA, Wenaweser P, Bonvini R, Pedrazzini G, Kornowski R, Weber K, Trelle S, Luscher TF, Taniwaki M, Matter CM, Meier B, Juni P, Windecker S. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. *JAMA* 2012;**308**:777–787.
 346. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vazquez N, Gomez-Hospital JA, Baz JA, Martin-Yuste V, van Geuns RJ, Alfonso F, Bordes P, Tebaldi M, Masotti M, Silvestro A, Backx B, Brugaletta S, van Es GA, Serruys PW. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (examination): 1 year results of a randomised controlled trial. *Lancet* 2012;**380**:1482–1490.
 347. Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study). *JACC Cardiovasc Interv* 2014;**7**:20–28.
 348. Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P, Andersson J, Calais F, Carlsson J, Collste O, Gotberg M, Hardhammar P, Ioanes D, Kallryd A, Linder R, Lundin A, Odenstedt J, Omerovic E, Puskar V, Todt T, Zellerroth E, Ostlund O, James SK. Outcomes 1 year after thrombus aspiration for myocardial infarction. *N Engl J Med* 2014;**371**:1111–1120.
 349. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, Budaj A, Niemela M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao P, Afzal R, Joyner CD, Chrolavicius S, Mehta SR. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. *Lancet* 2011;**377**:1409–1420.
 350. Rao SV, Hess CN, Barham B, Aberle LH, Anstrom KJ, Patel TB, Jorgensen JP, Mazzaferri EL Jr., Jolly SS, Jacobs A, Newby LK, Gibson CM, Kong DF, Mehran R, Waksman R, Gilchrist IC, McCourt BJ, Messenger JC, Peterson ED, Harrington RA, Krucoff MW. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. *JACC Cardiovasc Interv* 2014;**7**:857–867.
 351. Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, Sabate M, Mauri-Ferre J, Huber K, Niemela K, Haude M, Wijns W, Dudek D, Fajadet J, Kiemeneij F. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and working groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. *EuroIntervention* 2013;**8**:1242–1251.
 352. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLuca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med* 2001;**344**:1879–1887.
 353. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ. Randomized Intervention Trial of unstable Angina I. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable angina. *Lancet* 2002;**360**:743–751.
 354. Wallentin L, Lagerqvist B, Husted S, Konny F, Stahl E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. *Lancet* 2000;**356**:9–16.
 355. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, Colombo A, de Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Quantification of incomplete revascularization and its association with five-year mortality in the SYNERGY between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. *Circulation* 2013;**128**:141–151.
 356. Genereux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, Xu K, Parise H, Mehran R, Serruys PW, Stone GW. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (SYNERGY between PCI with TAXus and cardiac surgery) score. *J Am Coll Cardiol* 2012;**59**:2165–2174.
 357. Kurtis JP, Schreiner G, Wang Y, Chen J, Spertus JA, Rumsfeld JS, Brindis RG, Kurmholz HM. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of Medicare patients. *J Am Coll Cardiol* 2009;**54**:903–907.
 358. Meadows ES, Bae JP, Zagar A, Sugihara T, Ramaswamy K, McCracken R, Heiselman D. Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: a retrospective analysis. *BMC Res Notes* 2012;**5**:342.
 359. Ranasinghe I, Alprandi-Costa B, Chow V, Elliott JM, Waites J, Counsell JT, Lopez-Sendon J, Avezum A, Goodman SG, Granger CB, Brieger D. Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999–2007. *Am J Cardiol* 2011;**108**:617–624.
 360. Martensson S, Gyrd-Hansen D, Prescott E, Andersen PK, Zwisler AD, Osler M. Trends in time to invasive examination and treatment from 2001 to 2009 in patients admitted first time with non-ST elevation myocardial infarction or unstable angina in Denmark. *BMJ Open* 2014;**4**:e004052.
 361. Fukui T, Tabata M, Morita S, Takanashi S. Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. *J Thorac Cardiovasc Surg* 2013;**145**:1577–1583, e1571.
 362. Weiss ES, Chang DD, Joyce DL, Nwakanma LU, Yuh DD. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data. *J Thorac Cardiovasc Surg* 2008;**135**:503–511, e501–503.
 363. Deyell MW, Ghali WA, Ross DB, Zhang J, Hemmelgarn BR. Timing of non-emergent coronary artery bypass grafting and mortality after non-ST elevation acute coronary syndrome. *Am Heart J* 2010;**159**:490–496.
 364. Parikh SV, de Lemos JA, Jessen ME, Brilakis ES, Ohman EM, Chen AY, Wang TY, Peterson ED, Roe MT, Holper EM. Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). *JACC Cardiovasc Interv* 2010;**3**:419–427.
 365. Lim E, Ali Z, Ali A, Routledge T, Edmonds L, Altman DG, Large S. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. *BMJ* 2003;**327**:1309.
 366. Gavaghan TP, GebSKI V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. *Circulation* 1991;**83**:1526–1533.
 367. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. *Eur Heart J* 2006;**27**:2667–2674.
 368. Sun JC, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA, Teoh KH. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. *Eur Heart J* 2008;**29**:1057–1071.
 369. Deja MA, Kargul T, Domaradzki W, Stacel T, Mazur W, Wojakowski W, Gocol R, Gaszewska-Zurek E, Zurek P, Pytel A, Wos S. Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial. *J Thorac Cardiovasc Surg* 2012;**144**:204–209.

370. Biancari F, Airaksinen KE, Lip GY. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. *J Thorac Cardiovasc Surg* 2012;**143**:665–675, e664.
371. Nijjer SS, Watson G, Athanasiou T, Malik IS. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. *Eur Heart J* 2011;**32**:2970–2988.
372. Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, Cho P, Sell J, Fan J, Antonino MJ, Tantry US, Gurbel PA. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. *Circulation Cardiovasc Interv* 2012;**5**:261–269.
373. Rastan AJ, Eckenstein JI, Hentschel B, Funkat AK, Gummert JF, Doll N, Walther T, Falk V, Mohr FW. Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies. *Circulation* 2006;**114**:477–485.
374. Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, Argenziano M, Williams MR, Colombo A, Aylward PE, Stone GW. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. *JACC Cardiovasc Interv* 2010;**3**:1059–1067.
375. Harling L, Moscarelli M, Kidher E, Fattouch K, Ashrafian H, Athanasiou T. The effect of off-pump coronary artery bypass on mortality after acute coronary syndrome: a meta-analysis. *Int J Cardiol* 2013;**169**:339–348.
376. Stamou SC, Hill PC, Haile E, Prince S, Mack MJ, Corso PJ. Clinical outcomes of nonselective coronary revascularization with and without cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 2006;**131**:28–33.
377. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrie D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009;**373**:1190–1197.
378. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet* 2013;**381**:629–638.
379. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med* 2012;**367**:2375–2384.
380. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J* 2014;**35**:2541–2619.
381. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. *J Am Coll Cardiol* 2011;**57**:2389–2397.
382. Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW, Simoons ML, Deckers J, Topol EJ, Holmes DR Jr. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. *J Am Coll Cardiol* 2000;**36**:685–692.
383. Holmes DR Jr., Berger PB, Hochman JS, Granger CB, Thompson TD, Califf RM, Vahanian A, Bates ER, Topol EJ. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. *Circulation* 1999;**100**:2067–2073.
384. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. *Ann Intern Med* 1999;**131**:47–59.
385. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebel H, Schneider S, Schuler G, Werdan K. Intraaortic balloon support for myocardial infarction with cardiogenic shock. *N Engl J Med* 2012;**367**:1287–1296.
386. Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galati S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomized trials. *Lancet* 2013;**382**:1879–1888.
387. Kaiser C, Galati S, Erne P, Eberli F, Alber H, Rickli H, Pedrazzini G, Hornig B, Bertel O, Bonetti P, De Servi S, Brunner-La Rocca HP, Ricard I, Pfisterer M. Drug-eluting versus bare-metal stents in large coronary arteries. *N Engl J Med* 2010;**363**:2310–2319.
388. Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. *Cochrane Database Syst Rev* 2010;**5**:CD004587
389. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. *Circulation* 2009;**119**:3198–3206.
390. Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, Stone GW. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. *J Am Coll Cardiol* 2005;**45**:1165–1171.
391. Yan AT, Yan RT, Tan M, Fung A, Cohen EA, Fitchett DH, Langer A, Goodman SG, Canadian Acute Coronary Syndromes 1 and 2 Registry Investigators. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. *Arch Intern Med* 2007;**167**:1009–1016.
392. Poon S, Goodman SG, Yan RT, Bugiardini R, Bierman AS, Eagle KA, Johnston N, Huynh T, Grondin FR, Schenck-Gustafsson K, Yan AT. Bridging the gender gap: insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. *Am Heart J* 2012;**163**:66–73.
393. Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, Kiefe CI, Frederick PD, Sopko G, Zheng ZJ, Investigators N. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. *JAMA* 2012;**307**:813–822.
394. Mehilii J, Kastrati A, Dirschinger J, Pache J, Seyfarth M, Blasini R, Hall D, Neumann FJ, Schomig A. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. *JAMA* 2002;**287**:210–215.
395. Alfredsson J, Lindback J, Wallentin L, Swahn E. Similar outcome with an invasive strategy in men and women with non-ST-elevation acute coronary syndromes: from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). *Eur Heart J* 2011;**32**:3128–3136.
396. Chew DP, Juergens C, French J, Parsonage W, Horsfall M, Brieger D, Quinn S. An examination of clinical intuition in risk assessment among acute coronary syndromes patients: observations from a prospective multi-center international observational registry. *Int J Cardiol* 2014;**171**:209–216.
397. Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. *J Am Coll Cardiol* 2014;**63**:1441–1448.
398. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, Fitzgerald G, Jackson EA, Eagle KA, Global Registry of Acute Coronary Events Investigators. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. *Heart* 2009;**95**:20–26.
399. Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F, Aylward P, Topol EJ, Califf RM. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. *N Engl J Med* 1999;**341**:226–232.
400. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. *Circulation* 2004;**109**:580–586.
401. Terkelsen CJ, Sorensen JT, Maeng M, Jensen LO, Tilsted HH, Trautner S, Vach W, Johnsen SP, Thuesen L, Lassen JF. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. *JAMA* 2010;**304**:763–771.
402. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, Roe MT, Gibler WB, Ohman EM, Peterson ED. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. *Circulation* 2006;**114**:1380–1387.

403. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, Wells Q, Bozkurt B, Labresh KA, Liang L, Hong Y, Newby LK, Fletcher G, Peterson E, Wexler L. Sex differences in medical care and early death after acute myocardial infarction. *Circulation* 2008;**118**:2803–2810.
404. Vaccarino V, Parsons L, Peterson ED, Rogers WJ, Kiefe CI, Canto J. Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006. *Arch Intern Med* 2009;**169**:1767–1774.
405. Mehilli J, Kastrati A, Bollwein H, Dibra A, Schühlen H, Dirschinger J, Schomig A. Gender and restenosis after coronary artery stenting. *Eur Heart J* 2003;**24**:1523–1530.
406. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX Jr, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LK. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines) national quality improvement initiative. *J Am Coll Cardiol* 2005;**45**:832–837.
407. Gale CP, Cattle BA, Woolston A, Baxter PD, West TH, Simms AD, Blaxill J, Greenwood DC, Fox KA, West RM. Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. *The myocardial ischaemia national audit project 2003-2010*. *Eur Heart J* 2012;**33**:630–639.
408. Bauer T, Koeth O, Junger C, Heer T, Wienbergen H, Gitt A, Zahn R, Senges J, Zeymer U. Effect of an invasive strategy on in-hospital outcome in elderly patients with non-ST-elevation myocardial infarction. *Eur Heart J* 2007;**28**:2873–2878.
409. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. *Circulation* 2007;**115**:2549–2569.
410. Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, Hasdai D. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. *Eur Heart J* 2006;**27**:789–795.
411. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the global registry of acute coronary events. *Chest* 2004;**126**:461–469.
412. Reiter M, Twerenbold R, Reichlin T, Haaf P, Peter F, Meissner J, Hochholzer W, Stelzig C, Freese M, Heinisch C, Breidhardt T, Freidank H, Winkler K, Campodarve I, Gea J, Mueller C. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. *Eur Heart J* 2011;**32**:1379–1389.
413. Fox KA, Eagle KA, Gore JM, Steg PG, Anderson FA. The global registry of acute coronary events, 1999 to 2009—GRACE. *Heart* 2010;**96**:1095–1101.
414. Skolnick AH, Alexander KP, Chen AY, Roe MT, Pollack CV Jr, Ohman EM, Rumsfeld JS, Gibler WB, Peterson ED, Cohen DJ. Characteristics, management, and outcomes of 5,557 patients age ≥ 90 years with acute coronary syndromes: results from the CRUSADE initiative. *J Am Coll Cardiol* 2007;**49**:1790–1797.
415. Devlin G, Gore JM, Elliott J, Wijesinghe N, Eagle KA, Avezum A, Huang W, Brieger D. Management and 6-month outcomes in elderly and very elderly patients with high-risk non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. *Eur Heart J* 2008;**29**:1275–1282.
416. Malkin CJ, Prakash R, Chew DP. The impact of increased age on outcome from a strategy of early invasive management and revascularisation in patients with acute coronary syndromes: retrospective analysis study from the ACACIA registry. *BMJ Open* 2012;**2**:e000540.
417. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. *Ann Intern Med* 2004;**141**:186–195.
418. Savonitto S, Cavallini C, Petronio AS, Murena E, Antonicelli R, Sacco A, Steffenino G, Bonechi F, Mossuti E, Manari A, Tolaro S, Toso A, Daniotti A, Piscione F, Morici N, Cesana BM, Jori MC, De Servi S. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. *JACC Cardiovasc Interv* 2012;**5**:906–916.
419. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. *JAMA* 2005;**294**:3108–3116.
420. Afialo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Popma JJ, Ferrucci L, Forman DE. Frailty assessment in the cardiovascular care of older adults. *J Am Coll Cardiol* 2014;**63**:747–62.
421. Ekerstad N, Swahn E, Janzon M, Alfredsson J, Lofmark R, Lindenberg M, Carlsson P. Frailty is independently associated with short-term outcomes for elderly patients with non-ST-segment elevation myocardial infarction. *Circulation* 2011;**124**:2397–2404.
422. Giraldez RR, Clare RM, Lopes RD, Dalby AJ, Prabhakaran D, Brogan GX Jr, Giugliano RP, James SK, Tanguay JF, Pollack CV Jr, Harrington RA, Braunwald E, Newby LK. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. *Am Heart J* 2013;**165**:918–925, e912.
423. Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. *Am J Cardiol* 2005;**96**:363–365.
424. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. *Lancet* 2002;**359**:2140–2144.
425. Bartnik M, Ryden L, Malmberg K, Ohrvik J, Pyoralá K, Standl E, Ferrari R, Simoons M, Soler-Soler J. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. *Heart* 2007;**93**:72–77.
426. Dotevall A, Hasdai D, Wallentin L, Battler A, Rosengren A. Diabetes mellitus: clinical presentation and outcome in men and women with acute coronary syndromes. *Data from the Euro Heart Survey ACS*. *Diabet Med* 2005;**22**:1542–1550.
427. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. *JAMA* 2007;**298**:765–775.
428. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. *Diabetes Care* 2009;**32**:531–540.
429. Ferreira JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. *Circulation* 2011;**123**:798–813.
430. Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. *Eur Heart J* 2004;**25**:1990–1997.
431. De Caterina R, Madonna R, Sourij H, Wascher T. Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. *Eur Heart J* 2010;**31**:1557–1564.
432. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. *Eur Heart J* 2005;**26**:1255–1261.
433. Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskiran MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knutti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Torbicki A, Wijns W, Windecker S, De Backer G, Ezquerro EA, Avogaro A, Badimon L, Baranova E, Betteridge J, Ceriello A, Funck-Brentano C, Gulba DC, Kjekshus JK, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Viigimaa M, Vlachopoulos C, Xuereb RG. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2013;**34**:3035–3087.
434. Verges B, Avignon A, Bonnet F, Catargi B, Cattan S, Cosson E, Ducrocq G, Elbaz M, Fredenrich A, Gourdy P, Henry P, Lairez O, Leguerrier AM, Monpere C, Moulin P, Verges-Patois B, Roussel R, Steg G, Valensi P. Consensus statement on the care of the hyperglycaemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. *Diabetes Metab* 2012;**38**:113–127.
435. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. *Eur J Cardiothorac Surg* 2013;**43**:1006–1013.
436. Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDIA (Coronary Artery Revascularization in DIAbetes) trial. *J Am Coll Cardiol* 2010;**55**:432–440.
437. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. *Eur Heart J* 2011;**32**:2748–2757.
438. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic

- outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis In Myocardial Infarction 38. *Circulation* 2008;**118**:1626–1636.
439. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATElet inhibition and patient Outcomes (PLATO) trial. *Eur Heart J* 2010;**31**:3006–3016.
 440. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Theroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. *Circulation* 2001;**104**:2767–2771.
 441. O'Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MS. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. *J Am Coll Cardiol* 2012;**60**:106–111.
 442. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. *Eur Heart J* 2004;**25**:190–198.
 443. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. *Eur Heart J* 2007;**28**:26–32.
 444. Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M, Sud S, Gupta M, Singh S, Gupta N, Cheema AN, Leiter LA, Fedak PW, Teoh H, Latter DA, Fuster V, Friedrich JO. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol* 2013;**1**:317–328.
 445. Hakeem A, Garg N, Bhatti S, Rajurohit N, Ahmed Z, Uretsky BF. Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. *J Am Heart Assoc* 2013;**2**:e000354.
 446. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. *J Am Coll Cardiol* 2004;**44**:1587–1592.
 447. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. *J Intern Med* 2010;**268**:40–49.
 448. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). *Circulation* 2009;**120**:851–858.
 449. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the PLATElet inhibition and patient Outcomes (PLATO) trial. *Circulation* 2010;**122**:1056–1067.
 450. Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. *Am J Cardiovasc Drugs* 2005;**5**:291–305.
 451. Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. *Circulation* 2012;**125**:2649–2661.
 452. Kubitzka D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, Bruck H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. *Br J Clin Pharmacol* 2010;**70**:703–712.
 453. Collet JP, Montalescot G, Agnelli G, Van de Werf F, Gurfinkel EP, Lopez-Sendon J, Laufenberg CV, Klutman M, Gowda N, Gulba D. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. *Eur Heart J* 2005;**26**:2285–2293.
 454. Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. *Ann Intern Med* 2007;**147**:304–310.
 455. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. *JAMA* 2008;**300**:1038–1046.
 456. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA* 2004;**291**:2328–2334.
 457. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB, Kim HS. Renal toxicity evaluation and comparison between Visipaque (iodixanol) and Hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. *J Am Coll Cardiol* 2006;**48**:924–930.
 458. Maioli M, Toso A, Leoncini M, Micheletti C, Bellandi F. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial. *Circ Cardiovasc Interv* 2011;**4**:456–462.
 459. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med* 2003;**348**:491–499.
 460. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. *Circulation* 2007;**115**:3189–3196.
 461. Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN, Anstrom KJ, Eisenstein EL, Dokholyan RS, Peterson ED, Douglas PS. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. *J Am Coll Cardiol* 2011;**58**:1859–1869.
 462. Shenoy C, Boura J, Orshaw P, Harjai KJ. Drug-eluting stents in patients with chronic kidney disease: a prospective registry study. *PLoS One* 2010;**5**:e15070.
 463. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayer WC. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. *J Am Soc Nephrol* 2012;**23**:2042–2049.
 464. Zheng H, Xue S, Lian F, Huang RT, Hu ZL, Wang YY. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. *Eur J Cardiothorac Surg* 2013;**43**:459–467.
 465. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *Circulation* 2010;**121**:357–365.
 466. Yan LQ, Guo LJ, Zhang FC, Gao W. The relationship between kidney function and angiographically-derived SYNTAX score. *Can J Cardiol* 2011;**27**:768–772.
 467. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lopez-Sendon J, Budaj A, Goldberg RJ, Klein W, Anderson FA Jr. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). *Circulation* 2004;**109**:494–499.
 468. Roger VL. Epidemiology of heart failure. *Circ Res* 2013;**113**:646–659.
 469. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitler J, Seferovic A, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiger A. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J* 2012;**33**:1787–1847.
 470. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de Waha A, Richardt G, Hennesdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Bohm M, Ebel H, Schneider S, Werdan K, Schuler G. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. *Lancet* 2013;**382**:1638–1645.
 471. Kirklín JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Baldwin JT, Young JB. The Fourth INTERMACS Annual Report: 4,000 implants and counting. *J Heart Lung Transplant* 2012;**31**:117–126.
 472. Kirklín JK. Long-term mechanical circulatory support: could it really have a public health impact? *Eur J Cardiothorac Surg* 2013;**44**:198–200.
 473. Kirklín JK, Naftel DC, Pagani FD, Kormos RL, Stevenson L, Miller M, Young JB. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? *J Thorac Cardiovasc Surg* 2012;**144**:584–603; discussion 597–588.
 474. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;**371**:993–1004.

475. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, Lejemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. *N Engl J Med* 1999;**341**:625–634.
476. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. *JAMA* 2006;**295**:2511–2515.
477. Buerke M, Prondzinsky R, Lemm H, Dietz S, Buerke U, Ebel H, Bushnaq H, Silber RE, Werdan K. Intra-aortic balloon counterpulsation in the treatment of infarction-related cardiogenic shock—review of the current evidence. *Artif Organs* 2012;**36**:505–511.
478. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. *N Engl J Med* 1992;**327**:669–677.
479. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003;**349**:1893–1906.
480. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003;**362**:772–776.
481. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. *N Engl J Med* 1991;**325**:293–302.
482. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet* 2001;**357**:1385–1390.
483. CIBIS-II Investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. *Lancet* 1999;**353**:9–13.
484. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacs P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;**344**:1651–1658.
485. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). *Lancet* 1999;**353**:2001–2007.
486. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;**26**:215–225.
487. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011;**364**:11–21.
488. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *Randomized aldactone evaluation study investigators. N Engl J Med* 1999;**341**:709–717.
489. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;**346**:877–883.
490. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;**352**:225–237.
491. Al-Khatib SM, Hellkamp AS, Lee KL, Anderson J, Poole JE, Mark DB, Bardy GH. Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in HEart Failure Trial (SCD-HEFT). *J Cardiovasc Electrophysiol* 2008;**19**:1059–1065.
492. Barsheshet A, Goldenberg I, Moss AJ, Huang DT, Zareba W, McNitt S, Klein HU, Guetta V. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial. *J Cardiovasc Electrophysiol* 2011;**22**:1237–1242.
493. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;**33**:2719–2747.
494. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorennek B, Haldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). *Eur Heart J* 2010;**31**:2369–2429.
495. Lippi G, Picanza A, Formentini A, Bonfanti L, Cervellin G. The concentration of troponin I is increased in patients with acute-onset atrial fibrillation. *Int J Cardiol* 2014;**173**:579–580.
496. Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Circulation* 2014;**129**:625–634.
497. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med* 1999;**131**:492–501.
498. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, and the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med* 1991;**324**:781–788.
499. Younger JO, Nauta ST, Akkerhuis KM, Deckers JW, van Domburg RT. Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syndromes. *Am J Cardiol* 2012;**109**:506–510.
500. Bassand JP, Biondi-Zoccai GG, de Benedictis ML, Rigattieri S, Turri M, Anselmi M, Vassanelli C, Zardini P, Louvard Y, Hamon M. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures: systematic overview and meta-analysis of randomized trials. *J Am Coll Cardiol* 2004;**44**:349–356.
501. McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial experience. *Circulation* 1999;**99**:2892–2900.
502. Merlino PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. *Circulation* 2004;**109**:2203–2206.
503. Gore JM, Spencer FA, Gurfinkel EP, Lopez-Sendon J, Steg PG, Granger CB, FitzGerald G, Agnelli G. Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). *Am J Cardiol* 2009;**103**:175–180.
504. Vora AN, Chenier M, Schulte PJ, Goodman S, Peterson ED, Pieper K, Jolicoeur ME, Mahaffey KW, White H, Wang TY. Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. *Am Heart J* 2014;**168**:189–196. e181.
505. Greinacher A, Selleng K. Thrombocytopenia in the intensive care unit patient. *Hematology Am Soc Hematol Educ Program* 2010;**2010**:135–143.
506. Warkentin TE. Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. *N Engl J Med* 2007;**356**:891–893.
507. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. *Am Heart J* 2000;**140**:206–211.
508. Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AVW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. *Eur Heart J* 2010;**31**:35–49.
509. Tempelhof MW, Benzuly KH, Fintel D, Krichavsky MZ. Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty. *Tex Heart Inst J* 2012;**39**:86–91.

512. Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George JN, Kelton JG. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. *Transfus Med Rev* 2013;**27**:137–145.
513. McCullough J. Overview of platelet transfusion. *Semin Hematol* 2010;**47**:235–242.
514. Kelton JG, Arnold DM, Bates SM. Nonheparin anticoagulants for heparin-induced thrombocytopenia. *N Engl J Med* 2013;**368**:737–744.
515. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *N Engl J Med* 2001;**344**:1286–1292.
516. Patrignani P, Patrono C. Cyclooxygenase inhibitors: from pharmacology to clinical read-outs. *Biochim Biophys Acta* 2015;**1851**:422–432.
517. Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. *Circulation* 2014;**129**:907–916.
518. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanus A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet* 2013;**382**:769–779.
519. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, Leslie K, Rao-Melacini P, Chrolavicius S, Yang H, Macdonald C, Avezum A, Lanthier L, Hu W, Yusuf S. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. *Ann Intern Med* 2011;**154**:523–528.
520. Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, Wang CY, Garutti RI, Jacka MJ, Sigamani A, Srinathan S, Biccari BM, Chow CK, Abraham V, Tiboni M, Pettit S, Szczeklik W, Lurati Buse G, Botto F, Guyatt G, Heels-Ansdell D, Sessler DI, Thorlund K, Garg AX, Mrkoberada M, Thomas S, Rodseth RN, Pearce RM, Thabane L, McQueen MJ, VanHelder T, Bhandari M, Bosch J, Kurz A, Polanczyk C, Malaga G, Nagele P, Le Manach Y, Leuw M, Yusuf S. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. *JAMA* 2012;**307**:2295–2304.
521. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. *Circulation* 2010;**121**:750–758.
522. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;**350**:1495–1504.
523. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. *JAMA* 1982;**247**:1707–1714.
524. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Moye L, Pfeffer M. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) study. *J Am Coll Cardiol* 1997;**29**:229–236.
525. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003;**348**:1309–1321.
526. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *N Engl J Med* 1998;**339**:489–497.
527. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;**376**:1670–1681.
528. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;**352**:1425–1435.
529. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015;**372**:2387–97.
530. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;**342**:145–153.
531. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med* 2008;**358**:1547–1559.
532. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; Reach Registry Investigators. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. *JAMA* 2012;**308**:1340–1349.
533. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC guidelines for the management of arterial hypertension. *Eur Heart J* 2013;**34**:2159–2219.
534. Piepoli MF, Corra U, Abreu A, Cupples M, Davos C, Doherty P, Hofer S, Garcia-Porrero E, Rauch B, Vigorito C, Voller H, Schmid JP. Challenges in secondary prevention of cardiovascular diseases: a review of the current practice. *Int J Cardiol* 2015;**180**:114–119.
535. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. *Ann Intern Med* 2005;**143**:659–672.
536. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA* 2003;**290**:86–97.
537. Iestra JA, Kromhout D, van der Schouw YT, Grobbee DE, Boshuizen HC, van Staveren WA. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. *Circulation* 2005;**112**:924–934.
538. Fox KM; European trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet* 2003;**362**:782–788.
539. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998;**351**:1755–1762.
540. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998;**317**:703–713.
541. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. *Am J Med* 2004;**116**:682–692.
542. Taylor RS, Unal B, Critchley JA, Capewell S. Mortality reductions in patients receiving exercise-based cardiac rehabilitation: how much can be attributed to cardiovascular risk factor improvements? *Eur J Cardiovasc Prev Rehabil* 2006;**13**:369–374.
543. Hammill BG, Curtis LH, Schulman KA, Whellan DJ. Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. *Circulation* 2010;**121**:63–70.
544. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2012;**33**:1635–1701.
545. Heran BS, Chen JM, Ebrahim S, Moxham T, Oldridge N, Rees K, Thompson DR, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease. *Cochrane Database Syst Rev* 2011;**1**:CD001800.
546. Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. *Eur J Prev Cardiol* 2013;**20**:620–640.
547. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized fever trial. *Eur Heart J* 2011;**32**:1500–1508.
548. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro JM, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. *Lancet* 2004;**364**:849–857.
549. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. *J Hypertens* 2009;**27**:923–934.
550. Nallamothu B, Fox KA, Kellenly BM, Van de Werf F, Gore JM, Steg PG, Granger CB, Dabbous OH, Kline-Rogers E, Eagle KA. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events. *Heart* 2007;**93**:1552–1555.
551. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. *Circulation* 2004;**109**:745–749.